WO2008100624A2 - Antibodies against erbb3 and uses thereof - Google Patents

Antibodies against erbb3 and uses thereof Download PDF

Info

Publication number
WO2008100624A2
WO2008100624A2 PCT/US2008/002119 US2008002119W WO2008100624A2 WO 2008100624 A2 WO2008100624 A2 WO 2008100624A2 US 2008002119 W US2008002119 W US 2008002119W WO 2008100624 A2 WO2008100624 A2 WO 2008100624A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
variable region
chain variable
erbb3
Prior art date
Application number
PCT/US2008/002119
Other languages
French (fr)
Other versions
WO2008100624A3 (en
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2008216600A priority Critical patent/AU2008216600B2/en
Priority to JP2009549644A priority patent/JP5564266B2/en
Priority to SI200831098T priority patent/SI2129396T1/en
Priority to BRPI0808055-0A priority patent/BRPI0808055A2/en
Priority to CN200880009633.1A priority patent/CN101674846B/en
Priority to MX2009008656A priority patent/MX2009008656A/en
Priority to CA2678181A priority patent/CA2678181C/en
Priority to EP08725722.6A priority patent/EP2129396B1/en
Application filed by Merrimack Pharmaceuticals, Inc. filed Critical Merrimack Pharmaceuticals, Inc.
Priority to US12/281,925 priority patent/US7846440B2/en
Priority to ES08725722T priority patent/ES2431940T3/en
Priority to DK08725722.6T priority patent/DK2129396T3/en
Priority to EA200901119A priority patent/EA020465B1/en
Priority to PL08725722T priority patent/PL2129396T3/en
Priority to NZ579644A priority patent/NZ579644A/en
Priority to RS20130512A priority patent/RS53042B/en
Publication of WO2008100624A2 publication Critical patent/WO2008100624A2/en
Publication of WO2008100624A3 publication Critical patent/WO2008100624A3/en
Priority to US12/425,874 priority patent/US20100056761A1/en
Priority to IL200373A priority patent/IL200373A/en
Priority to US12/545,279 priority patent/US8691225B2/en
Priority to ZA2009/06360A priority patent/ZA200906360B/en
Priority to MA32222A priority patent/MA31254B1/en
Priority to EC2009009637A priority patent/ECSP099637A/en
Priority to HK10105467.1A priority patent/HK1138771A1/en
Priority to US12/904,492 priority patent/US8961966B2/en
Priority to HRP20131113AT priority patent/HRP20131113T1/en
Priority to US14/181,334 priority patent/US9487588B2/en
Priority to US15/274,989 priority patent/US20170073427A1/en
Priority to US16/181,054 priority patent/US20190292271A1/en
Priority to US17/376,627 priority patent/US20220204642A1/en
Priority to US18/630,602 priority patent/US20240360243A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the ErbB/HER subfamily of polypeptide growth factor receptors include the epidermal growth factor (EGF) receptor (EGFR, ErbBl/HERl), the neu oncogene product (ErbB2/HER2), and the more recently identified ErbB3/HER3 and ErbB4/HER4 receptor proteins (see, e.g., Hynes et. al. (1994) Biochim. Biophys. Acta Rev. Cancer 1198, 165-184).
  • Each of these receptors is predicted to consist of an extracellular ligand-binding domain, a membrane-spanning domain, a cytosolic protein tyrosine kinase (PTK) domain and a C-terminal phosphorylation domain (see, e.g., Kim et al., ( ⁇ 99S) Biochem. J. 334, 189-195).
  • PTK cytosolic protein tyrosine kinase
  • ErbB3 is constitutively phosphorylated on tyrosine residues in a subset of human breast cancer cell lines overexpressing this protein (see, e.g., Kraus et al. (1993) Proc. Natl. Acad. Sci. USA. 90, 2900-2904; and Kim et al. Supra; see, also, Schaefer et al. (2006) Neoplasia 8(7): 613-22 and Schaefer et al. Cancer Res (2004) 64(10):3395-405).
  • ErbB3 remains largely unappreciated as a target for clinical intervention.
  • Current immunotherapies primarily focus on inhibiting the action of ErbB2 and, in particular, heterodimerization of ErbB2/ErbB3 complexes (see, e.g., Sliwkowski et al. (1994) J. Biol. Chem. 269(20): 14661-14665 (1994)). Accordingly, it is an object of the present invention to provide improved immunotherapies that effectively inhibit ErbB3 signaling, and can be used to treat and diagnose a variety of cancers.
  • the present invention provides a novel class of monoclonal antibodies which binds to the ErbB3 receptor and inhibits various ErbB3 functions.
  • the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.
  • EGF-like ligands include EGF, TGF- ⁇ , betacellulin, heparin-binding epidermal growth factor, biregulin and amphiregulin, which bind to EGFR and induce dimerization of EGFR with ErbB3. This dimerization, in turn, causes phosphorylation of ErbB3, and activates signaling through the receptor.
  • Monoclonal antibodies of the present invention are useful for treating and diagnosing a variety of cancers associated with ErbB3 -mediated cellular signaling. Accordingly, in one embodiment, the present invention provides monoclonal antibodies (and antigen binding portions thereof) which bind to ErbB3 and inhibit EGF- like ligand mediated phosphorylation of ErbB3.
  • the antibodies are further characterized by one or more of the following properties: (i) inhibition of ErbB3 ligand-mediated signaling, including signaling mediated by binding of ErbB3 ligands, such as heregulin, epiregulin, epigen and BIR, to ErbB3; (ii) inhibition of proliferation of cells expressing ErbB3; (iii) the ability to decrease levels of ErbB3 on cell surfaces (e.g., by inducing internalization of ErbB3); (iv) inhibition of VEGF secretion of cells expressing ErbB3; (v) inhibition of the migration of cells expressing ErbB3; (vi) inhibition of spheroid growth of cells expressing ErbB3 ; and/or (vii) binding to an epitope located on domain I (residues 20- 209) of ErbB3, for example, an epitope involving or spanning residues 20-202 of the amino acid sequence of ErbB3.
  • ErbB3 ligand-mediated signaling
  • Particular monoclonal antibodies and antigen binding portions thereof of the present invention exhibit a K D of 50 nM or less, as measured by a surface plasmon resonance assay or a cell binding assay
  • particular monoclonal antibodies and antigen binding portions thereof of the present invention include a heavy chain variable region comprising an amino acid sequence which is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:35, or SEQ ID NO: 37.
  • antibodies and antigen binding portions thereof of the present invention include a light chain variable region comprising an amino acid sequence which is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to the light chain variable region amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:36, or SEQ ID NO:38.
  • the antibodies may also include both of the aforementioned heavy chain and light chain variable regions.
  • variable heavy and light chain regions of the antibodies or antigen binding portions thereof typically include one or more complementarity determining regions (CDRs). These include one or more CDRl, CDR2, and CDR3 regions. Accordingly, other particular antibodies and antigen binding portions thereof of the present invention include one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ID NO: 7; a heavy chain variable region CDR2 comprising SEQ ID NO:8; a heavy chain variable region CDR3 comprising SEQ ID NO:9; a light chain variable region CDRl comprising SEQ ID NO: 10; a light chain variable region CDR2 comprising SEQ ID NO: 11 ; a light chain variable region CDR3 comprising SEQ ID NO: 12; and combinations thereof.
  • CDRs complementarity determining regions
  • Still other particular antibodies and antigen binding portions thereof of the present invention include one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ID NO: 13; a heavy chain variable region CDR2 comprising SEQ ID NO: 14; a heavy chain variable region CDR3 comprising SEQ ID NO: 15; a light chain variable region CDRl comprising SEQ ID NO: 16; a light chain variable region CDR2 comprising SEQ ID NO: 17; a light chain variable region CDR3 comprising SEQ ID NO: 18; and combinations thereof.
  • Still other particular antibodies and antigen binding portions thereof of the present invention include; or one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ID NO: 19; a heavy chain variable region CDR2 comprising SEQ ID NO:20; a heavy chain variable region CDR3 comprising SEQ ID NO:21; a light chain variable region CDRl comprising SEQ ID NO:22; a light chain variable region CDR2 comprising SEQ ED NO: 23; a light chain variable region CDR3 comprising SEQ DD NO:24; and combinations thereof.
  • Still other particular antibodies and antigen binding portions thereof of the present invention include; or one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ID NO:39; a heavy chain variable region CDR2 comprising SEQ ID NO:40; a heavy chain variable region CDR3 comprising SEQ ID NO:41; a light chain variable region CDRl comprising SEQ ID NO:42; a light chain variable region CDR2 comprising SEQ ED NO:43; a light chain variable region CDR3 comprising SEQ ED NO:44; and combinations thereof.
  • Still other particular antibodies and antigen binding portions thereof of the present invention include; or one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ED NO:45; a heavy chain variable region CDR2 comprising SEQ ED NO:46; a heavy chain variable region CDR3 comprising SEQ ED NO:47; a light chain variable region CDRl comprising SEQ ED NO:48; a light chain variable region CDR2 comprising SEQ ED NO:49; a light chain variable region CDR3 comprising SEQ ED NO:50; and combinations thereof.
  • the antibodies and antigen binding portions thereof may also comprise one or more CDRs which are at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to any of the aforementioned CDRs, or combinations of CDRs.
  • the antibodies and antibody portions thereof are fully human
  • Particular human antibodies of the present invention include those having a heavy chain variable region that is from a human VH3 germ line gene, and/or a light chain variable region from human VL2 germ line gene.
  • antibodies and portions thereof that bind to the same or overlapping epitopes bound by any of the antibodies or portions thereof described herein (e.g., an epitope located on domain I of ErbB3, such as an epitope involving or spanning, residues 20-202 of the amino acid sequence of ErbB3).
  • Antibodies which have the same activity as the antibodies described herein, e.g., antibodies having the same sequence as Ab #6, are also encompassed by the present invention.
  • Antibodies of the present invention include all known forms of antibodies and other protein scaffolds with antibody-like properties.
  • the antibody can be a human antibody, a humanized antibody, a bispecific antibody, a chimeric antibody or a protein scaffold with antibody-like properties, such as fibronectin or Ankyrin repeats.
  • the antibody also can be a Fab, Fab'2, ScFv, SMTP, af ⁇ body, nanobody, or a domain antibody.
  • the antibody also can have any of the following isotypes: IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD, and IgE.
  • the present invention further provides compositions comprising combinations of antibodies or antigen binding portions described herein, formulated with an acceptable carrier and/or adjuvant.
  • the composition comprises two or more antibodies that bind different epitopes on ErbB3 or antibodies described herein combined with anti-cancer antibodies which do not bind ErbB3.
  • the present invention provides isolated nucleic acids encoding the antibodies and antigen binding portions thereof described herein.
  • the nucleic acid encodes a heavy chain variable region comprising a nucleotide sequence which is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to, or which hybridizes under high stringency conditions to, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:35, or SEQ ID NO:37; or a light chain variable region comprising a nucleotide sequence which is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to, or which hybridizes under high stringency conditions to, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:36, or SEQ ID NO:38; or combinations of such heavy and light variable regions.
  • the present invention further provides transgenic non-human mammals, hybridomas, and transgenic plants that express and/or produce the antibodies and antigen binding portions described herein.
  • kits comprising one or more isolated monoclonal antibodies or antigen binding portions thereof described herein and, optionally, instructions for use in treating or diagnosing a disease associated with ErbB3 dependent signaling, such as cancers.
  • Antibodies and antigen binding portions thereof of the present invention can be used in a broad variety of therapeutic and diagnostic applications, particularly oncological applications. Accordingly, in another aspect, the invention provides method for inhibiting EGF-like ligand mediated phosphorylation of ErbB3 in a subject by administering one or more antibodies or antigen binding portions thereof described herein in an amount sufficient to inhibit EGF-like mediated phosphorylation of ErbB3.
  • the invention further provides methods for treating a variety of cancers in a subject, including, but not limited to, melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal/colon cancer, lung cancer, clear cell sarcoma, and prostate cancer, by administering one or more antibodies or antigen binding portions thereof described herein in an amount sufficient to treat the cancer.
  • the antibodies or antigen binding portions thereof can be administered alone or in combination with other therapeutic agents, such as anti-cancer agents, e.g., other antibodies, chemotherapeutic agents and/or radiation.
  • the invention provides methods for diagnosing and prognosing diseases ⁇ e.g., cancers) associated with ErbB3. In one embodiment, this is achieved by contacting antibodies or antigen binding portions of the invention (e.g., ex vivo or in vivo) with cells from the subject, and measuring the level of binding to ErbB3 on the cells, wherein abnormally high levels of binding to ErbB3 indicate that the subject has a cancer associated with ErbB3.
  • antibodies or antigen binding portions of the invention e.g., ex vivo or in vivo
  • Figures IA and IB are bar graphs depicting the binding of various anti-ErbB3 antibody candidates (Fabs, referred to as Abs herein) to ErbB3 expressed on MALME- 3M melanoma cells using a goat anti-human Alexa 647 secondary antibody.
  • Figures 2A-2D are graphs depicting the K D values of various anti-ErbB3 antibody candidates.
  • Figures 2A and 2B are graphs depicting the K D value of Antibody # 6 (referred to as Ab #6) and Antibody # 3 (referred to as Ab #3), respectively, as measured using surface plasmon resonance (SPR) technology.
  • Figures 2C and 2D are graphs depicting the K D values of Ab #6 and Ab #3, respectively, as measured using a cell binding assay using MALME-3M melanoma cells.
  • Figure 3 is a graph depicting the binding specificity of an anti-ErbB3 antibody (Ab #6) to ErbB3 using ELISA.
  • EGFR, BSA and TGF- ⁇ were used as controls.
  • Figure 4 is a graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to decrease total ErbB3 levels in MALME-3M melanoma cells in vitro, as measured using ELISA.
  • Figures 5 A and 5B are graphs depicting the ability of an anti-ErbB3 antibody (Ab #6) to downregulate ErbB3 receptors on MALME-3M cells, measured using FACS analysis.
  • Figure 5A shows the results using an IgGl isotype of the antibody.
  • Figure 5B shows the results using an IgG2 isotype of the antibody.
  • Figures 6A-6D are graphs depicting the timecourse of antibody-mediated ErbB3 downregulation (Ab #6), as measured using FACS analysis.
  • Figure 7 is a bar graph depicting the ability of various anti-ErbB3 antibodies to downregulate ErbB3 in melanoma cells in vivo.
  • Figure 8 is a bar graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to downregulate ErbB3 in ADRr xenografts in vivo.
  • Figure 9 is a graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit proliferation of MALME-3M cells in a Cell Titer Glow Assay.
  • Figure 10 is a graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit cell proliferation in an ovarian cell line, ADRr.
  • Figure 11 is a graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit proliferation of ACHN cells.
  • Figure 12 is a bar graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit ErbB3 phosphorylation in ADRr xenografts in vivo.
  • Figures 13A-13C are graphs depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit betacellulin and heregulin-mediated phosphorylation of ErbB3 in ADRr cells.
  • Figures 14A-14B are graphs depicting the ability of an anti-ErbB3 antibody (Ab
  • Figures 15A-15C are graphs depicting the ability of betacellulin (BTC) to bind ErbBl as shown by a lack of binding to ErbBl negative MALME-3M cells (Figure 17A); binding to ErbBl positive ADRr cells at concentrations of 10 nM ( Figure 17B) and 200 nM ( Figure 17B), respectively, and the inhibition of such binding by Erbitux.
  • BTC betacellulin
  • Figures 16A-16B are graphs depicting the ability of an anti-ErbB3 antibody (Ab #6 IgG2 isotype) to inhibit heregulin-mediated signaling in MALME-3M cells.
  • Figure 16A depicts the ability of the Ab #6 to inhibit heregulin-mediated phosphorylation of ErbB3 in MALME-3M cells and 16B depicts the ability of Ab #6 to inhibit phosphorylation of AKT in MALME-3M cells.
  • Figures 17A-D are graphs depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit (A) ovarian (ADRr cells), (B) prostate Dul45 cells), (C) ovarian (0vCAR8 cells), and (D) pancreatic (Colo357 cells) tumor growth via xenograft studies.
  • Ab #6 anti-ErbB3 antibody
  • Figures 18Aand 18B are graphs depicting the ability of Ab #6 ( Figure 18A) and Fab for Ab #3 ( Figure 18B) to inhibit heregulin binding to ErbB3 on MALME-3M cells, as measured using FACS analysis.
  • Figures 19Aand 19B are graphs depicting the ability of Ab #6 to inhibit the binding of epiregulin to ErbB3 on ADRr cells.
  • Figure 19A depicts the binding of epiregulin to ADRr cells
  • Figure 19B depicts the ability of both Erbitux and Ab #6 to inhibit epiregulin binding to ADRr cells.
  • Figures 2OA and 2OB are graphs depicting the ability of heparin binding epidermal growth factor (HB-EGF) to bind ErbB on ADRr cells ( Figure 20A) and the inability of an anti-ErbB3 antibody (Ab #6) to inhibit such binding ( Figure 20B).
  • HB-EGF heparin binding epidermal growth factor
  • Figures 21 A-21C show the amino acid sequences of the variable heavy and light chain regions of antibodies: Ab #6, Ab #3, Ab #14, Ab #17, and Ab #19.
  • Figures 22A-22B show the nucleotide sequences of the variable heavy and light chain regions of antibodies: Ab #6, Ab #3, and Ab #14.
  • Figure 23 shows the amino acid sequences of the variable light chain regions of antibodies: Ab #6, Ab #17, and Ab #19, which have been reverted to the corresponding germline amino acid sequence. Amino acid residue changes are underlined.
  • Figures 24A-24C are graphs showing the ability of Ab #6 to inhibit VEGF secretion of tumor cells.
  • Figure 25 is a graph showing the effect of Ab #6 on cell migration.
  • Figures 26 A-C are graphs showing (A) inhibition of spheroid growth in AdrR cells, (B) inhibition of HRG induced spheroid growth in AdrR, and (C) inhibition of HRG induced spheroid growth in Du 145 cells.
  • Figures 27 A and B are graphs showing the effect of Ab #6 on (A) HRG and (B) BTC binding to AdrR cells.
  • Figure 28 is a graph showing the effect of Ab #6 on HGF induced ErbB3 phosphorylation.
  • Figures 29 A and B show the effect of Ab #6 on phosphorylation of (A) pErbBl and pErbB3 and (B) HRG induced ErbB2/3 complex formation.
  • Figure 30 is a graph showing Ab #6 binds amino acid residues 20-202 of ErbB3.
  • ErbB3 refers human ErbB3 protein, as described in U.S. Pat. No. 5,480,968 and Plowman et al., Proc. Natl. Acad. Sci. USA, 87:4905-4909 (1990); see, also, Kani et al., Biochemistry 44: 15842-857 (2005), Cho and Leahy, Science 297: 1330- 1333 (2002)).
  • EGF-like ligand refers to ligands of epidermal growth factor receptor (EGFR), including epidermal growth factor (EGF) and closely related proteins, such as transforming growth factor- ⁇ (TGF- ⁇ ), betacellulin (BTC), heparin-binding epidermal growth factor (HB-EGF), biregulin (BIR) and amphiregulin (AR), which bind to EGFR on the surface of cells and stimulate the receptor's intrinsic protein-tyrosine kinase activity.
  • EGF- ⁇ transforming growth factor- ⁇
  • BTC betacellulin
  • HB-EGF heparin-binding epidermal growth factor
  • BIR biregulin
  • AR amphiregulin
  • EGF-like ligands induce formation of EGFR (also referred to as ErbBl) and ErbB3 protein complex (see e.g., Kim et al., (1998) Biochem J., 334: 189-195), which results in phosphorylation of tyrosine residues in the complex.
  • EGFR also referred to as ErbBl
  • ErbB3 protein complex see e.g., Kim et al., (1998) Biochem J., 334: 189-195
  • the antibodies and antigen binding portions thereof of the present invention inhibit EGF-like ligand mediated phosphorylation of ErbB3 and, in certain embodiments, exhibit one or more of the following additional properties: (i) inhibition of one or more of heregulin, epiregulin, epigen and biregulin (BIR)-mediated signaling through ErbB3; (ii) inhibition of proliferation of cells expressing ErbB3; (iii) the ability to decrease levels of ErbB3 on cell surfaces; (iv) inhibition of VEGF secretion of cells expressing ErbB3; (v) inhibition of the migration of cells expressing ErbB3; (vi) inhibition of spheroid growth of cells expressing ErbB3; and/or (vii) binding to an epitope located on domain I of ErbB3, e.g., an epitope which involves or spans residues 20-202 of the amino acid sequence of ErbB3.
  • BIR biregulin
  • inhibitor refers to any statistically significant decrease in biological activity, including full blocking of the activity.
  • “inhibition” can refer to a decrease of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% in biological activity.
  • the phrase “inhibition of EGF-like ligand mediated phosphorylation of ErbB3,” as used herein, refers to the ability of an antibody or antigen binding portion to statistically significantly decrease the phosphorylation of ErbB3 induced by an EGF- like ligand, relative to the phosphorylation in an untreated (control) cell.
  • the cell which expresses ErbB3 can be a naturally occurring cell or cell line or can be recombinantly produced by introducing nucleic acid encoding ErbB3 into a host cell.
  • the antibody or antigen binding portion thereof inhibits EGF-like ligand mediated phosphorylation of ErbB3 by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100%, as determined, for example, by Western blotting followed by probing with an anti-phosphotyrosine antibody as described in Kim et al., (1998) Biochem J., 334:189-195 and the Examples infra.
  • the phrase "inhibition of heregulin, epiregulin, epigen or biregulin-mediated signaling through ErbB3,” as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease signaling mediated by an ErbB3 ligand (e.g., heregulin, epiregullin, epigen and biregulin) through ErbB3, relative to the signaling in the absence of the antibody (control).
  • an ErbB3 ligand e.g., heregulin, epiregullin, epigen and biregulin
  • ErbB3-ligands are also referred to herein as "heregulin-like ligands.” This means that, in the presence of the antibody or antigen binding portion thereof, a signal mediated in a cell expressing ErbB3 by one or more of heregulin, epiregulin, epigen and biregulin, relative to a control (no antibody), is statistically significantly decreased.
  • An ErbB3-ligand mediated signal can be measured by assaying for the level or activity of an ErbB3 substrate, and/or a protein which is present in a cellular cascade involving ErbB3.
  • the antibody or antigen binding portion thereof decreases the level or activity of an ErbB3 substrate and/or that of a protein in a cellular cascade involving ErbB3, by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% relative to the level or activity in the absence of such antibody or antigen binding portion thereof (control).
  • ErbB3- ligand mediated signaling can be measured using art recognized techniques which measure the level or activity of a substrate of ErbB3 (e.g., SHC or PI3K) or a protein in a cellular cascade involving ErbB3 (e.g., AKT) using kinase assays for such proteins (see, e.g., Horst et al. supra, Sudo et al. (2000) Methods Enzymol, 322:388-92; and Morgan et al. (1990) Eur. J. Biochem., 191:761-767).
  • a substrate of ErbB3 e.g., SHC or PI3K
  • AKT a protein in a cellular cascade involving ErbB3
  • the antibody or antigen binding portion thereof inhibits ErbB3-ligand (e.g., heregulin, epiregulin, epigen or biregulin) mediated signaling through ErbB3 by inhibiting the binding of the ErbB3-ligand (e.g., one or more of heregulin, epiregulin, epigen or biregulin) to ErbB3.
  • ErbB3-ligand e.g., one or more of heregulin, epiregulin, epigen or biregulin
  • Some ligands e.g., biregulin or BIR
  • an ErbB3 ligand e.g., one or more of heregulin, epiregulin, epigen or biregulin
  • the amount of an ErbB3 ligand which binds ErbB3 may be decreased in the presence of an antibody or antigen binding portion thereof of the invention by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% relative to the amount in the absence of the antibody or antigen binding portion thereof (control).
  • a decrease in ErbB3-ligand binding can be measured using art recognized techniques which measure the level of binding of labeled ErbB3-ligand (e.g., radiolabeled heregulin, epiregulin, epigen or biregulin) to cells expressing ErbB3 in the presence or absence (control) of the antibody or antigen binding portion thereof.
  • the phrase "inhibition of proliferation of a cell expressing ErbB3,” as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease proliferation of a cell expressing ErbB3 relative to the proliferation in the absence of the antibody.
  • the proliferation of a cell expressing ErbB3 (e.g., a cancer cell) may be decreased by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen binding portion thereof of the present invention, relative to the proliferation measured in the absence of the antibody or antigen binding portion thereof (control).
  • Cellular proliferation can be assayed using art recognized techniques which measure rate of cell division, the fraction of cells within a cell population undergoing cell division, and/or rate of cell loss from a cell population due to terminal differentiation or cell death (e.g., using a cell titer glow assay or thymidine incorporation).
  • the ability to decrease levels of ErbB3 on cell surfaces refers to the ability of an antibody or antigen binding portion thereof to statistically significantly reduce the amount of ErbB3 found on the surface of a cell which has been exposed to the antibody relative to an untreated (control) cell.
  • a decrease in levels of ErbB3 on cell surfaces may result from increased internalization of ErbB3 (or increased ErbB3 endocytosis).
  • the antibody or antigen binding portion thereof decreases cell surface expression of ErbB3 by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% and/or increases internalization of the ErbB3 receptor by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% relative to the cell surface expression or internalization in the absence of the antibody or antigen binding portion thereof (control).
  • the levels of ErbB3 on surfaces of cells and/or internalization of the ErbB3 receptor in the absence and the presence of an antibody or antigen-binding portion thereof can be readily measured using art recognized techniques, such as those described in Horst et al., supra and in the examples herein.
  • the phrase "inhibition of VEGF secretion of cells expressing ErbB3," as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease VEGF secretion of a cell expressing ErbB3 relative to the VEGF secretion in the absence of the antibody.
  • the VEGF secretion of a cell expressing ErbB3 may be decreased by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen binding portion thereof of the present invention, relative to the VEGF secretion measured in the absence of the antibody or antigen binding portion thereof (control).
  • VEGF secretion can be assayed using art recognized techniques, such as those described herein.
  • the phrase "inhibition of the migration of cells expressing ErbB3,” as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease the migration of a cell expressing ErbB3 relative to the migration of the cell in the absence of the antibody.
  • the migration of a cell expressing ErbB3 (e.g., a cancer cell) may be decreased by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen binding portion thereof of the present invention, relative to cell migration measured in the absence of the antibody or antigen binding portion thereof (control).
  • Cell migration can be assayed using art recognized techniques, such as those described herein.
  • inhibitortion of spheroid growth of cells expressing ErbB3 refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease the migration of a cell expressing ErbB3 relative to the migration of the cell in the absence of the antibody.
  • the migration of a cell expressing ErbB3 may be decreased by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen binding portion thereof of the present invention, relative to cell migration measured in the absence of the antibody or antigen binding portion thereof (control).
  • Cell migration can be assayed using art recognized techniques, such as those described herein.
  • the term "antibody” or "immunoglobulin,” as used interchangeably herein, includes whole antibodies and any antigen binding fragment (i.e., "antigen- binding portion") or single chains thereof.
  • An “antibody” comprises at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as V H ) and a heavy chain constant region.
  • the heavy chain constant region is comprised of three domains, CHl, CH2 and CH3.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as V L ) and a light chain constant region.
  • the light chain constant region is comprised of one domain, CL.
  • the V H and V L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • Each V H and V L is composed of three CDRs and four FRs, arranged from amino- te ⁇ ninus to carboxy-terminus in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (CIq) of the classical complement system.
  • Exemplary antibodies of the invention include antibodies#l, 3 and 14, and antigen-binding portions thereof.
  • antibody portion refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., ErbB3). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
  • binding fragments encompassed within the term "antigen- binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V L , V H , CL and CHl domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (Hi) a Fd fragment consisting of the V H and CHl domains; (iv) a Fv fragment consisting of the V L and V H domains of a single arm of an antibody, (v) a dAb including VH and VL domains; (vi) a dAb fragment (Ward et al.
  • V H domain a dAb which consists of a VH or a VL domain
  • CDR an isolated complementarity determining region
  • ix a combination of two or more isolated CDRs which may optionally be joined by a synthetic linker.
  • the two domains of the Fv fragment, V L and V H are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V L and V H regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al.
  • scFv single chain Fv
  • Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody.
  • antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.
  • Antigen-binding portions can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact immunoglobulins.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
  • Monoclonal antibodies can be prepared using any art recognized technique and those described herein such as, for example, a hybridoma method, as described by Kohler et al (1975) Nature, 256:495, a transgenic animal, as described by, for example, (see e.g., Lonberg, et al. (1994) Nature 368(6474): 856-859), recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567), or using phage antibody libraries using the techniques described in, for example, Clackson et al, Nature, 352:624-628 (1991) and Marks et al, J. MoI. Biol, 222:581-597 (1991). Monoclonal antibodies include chimeric antibodies, human antibodies and humanized antibodies and may occur naturally or be recombinantly produced.
  • recombinant antibody refers to antibodies that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for immunoglobulin genes (e.g., human immunoglobulin genes) or a hybridoma prepared therefrom, (b) antibodies isolated from a host cell transformed to express the antibody, e.g., from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial antibody library (e.g., containing human antibody sequences) using phage display, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of immunoglobulin gene sequences (e.g., human immunoglobulin genes) to other DNA sequences.
  • a host cell transformed to express the antibody e.g., from a transfectoma
  • combinatorial antibody library e.g., containing human antibody sequences
  • Such recombinant antibodies may have variable and constant regions derived from human germline immunoglobulin sequences.
  • such recombinant human antibodies can be subjected to in vitro mutagenesis and thus the amino acid sequences of the V H and V L regions of the recombinant antibodies are sequences that, while derived from and related to human germline V H and V L sequences, may not naturally exist within the human antibody germline repertoire in vivo.
  • chimeric immunoglobulin refers to an immunoglobulin or antibody whose variable regions derive from a first species and whose constant regions derive from a second species. Chimeric immunoglobulins or antibodies can be constructed, for example by genetic engineering, from immunoglobulin gene segments belonging to different species.
  • human antibody as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences as described, for example, by Kabat et al. (See Kabat, et al. (1991) Sequences of proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242).
  • the constant region also is derived from human germline immunoglobulin sequences.
  • the human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • the term "human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • the human antibody can have at least one ore more amino acids replaced with an amino acid residue, e.g., an activity enhancing amino acid residue which is not encoded by the human germline immunoglobulin sequence.
  • the human antibody can have up to twenty positions replaced with amino acid residues which are not part of the human germline immunoglobulin sequence. In a particular embodiment, these replacements are within the CDR regions as described in detail below.
  • the term "humanized immunoglobulin” or “humanized antibody” refers to an immunoglobulin or antibody that includes at least one humanized immunoglobulin or antibody chain (i.e., at least one humanized light or heavy chain).
  • humanized immunoglobulin chain or “humanized antibody chain” (i.e., a “humanized immunoglobulin light chain” or “humanized immunoglobulin heavy chain”) refers to an immunoglobulin or antibody chain (i.e., a light or heavy chain, respectively) having a variable region that includes a variable framework region substantially from a human immunoglobulin or antibody and complementarity determining regions (CDRs) (e.g., at least one CDR, preferably two CDRs, more preferably three CDRs) substantially from a non-human immunoglobulin or antibody, and further includes constant regions (e.g., at least one constant region or portion thereof, in the case of a light chain, and preferably three constant regions in the case of a heavy chain).
  • CDRs complementarity determining regions
  • humanized variable region refers to a variable region that includes a variable framework region substantially from a human immunoglobulin or antibody and complementarity determining regions (CDRs) substantially from a non-human immunoglobulin or antibody.
  • CDRs complementarity determining regions
  • bispecific or “bifunctional antibody” is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites.
  • Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab 1 fragments. See, e.g., Songsivilai & Lachmann, (1990) Clin. Exp. Immunol. 79, 315-321; Kostelny et al. (1992) J. Immunol. 148, 1547-1553.
  • a bispecific antibody according to the present invention includes binding sites for both ErbB3 and IGFl-R (i.e., insulin-like growth factor 1-receptor).
  • a bispecific antibody according to the present invention includes binding sites for both ErbB3 and C-MET.
  • a bispecific antibody includes a binding site for ErbB3 and a binding site for ErbB2, ERbB3, ErbB4, EGFR, Lewis Y, MUC-I, EpCAM, CA125, prostate specific membrane antigen, PDGFR- ⁇ , PDGFR- ⁇ , C-KIT, or any of the FGF receptors.
  • a heterologous antibody is defined in relation to the transgenic non-human organism or plant producing such an antibody.
  • an “isolated antibody,” as used herein, is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to ErbB3 is substantially free of antibodies that specifically bind antigens other than ErbB3).
  • an isolated antibody is typically substantially free of other cellular material and/or chemicals.
  • a combination of "isolated" monoclonal antibodies having different ErbB3 binding specificities are combined in a well defined composition.
  • “isotype” refers to the antibody class (e.g., IgM or IgGl) that is encoded by heavy chain constant region genes.
  • an antibody or antigen binding portion thereof is of an isotype selected from an IgGl, an IgG2, an IgG3, an IgG4, an IgM, an IgAl, an IgA2, an IgAsec, an IgD, or an IgE antibody isotype.
  • a monoclonal antibody of the invention is of the IgGl isotype. In other embodiments, a monoclonal antibody of the invention is of the IgG2 isotype.
  • isotype switching refers to the phenomenon by which the class, or isotype, of an antibody changes from one Ig class to one of the other Ig classes.
  • nonswitched isotype refers to the isotypic class of heavy chain that is produced when no isotype switching has taken place; the CH gene encoding the nonswitched isotype is typically the first CH gene immediately downstream from the functionally rearranged VDJ gene. Isotype switching has been classified as classical or non-classical isotype switching. Classical isotype switching occurs by recombination events which involve at least one switch sequence regions in a gene encoding an antibody.
  • Non-classical isotype switching may occur by, for example, homologous recombination between human ⁇ ⁇ and human ⁇ ⁇ ( ⁇ -associated deletion).
  • Alternative non-classical switching mechanisms such as intertransgene and/or interchromosomal recombination, among others, may occur and effectuate isotype switching.
  • switch sequence refers to those DNA sequences responsible for switch recombination.
  • a "switch donor" sequence typically a ⁇ switch region, will be 5' (i.e., upstream) of the construct region to be deleted during the switch recombination.
  • the "switch acceptor" region will be between the construct region to be deleted and the replacement constant region (e.g., ⁇ , ⁇ , etc.). As there is no specific site where recombination always occurs, the final gene sequence will typically not be predictable from the construct.
  • an “antigen” is an entity (e.g., a proteinaceous entity or peptide) to which an antibody or antigen-binding portion thereof binds.
  • an antigen is ErbB3 or a ErbB3-like molecule.
  • an antigen is human ErbB3.
  • epitopes refers to a site on an antigen to which an immunoglobulin or antibody specifically binds.
  • Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents.
  • An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation.
  • Methods of determining spatial conformation of epitopes include techniques in the art and those described herein, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g. , Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E. Morris, Ed. (1996).
  • antibodies that bind the same or an overlapping epitope as the antibodies of the present invention i.e., antibodies that compete for binding to ErbB3, or bind epitopes which overlap with epitopes bound by the antibodies described herein, i.e., an epitope located on domain I of ErbB3.
  • Antibodies that recognize the same epitope can be identified using routine techniques such as an immunoassay, for example, by showing the ability of one antibody to block the binding of another antibody to a target antigen, i.e., a competitive binding assay.
  • Competitive binding is determined in an assay in which the immunoglobulin under test inhibits specific binding of a reference antibody to a common antigen, such as ErbB3.
  • RIA solid phase direct or indirect radioimmunoassay
  • EIA solid phase direct or indirect enzyme immunoassay
  • sandwich competition assay see Stahli et al., (1983) Methods in Enzymology 9:242
  • solid phase direct biotin-avidin EIA see Kirkland et al, (1986) J. Immunol. 137:3614
  • solid phase direct labeled assay solid phase direct labeled sandwich assay
  • solid phase direct label RIA using 1-125 label see Morel et al., (1988) MoI. Immunol.
  • the terms “specific binding,” “specifically binds,” “selective binding,” and “selectively binds,” mean that an antibody or antigen-binding portion thereof, exhibits appreciable affinity for a particular antigen or epitope and, generally, does not exhibit significant cross-reactivity with other antigens and epitopes.
  • “Appreciable” or preferred binding includes binding with an affinity of at least 10 6 , 10 7 , 10 8 , 10 9 M “1 , or 10 10 M "1 . Affinities greater than 10 7 M '1 , preferably greater than 10 8 M "1 are more preferred.
  • a preferred binding affinity can be indicated as a range of affinities, for example, 10 6 to 10 10 M “1 , preferably 10 7 to 10 10 M " ⁇ more preferably 10 8 to 10 10 M “1 .
  • An antibody that "does not exhibit significant cross- reactivity" is one that will not appreciably bind to an undesirable entity (e.g., an undesirable proteinaceous entity).
  • an antibody or antigen-binding portion thereof that specifically binds to ErbB3 will appreciably bind that ErbB3 molecule but will not significantly react with other ErbB molecules and non- ErbB proteins or peptides.
  • Specific or selective binding can be determined according to any art-recognized means for determining such binding, including, for example, according to Scatchard analysis and/or competitive binding assays.
  • K D is intended to refer to the dissociation equilibrium constant of a particular antibody-antigen interaction or the affinity of an antibody for an antigen.
  • the antibody or antigen binding portion thereof according to the present invention binds an antigen (e.g., ErbB3) with an affinity (K D ) of 50 nM or better (i.e., or less) (e.g., 40 nM or 30 nM or 20 nM or 10 nM or less), as measured using a surface plasmon resonance assay or a cell binding assay.
  • an antibody or antigen binding portion thereof binds ErbB3 with an affinity (K D ) of 8 nM or better (e.g., 7 nM, 6 nM, 5 nM, 4 nM, 2 nM, 1.5 nM, 1.4 nM, 1.3 nM, InM or less), as measured by a surface plasmon resonance assay or a cell binding assay.
  • K D affinity
  • an antibody or antigen binding portion thereof binds an antigen (e.g., ErbB3) with an affinity (KD) of approximately less than 10 "7 M, such as approximately less than 10 "8 M, 10 '9 M or 10 '10 M or even lower when determined by surface plasmon resonance (SPR) technology in a BIACORE 3000 instrument using recombinant ErbB3 as the analyte and the antibody as the ligand, and binds to the predetermined antigen with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.
  • an antigen e.g., ErbB3
  • KD affinity
  • KD surface plasmon resonance
  • K 0Jf is intended to refer to the off rate constant for the dissociation of an antibody from the antibody/antigen complex.
  • EC50 refers to the concentration of an antibody or an antigen-binding portion thereof, which induces a response, either in an in vitro or an in vivo assay, which is 50% of the maximal response, i.e., halfway between the maximal response and the baseline.
  • glycosylation pattern is defined as the pattern of carbohydrate units that are covalently attached to a protein, more specifically to an immunoglobulin protein.
  • naturally-occurring refers to the fact that an object can be found in nature.
  • a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.
  • rearranged refers to a configuration of a heavy chain or light chain immunoglobulin locus wherein a V segment is positioned immediately adjacent to a D-J or J segment in a conformation encoding essentially a complete V H or V L domain, respectively.
  • a rearranged immunoglobulin gene locus can be identified by comparison to germline DNA; a rearranged locus will have at least one recombined heptamer/nonamer homology element.
  • nucleic acid molecule as used herein, is intended to include DNA molecules and RNA molecules.
  • a nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.
  • isolated nucleic acid molecule as used herein in reference to nucleic acids encoding antibodies or antibody portions (e.g., V H , V L , CDR3) that bind to ErbB3, is intended to refer to a nucleic acid molecule in which the nucleotide sequences encoding the antibody or antibody portion are free of other nucleotide sequences encoding antibodies that bind antigens other than ErbB3, which other sequences may naturally flank the nucleic acid in human genomic DNA.
  • modifying or “modification,” as used herein, is intended to refer to changing one or more amino acids in the antibodies or antigen-binding portions thereof. The change can be produced by adding, substituting or deleting an amino acid at one or more positions.
  • the change can be produced using known techniques, such as PCR mutagenesis.
  • an antibody or an antigen-binding portion thereof identified using the methods of the invention can be modified, to thereby modify the binding affinity of the antibody or antigen-binding portion thereof to ErbB3.
  • the present invention also encompasses "conservative amino acid substitutions" in the sequences of the antibodies of the invention, i.e., nucleotide and amino acid sequence modifications which do not abrogate the binding of the antibody encoded by the nucleotide sequence or containing the amino acid sequence, to the antigen, i.e., ErbB3.
  • Conservative amino acid substitutions include the substitution of an amino acid in one class by an amino acid of the same class, where a class is defined by common physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature, as determined, for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix.
  • Six general classes of amino acid side chains have been categorized and include: Class I (Cys); Class II (Ser, Thr, Pro, Ala, GIy); Class III (Asn, Asp, GIn, GIu); Class IV (His, Arg, Lys); Class V (He, Leu, VaI, Met); and Class VI (Phe, Tyr, Trp).
  • substitution of an Asp for another class III residue such as Asn, GIn, or GIu is a conservative substitution.
  • a predicted nonessential amino acid residue in an anti-ErbB3 antibody is preferably replaced with another amino acid residue from the same class.
  • non-conservative amino acid substitution refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, GIu, or GIn.
  • mutations can be introduced randomly along all or part of an anti-ErbB3 antibody coding sequence, such as by saturation mutagenesis, and the resulting modified anti- ErbB3 antibodies can be screened for binding activity.
  • a "consensus sequence” is a sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence.
  • a "consensus framework" of an immunoglobulin refers to a framework region in the consensus immunoglobulin sequence.
  • the consensus sequence for the CDRs of can be derived by optimal alignment of the CDR amino acid sequences of ErbB3 antibodies of the present invention.
  • nucleic acids For nucleic acids, the term "substantial homology" indicates that two nucleic acids, or designated sequences thereof, when optimally aligned and compared, are identical, with appropriate nucleotide insertions or deletions, in at least about 80% of the nucleotides, usually at least about 90% to 95%, and more preferably at least about 98% to 99.5% of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to the complement of the strand.
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
  • the percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.
  • the percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM 120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
  • the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. MoI. Biol.
  • the nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify related sequences.
  • Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. MoI. Biol. 215:403-10.
  • Gapped BLAST can be utilized as described in Altschul et al, (1997) Nucleic Acids Res. 25(17):3389-3402.
  • the default parameters of the respective programs ⁇ e.g., XBLAST and NBLAST.
  • the nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.
  • a nucleic acid is "isolated” or “rendered substantially pure” when purified away from other cellular components or other contaminants, e.g., other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis and others well known in the art. See, F. Ausubel, et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
  • nucleic acid compositions of the present invention while often in a native sequence (except for modified restriction sites and the like), from either cDNA, genomic or mixtures thereof may be mutated, in accordance with standard techniques to provide gene sequences. For coding sequences, these mutations, may affect amino acid sequence as desired.
  • DNA sequences substantially homologous to or derived from native V, D, J, constant, switches and other such sequences described herein are contemplated (where "derived” indicates that a sequence is identical or modified from another sequence).
  • operably linked refers to a nucleic acid sequence placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites.
  • a nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence.
  • operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.
  • operably linked indicates that the sequences are capable of effecting switch recombination.
  • vector is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments may be ligated.
  • viral vector Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • vectors e.g., non-episomal mammalian vectors
  • vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • certain vectors are capable of directing the expression of genes to which they are operatively linked.
  • Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors”).
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and vector may be used interchangeably.
  • the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno- associated viruses), which serve equivalent functions.
  • recombinant host cell (or simply “host cell”), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein.
  • the methods of "treatment” employ administration to a subject, an antibody or antigen binding portion of the present invention, for example, a subject having a disease or disorder associated with ErbB3 dependent signaling or predisposed to having such a disease or disorder, in order to prevent, cure, delay, reduce the severity of, or ameliorate one or more symptoms of the disease or disorder or recurring disease or disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
  • disease associated with ErbB3 dependent signaling or “disorder associated with ErbB3 dependent signaling,” as used herein, includes disease states and/or symptoms associated with a disease state, where increased levels of ErbB3 and/or activation of cellular cascades involving ErbB3 are found.
  • the term “disease associated with ErbB3 dependent signaling,” also includes disease states and/or symptoms associated with disease states where increased levels of EGFR/ErbB3 and/or ErbB2/ErbB3 heterodimers are found.
  • the term “disease associated with ErbB3 dependent signaling” refers to any disorder, the onset, progression or the persistence of the symptoms of which requires the participation of ErbB3.
  • Exemplary ErbB3 -mediated disorders include, but are not limited to, for example, cancer.
  • cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
  • cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, melanoma, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.
  • a cancer treated or diagnosed using the methods of the present invention is selected from melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal/colon cancer, lung cancer, and prostate cancer.
  • an effective amount refers to that amount of an antibody or an antigen binding portion thereof that binds ErbB3, which is sufficient to effect treatment, prognosis or diagnosis of a disease associated with ErbB3 dependent signaling, as described herein, when administered to a subject.
  • a therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • the dosages for administration can range from, for example, about 1 ng to about 10,000 mg, about 5 ng to about 9,500 mg, about 10 ng to about 9,000 mg, about 20 ng to about 8,500 mg, about 30 ng to about 7,500 mg, about 40 ng to about 7,000 mg, about 50 ng to about 6,500 mg, about 100 ng to about 6,000 mg, about 200 ng to about 5,500 mg, about 300 ng to about 5,000 mg, about 400 ng to about 4,500 mg, about 500 ng to about 4,000 mg, about 1 ⁇ g to about 3,500 mg, about 5 ⁇ g to about 3,000 mg, about 10 ⁇ g to about 2,600 mg, about 20 ⁇ g to about 2,575 mg, about 30 ⁇ g to about 2,550 mg, about 40 ⁇ g to about 2,500 mg, about 50 ⁇ g to about 2,475 mg, about 100 ⁇ g to about 2,450 mg, about 200 ⁇ g to about 2,425 mg, about 300 ⁇ g to about 2,000, about 400 ⁇ g to about 1,175 mg
  • patient includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.
  • the term "subject” includes any human or non-human animal.
  • the methods and compositions of the present invention can be used to treat a subject having cancer.
  • the subject is a human.
  • non-human animal includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.
  • sample refers to tissue, body fluid, or a cell from a patient or a subject. Normally, the tissue or cell will be removed from the patient, but in vivo diagnosis is also contemplated.
  • a tissue sample can be taken from a surgically removed tumor and prepared for testing by conventional techniques.
  • lymphomas and leukemias lymphocytes, leukemic cells, or lymph tissues can be obtained and appropriately prepared.
  • Other patient samples including urine, tear drops, serum, cerebrospinal fluid, feces, sputum, cell extracts etc. can also be useful for particular tumors.
  • anti-cancer agent and “antineoplastic agent” refer to drugs used to treat malignancies, such as cancerous growths. Drug therapy may be used alone, or in combination with other treatments such as surgery or radiation therapy. Several classes of drugs may be used in cancer treatment, depending on the nature of the organ involved. For example, breast cancers are commonly stimulated by estrogens, and may be treated with drugs which inactive the sex hormones. Similarly, prostate cancer may be treated with drugs that inactivate androgens, the male sex hormone.
  • Anti-cancer agents of the present invention include, among others, the following agents:
  • Antibodies which bind Al 2 (fully humanized mAb)
  • Antibodies which bind AVEO (AV299) (AVEO) cMET (Mesenchymal AMG102 (Amgen) epithelial transition 5D5 (OA-5D5) (Genentech) factor); a member of the MET family of receptor tyrosine kinases)
  • Anti-ErbB3 antibodies Ab #14 (MM 121-14) described herein which bind different Herceptin® (Trastuzumab; Genentech) epitopes 1B4C3; 2D1D12 (U3 Pharma AG)
  • IGF-IR insulin-like NVP-AEW541-A Targeting IGFlR growth factor type 1 BMS-536,924 (lH-benzoimidazol-2-yl)-lH- receptor), which is pyridin-2-one expressed on the cell BMS-554,417 surface of must human Cycloligan cancers TAE226
  • EGFR epidermal growth Iressa® / Gefitinib (AstraZeneca) Targeting EGFR factor receptor
  • CI-1033 PD 183805) (Pfizer) Mutations affecting Lapatinib (GW-572016) (GlaxoSmithKline) EGFR expression or Tykerb® / Lapatinib Ditosylate (SmithKline activity could result in Beecham) cancer Tarceva®/ Erlotinib HCL (OSI-774) (OSI
  • cMET Mesenchymal PHA665752 Targeting cMET epithelial transition ARQ 197 factor
  • a member of the MET family of receptor tyrosine kinases a member of the MET family of receptor tyrosine kinases
  • An antimetabolite is a Flourouracil (5-FU) chemical with a similar Capecitabine / XELODA® (HLR Roche) structure to a substance (a 5-Trifluoromethyl-2'-deoxyuridine metabolite) required for Methotrexate sodium (Trexall) (Barr) normal biochemical Raltitrexed / Tomudex® (AstraZaneca) reactions, yet different Pemetrexed / Alimta® (Lilly) enough to interfere with Tegafur the normal functions of Cytosine Arabinoside (Cytarabine, Ara-C) / cells, including cell Thioguanine® (GlaxoSmithKline) division. 5-azacytidine
  • 6-mercaptopurine (Mercaptopurine, 6-MP)
  • 6-thioguanine (6-TG) / Purinethol® (TEVA)
  • Pentostatin / Nipent® Hospira Inc.
  • RNR Ribonucleotide Reductase Inhibitor
  • BMS Cyclophosphamide / Cytoxan alkylating agent that Neosar (TEVA) attaches an alkyl group to Ifosfamide /Mitoxana® (ASTA Medica) DNA.
  • TEVA Neosar
  • Hexamethylmelamine (Altretamine, HMM) / more sensitive to DNA
  • Busulfan / Myleran (GlaxoSmithKline) agents are used clinically
  • Topoisomerase Topoisomerase inhibitors Doxorubicin HCL / Doxil® (Alza) inhibitors are chemotherapy agents Daunorubicin citrate / Daunoxome® (Gilead)
  • Microtubule Microtubules are one of Vincristine / Oncovin® (Lilly) the Vinblastine sulfate/Velban®(discontinued) targeting agents the components of cytoskeleton. They have (Lilly) diameter of ⁇ 24 run and Vinorelbine tartrate / Navelbine® length varying from (PierreFabre) several micrometers to Vindesine sulphate / Eldisine® (Lilly) possibly millimeters in Paclitaxel / Taxol® (BMS) axons of nerve cells.
  • Vincristine / Oncovin® Liilly
  • Vinblastine sulfate/Velban®(discontinued) targeting agents the components of cytoskeleton have (Lilly) diameter of ⁇ 24 run and Vinorelbine tartrate / Navelbine® length varying from (PierreFabre) several micrometers to Vindesine sulphate / Eldisine® (Lilly)
  • Docetaxel / Taxotere® (Sanofi Aventis US) Microtubules serve as Nanoparticle paclitaxel (ABI-007) / structural components Abraxane® (Abraxis BioScience, Inc.) within cells and are Ixabepilone / IXEMPRATM (BMS) involved in many cellular processes including mitosis, cytokinesis, and vesicular transport.
  • ABS Nanoparticle paclitaxel
  • BMS Ixabepilone / IXEMPRATM
  • Tyrosine kinases are Sunitinib malate / Sutent® (Pfizer) enzymes within the cell Sorafenib tosylate / Nexavar® (Bayer) that function to attach Nilotinib hydrochloride monohydrate / phosphate groups to the Tasigna® (Novartis) amino acid tyrosine. By blocking the ability of protein tyrosine kinases to function, these compounds provide a tool for controlling cancerous cell growth.
  • Raloxifene HCL / Evista® (Lilly) menopause and aging
  • Anastrazole / Arimidex® (AstraZeneca) seek to increase the
  • Leuprolide acetate / Eligard® declines.
  • Hormone Lupron® (TAP Pharm.) therapy as a cancer Goserelin acetate / Zoladex® (AstraZeneca) treatment either reduces Triptorelin pamoate / Trelstar® (Watson the level of specific Labs) hormones or alters the Buserelin / Suprefact® (Sanofi Aventis) cancer's ability to use Nafarelin these hormones to grow Cetrorelix / Cetrotide® (EMD Serono) and spread.
  • Bicalutamide / Casodex® (AstraZeneca)
  • Nilutamide / Nilandron® (Aventis Pharm.)
  • Glucocorticoids Anti-inflammatory drugs Prednisolone used to reduce swelling Dexamethasone / Decadron® (Wyeth) that causes cancer pain.
  • Aromatose inhibitors Includes imidazoles Ketoconazole
  • Rapamune® (Wyeth) pathway was originally Temsirolimus (CCI-779) / Torisel® (Wyeth) discovered during studies Deforolimus (AP23573) (Ariad Pharm.) of the Everolimus (RADOOl) /Certican® (Novartis) immunosuppressive agent rapamycin. This highly conserved pathway regulates cell proliferation and metabolism in response to environmental factors, linking cell growth factor receptor signaling via phosphoinositide-3 - kinase (PI-3K) to cell growth, proliferation, and angiogenesis.
  • PI-3K phosphoinositide-3 - kinase
  • Chemotherapeutic Adriamycin 5-Fluorouracil, Cytoxin, agents Bleomycin, Mitomycin C, Daunomycin,
  • One or more anti-cancer agents may be administered either simultaneously or before or after administration of an antibody or antigen binding portion thereof of the present invention.
  • Monoclonal antibodies of the invention can be produced using a variety of known techniques, such as the standard somatic cell hybridization technique described by Kohler and Milstein (1975) Nature 256: 495, viral or oncogenic transformation of B lymphocytes or phage display technique using libraries of human antibody genes.
  • the antibodies are fully human monoclonal antibodies.
  • a hybridoma method is used for producing an antibody that binds ErbB3.
  • a mouse or other appropriate host animal can be immunized with a suitable antigen in order to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the antigen used for immunization.
  • lymphocytes may be immunized in vitro. Lymphocytes can then be fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and
  • Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies:Principles and Practice, pp. 59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI- 1640 medium.
  • the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • the monoclonal antibodies secreted by the subclones can be separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • antibodies and antibody portions that bind ErbB3 can be isolated from antibody phage libraries generated using the techniques described in, for example, McCafferty et al, Nature, 348:552-554 (1990). Clackson et al, Nature, 352:624-628 (1991), Marks et al, J. MoI. Biol., 222:581-597 (1991) and Hoet et al (2005) Nature Biotechnology 23, 344-348 ; U.S. Patent Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner et al; U.S. Patent Nos. 5,427,908 and 5,580,717 to Dower et al; U. S.
  • the monoclonal antibody or antigen binding portion thereof that binds ErbB3 is produced using the phage display technique described by Hoet et al, supra. This technique involves the generation of a human Fab library having a unique combination of immunoglobulin sequences isolated from human donors and having synthetic diversity in the heavy-chain CDRs is generated. The library is then screened for Fabs that bind to ErbB3.
  • human monoclonal antibodies directed against ErbB3 can be generated using transgenic or transchromosomic mice carrying parts of the human immune system rather than the mouse system (see e.g., Lonberg, et al. (1994) Nature 368(6474): 856-859; Lonberg, N. et al (1994), supra; reviewed in Lonberg, N. (1994) Handbook of Experimental Pharmacology 113:49-101; Lonberg, N. and Huszar, D. (1995) Intern. Rev. Immunol 13: 65-93, and Harding, F. and Lonberg, N. (1995) Ann. NY. Acad Sci. 764:536-546. See further, U.S. Patent Nos.
  • human antibodies of the invention can be raised using a mouse that carries human immunoglobulin sequences on transgenes and transchomosomes, such as a mouse that carries a human heavy chain transgene and a human light chain transchromosome (see e.g., PCT Publication WO 02/43478 to Ishida et al).
  • alternative transgenic animal systems expressing human immunoglobulin genes are available in the art and can be used to raise anti-ErbB3 antibodies of the invention.
  • an alternative transgenic system referred to as the Xenomouse (Abgenix, Inc.) can be used; such mice are described in, for example, U.S. Patent Nos. 5,939,598; 6,075,181; 6,114,598; 6, 150,584 and 6,162,963 to Kucherlapati et al.
  • mice carrying both a human heavy chain transchromosome and a human light chain tranchromosome can be used; as described in Tomizuka et al. (2000) Proc. Natl. Acad Sci. USA 97:722-727.
  • cows carrying human heavy and light chain transchromosomes have been described in the art (Kuroiwa et al. (2002) Nature Biotechnology 20:889-894) and can be used to raise anti- ErbB3 antibodies of the invention.
  • antibodies of the present invention can be prepared using a transgenic plant and/or cultured plant cells (such as, for example, tobacco, maize and duckweed) that produce such antibodies.
  • transgenic tobacco leaves expressing antibodies or antigen binding portions thereof can be used to produce such antibodies by, for example, using an inducible promoter (see, e.g., Cramer et al., Curr. Top. Microbol. Immunol. 240:95 118 (1999)).
  • transgenic maize can be used to express such antibodies and antigen binding portions thereof (see, e.g., Hood et al., Adv. Exp. Med Biol. 464:127 147 (1999)).
  • Antibodies can also be produced in large amounts from transgenic plant seeds including antibody portions, such as single chain antibodies (scFv's), for example, using tobacco seeds and potato tubers (see, e.g., Conrad et al., Plant MoI. Biol. 38:101 109 (1998)).
  • Methods of producing antibodies or antigen binding portions in plants can also be found in, e.g., Fischer et al., Biotechnol. Appl. Biochem. 30:99 108 (1999), Ma et al, Trends Biotechnol. 13:522 7 (1995); Ma et al., Plant Physiol. 109:341 6 (1995); Whitelam et al, Biochem. Soc. Trans. 22:940 944 (1994) and U.S. Patent Nos. 6,040,498 and 6,815,184.
  • ErbB3 prepared using any technique including those disclosed here, can be determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme- linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme- linked immunoabsorbent assay
  • the binding affinity of a monoclonal antibody or portion thereof also can be determined by the Scatchard analysis of Munson et al, Anal. Biochem., 107:220 (1980).
  • an ErbB3 antibody or portion thereof produced using any of the methods discussed above may be further altered or optimized to achieve a desired binding specificity and/or affinity using art recognized techniques, such as those described herein.
  • partial antibody sequences derived from an ErbB3 antibody may be used to produce structurally and functionally related antibodies.
  • antibodies interact with target antigens predominantly through amino acid residues that are located in the six heavy and light chain complementarity determining regions (CDRs). For this reason, the amino acid sequences within CDRs are more diverse between individual antibodies than sequences outside of CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of specific naturally occurring antibodies by constructing expression vectors that include CDR sequences from the specific naturally occurring antibody grafted onto framework sequences from a different antibody with different properties (see, e.g., Riechmann, L.
  • Such framework sequences can be obtained from public DNA databases that include ge ⁇ nline antibody gene sequences.
  • an anti-ErbB3 antibody of the invention can be used to create structurally related anti-ErbB3 antibodies that retain at least one functional property of the antibodies of the invention, e.g., inhibiting EGF-like ligand mediated phosphorylation of ErbB3; inhibiting one or more of heregulin, epiregulin, epigen or biregulin-mediated signaling through ErbB3; inhibiting proliferation or cells expressing ErbB3; and/or decreasing levels of ErbB3 on cell surfaces.
  • one or more CDR regions selected from SEQ ID NOs:7-12, SEQ ID NOs: 13-18, SEQ ID NOs: 19-24, SEQ ID NOs:39-44, and SEQ ID NOs:45-50 is combined recombinantly with known human framework regions and CDRs to create additional, recombinantly-engineered, anti-ErbB3 antibodies of the invention.
  • the heavy and light chain variable framework regions can be derived from the same or different antibody sequences. It is well known in the art that antibody heavy and light chain CDR3 domains play a particularly important role in the binding specificity/affinity of an antibody for an antigen (see, Hall et al, J.
  • antibodies are generated that include the heavy and/or light chain CDR3s of the particular antibodies described herein (e.g., SEQ ED NOs:9, 15, 21, 41, 47 and/or SEQ ID NOs:12, 18, 24, 44, 50).
  • the antibodies can further include the heavy and/or light chain CDRl and/or CDR2s of the antibodies of the present invention (e.g., SEQ ID NOs:7-8 and/or SEQ ED NOs: 10-11; SEQ ID NOs: 13- 14 and/or SEQ ID NOs: 16-17; SEQ ID NOs:20-21 and/or SEQ ID NOs:22-23; SEQ ID NOs:39-40 and/or SEQ ID NOs:42-43; or SEQ ID NOs:45-46 and/or SEQ ID NOs:48- 49).
  • SEQ ID NOs:7-8 and/or SEQ ED NOs: 10-11 e.g., SEQ ID NOs: 13- 14 and/or SEQ ID NOs: 16-17
  • SEQ ID NOs:20-21 and/or SEQ ID NOs:22-23 e.g., SEQ ID NOs:39-40 and/or SEQ ID NOs:42-43
  • the CDRl, 2, and/or 3 regions of the engineered antibodies described above can comprise the exact amino acid sequence(s) as those disclosed herein (e.g., CDRs of Ab #6, Ab #3, Ab #14, Ab #17, or Ab #19, set forth in SEQ ID NOs:7-12, 13-18, 19-24, 39- 44, and 45-50, respectively).
  • the engineered antibody may be composed of one or more CDRs that are, for example, 90%, 95%, 98%, 99% or 99.5% identical to one or more CDRs of Ab #6, Ab #3 or Ab #14.
  • one or more residues of a CDR may be altered to modify binding to achieve a more favored on-rate of binding.
  • an antibody having ultra high binding affinity of, for example, 10 10 M '1 or more can be achieved.
  • Affinity maturation techniques well known in the art and those described herein, can be used to alter the CDR region(s) followed by screening of the resultant binding molecules for the desired change in binding. Accordingly, as CDR(s) are altered, changes in binding affinity as well as immunogenicity can be monitored and scored such that an antibody optimized for the best combined binding and low immunogenicity are achieved.
  • modifications can also be made within one or more of the framework regions, FRl, FR2, FR3 and FR4, of the heavy and/or the light chain variable regions of an antibody, so long as these modifications do not eliminate the binding affinity of the antibody.
  • the antibody is further modified with respect to effector function, so as to enhance the effectiveness of the antibody in treating cancer, for example.
  • cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176: 1191-1195 (1992) and Shopes, B. J. Immunol.
  • Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 53:2560-2565 (1993).
  • an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al. Anti-Cancer Drug Design 3:219-230 (1989).
  • bispecific antibodies and immunoconjugates are also encompassed by the present invention.
  • Bispecific antibodies of the present invention include at least one binding specificity for ErbB3 and at least one binding specificity for another antigen, such as the product of an oncogene.
  • Bispecific antibodies can be prepared as full length antibodies or antibody fragments ⁇ e.g. F(ab') 2 bispecific antibodies).
  • bispecific antibodies are well known in the art (see, e.g., WO 05117973 and WO 06091209).
  • production of full length bispecific antibodies can be based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (see, e.g., Millstein et al, Nature, 305:537-539 (1983)).
  • Further details of generating bispecific antibodies can be found, for example, in Suresh et al., Methods in Enzymology, 121:210 (1986) and in Brennan et al., Science, 229: 81 (1985), which describes a chemical linkage process for making bispecific antibodies.
  • bispecific antibodies have been produced using leucine zippers (see, e.g., Kostelny et al., J. Immunol, 148(5):1547-1553 (1992)).
  • Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported (see, e.g., Gruber et al, J. Immunol, 152:5368 (1994)).
  • the bispecific antibody comprises a first antibody or binding portion thereof which binds to ErbB3 and a second antibody or binding portion thereof which binds to ErbB2, ERbB3, ErbB4, EGFR, IGFl-R, C-MET, Lewis Y, MUC-I, EpCAM, CAl 25, prostate specific membrane antigen, PDGFR- ⁇ , PDGFR- ⁇ , C-KIT, or any of the FGF receptors.
  • Immunoconjugates of the present invention can be formed by conjugating the antibodies or antigen binding portions thereof described herein to another therapeutic agent.
  • Suitable agents include, for example, a cytotoxic agent (e.g., a chemotherapeutic agent), a toxin ⁇ e.g. an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), and/or a radioactive isotope (i.e., a radio conjugate).
  • Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes.
  • a variety of radionuclides are available for the production of radioconjugated anti-ErbB3 antibodies. Examples include 212 Bi, 131 1, 131 In, 90 Y and 186 Re.
  • Immunoconjugates of the invention can be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), d ⁇ socyanates (such as tolyene 2,6-d ⁇ socyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene).
  • SPDP N-succinimidyl-3
  • a ricin immunotoxin can be prepared as described in Yitetta et al., Science 238: 1098 (1987).
  • Carbon- 14-labeled 1- isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody (see, e.g., WO94/11026).
  • the antibodies or antigen binding portions thereof can be screened for various properties, such as those described herein, using a variety of assays that are well known in the art.
  • the antibodies or antigen binding portions thereof are screened for the ability to inhibit EGF- like ligand mediated phosphorylation of ErbB3. This can be done by treating cells expressing ErbB3 with an EGF-like ligand in the presence and absence of the antibody or antigen binding portion thereof. The cells can then be lysed and the crude lysates can be centrifuged to remove insoluble material. ErbB3 phosphorylation can be measured, for example, by Western blotting followed by probing with an anti-phosphotyrosine antibody as described in Kim et al, supra and the Examples below.
  • the antibodies and antigen binding portions are further screened for one or more of the following properties: (1) inhibition of ErbB3 -ligand ⁇ e.g., heregulin, epiregulin, epigen or biregulin) mediated signaling through ErbB3; (2) inhibition of proliferation of cells expressing ErbB3; (3) the ability to decrease levels of ErbB3 on cell surface (e.g., by inducing internalization of ErbB3), (4) inhibition of VEGF secretion of cells expressing ErbB3; (5) inhibition of the migration of cells expressing ErbB3; (6) inhibition of spheroid growth of cells expressing ErbB3; and/or (7) binding to an epitope located on domain I of ErbB3, each of which can be readily measured using art recognized techniques and those discussed herein.
  • ErbB3 -ligand ⁇ e.g., heregulin, epiregulin, epigen or biregulin
  • Inhibition of one or more of heregulin, epiregulin, epigen or biregulin-mediated signaling through ErbB3 can be readily measured using routine assays, such as, described in Horst et al. supra.
  • the ability of an antibody or antigen binding portion thereof to inhibit heregulin, epiregulin, epigen or biregulin-mediated signaling through ErbB3 can be measured by kinase assays for known substrates of ErbB3 such as, for example, SHC and PI3K, as described in, for example, Horst et al. supra, Sudo et al, (2000) Methods Enzymol, 322:388-92; and Morgan et al. (1990) Eur. J.
  • Biochem., 191:761-767 following stimulation by one or more of heregulin, epiregulin, epigen or biregulin. Accordingly, cells expressing ErbB3 can be stimulated with one or more of heregulin, epiregulin, epigen or biregulin, and incubated with a candidate antibody or antigen-binding portion thereof.
  • Cell lysates subsequently prepared from such cells can be immunoprecipitated with an antibody for a substrate of ErbB3 (or a protein in a cellular pathway involving ErbB3) such as, for example, an anti- JNK-I antibody, and assayed for kinase activity (e.g., JNK kinase activity or PI3- kinase activity) using art recognized techniques.
  • an antibody for a substrate of ErbB3 or a protein in a cellular pathway involving ErbB3
  • kinase activity e.g., JNK kinase activity or PI3- kinase activity
  • a decrease in or complete disappearance in level or activity (e.g., kinase activity) of a ErbB3 substrate or protein in a pathway involving ErbB3 in the presence of the antibody or antigen binding portion thereof, relative to the level or activity in the absence of the antibody or antigen binding portion thereof, is indicative of an antibody or antigen binding portion which inhibits one or more of heregulin, epiregulin, epigen or biregulin-mediated signaling.
  • the antibody or antigen binding portion thereof inhibits ErbB3-ligand (e.g., heregulin, epiregulin, epigen or biregulin) mediated signaling by decreasing the binding of one or more of heregulin, epiregulin, epigen or biregulin to ERbB3.
  • ErbB3-ligand e.g., heregulin, epiregulin, epigen or biregulin
  • cells which express ErbB3 e.g. MALME-3M cells, as described in the Examples infra
  • a labeled ErbB3-ligand e.g., radiolabeled heregulin, epiregulin, epigen or biregulin
  • the antibody or antigen binding portion thereof inhibits heregulin, epiregulin, epigen or biregulin binding to ErbB3, then a statistically significantly decrease in the amount of label recovered (e.g., radiolabeled heregulin, epiregulin, epigen or biregulin), relative to the amount in the absence of the antibody or antigen binding portion thereof, will be observed.
  • the antibody or antigen binding portion thereof may inhibit the binding of the ErbB3-ligand (e.g., heregulin, epiregulin, epigen or biregulin) by any mechanism.
  • the antibody or antigen binding portion thereof may inhibit binding of the ErbB3 ligand (e.g., one or more of heregulin, epiregulin, epigen or biregulin) to ErbB3 by binding to the same site or an overlapping site on ErbB3 as the ErbB3 ligand.
  • the ErbB3 ligand e.g., one or more of heregulin, epiregulin, epigen or biregulin
  • the antibody or antigen binding portion thereof may inhibit binding of an ErbB3 ligand by altering or distorting the conformation of ErbB3, such that it is unable to bind to the ErbB3 ligand.
  • Antibodies and antigen binding portions thereof that decrease levels of ErbB3 on cell surfaces can be identified by their ability to downregulate ErbB3 on tumor cells.
  • the antibodies or antigen binding portions thereof decrease ErbB3 cell surface expression by inducing internalization (or increasing endocytosis) of Erbb3.
  • ErbB3 can be biotinylated and the number of ErbB3 molecules on the cell surface can be readily determined, for example, by measuring the amount of biotin on a monolayer of cells in culture in the presence or absence of an antibody or antigen binding portion thereof, for example, as described in, e.g., Waterman et al., J. Biol. Chem.
  • Antibodies or antigen binding portions thereof of the present invention can also be tested for their ability to inhibit proliferation of cells expressing ErbB3, for example, tumor cells, using art recognized techniques, such as the Cell Titer Glow Assay described in the Examples below (also see, e.g., Macallan et al, Proc. Natl. Acad Sd. (1998) 20;95(2):708-13; Perez et al. (1995) Cancer Research 55, 392-398).
  • the antibodies or antigen binding portions thereof are screened for the ability to inhibit VEGF secretion of cells expressing ErbB3. This can be done by using well-known assays, such as the VEGF ELISA kit available from R&D Systems (Minneapolis, MN, Cat.#DY293B). Similarly, the antibodies or portions can be screened for the ability to inhibit the migration of cells expressing ErbB3 (e.g., MCF-7 cells) using a trans-well assay (Millipore Corp., Billerica, MA, Cat # ECM552) as described herein.
  • a trans-well assay Millipore Corp., Billerica, MA, Cat # ECM552
  • the antibodies or antigen binding portions thereof are screened for the ability to inhibit spheroid growth of cells expressing ErbB3. This can be done by using an assay which approximates conditions of a developing tumor growth (see, e.g., Herman et al. (2007) Journal of Biomolecular Screening Electronic publication) as described herein.
  • Antibodies or antigen binding portions thereof that bind to the same or overlapping epitopes as one or more antibodies of the present invention can also be identified using standard techniques known in the art and described herein.
  • a cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed.
  • compositions in another aspect, provides a composition, e.g., a pharmaceutical composition, containing one or a combination of monoclonal antibodies, or antigen-binding portion(s) thereof, of the present invention, formulated together with a pharmaceutically acceptable carrier.
  • the compositions include a combination of multiple ⁇ e.g., two or more) isolated antibodies of the invention, which bind different epitopes on ErbB3.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion).
  • the active compound i.e., antibody, bispecif ⁇ c and multispecific molecule, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.
  • a “pharmaceutically acceptable salt” refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see e.g., Berge, S.M., et al. (1977) J. Pharm. Sci. 66:1-19). Examples of such salts include acid addition salts and base addition salts.
  • Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl- substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like.
  • nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like
  • nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl- substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like.
  • Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N- methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.
  • compositions of the invention can be administered alone or in combination therapy, i.e., combined with other agents.
  • the combination therapy can include a composition of the present invention with at least one or more additional therapeutic agents, such as the anti-cancer agents described infra.
  • the pharmaceutical compositions of the invention can also be administered in conjunction with radiation therapy and/or surgery.
  • a composition of the present invention can be administered by a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results.
  • the active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
  • the compound may be administered to a subject in an appropriate carrier, for example, liposomes, or a diluent.
  • suitable diluents include saline and aqueous buffer solutions.
  • Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al. (1984) J. Neuroimmunol. 7:27).
  • Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage.
  • the composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization micro filtration.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze- drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
  • the human antibodies of the invention may be administered once or twice weekly by subcutaneous injection or once or twice monthly by subcutaneous injection. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
  • antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
  • formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated, and the particular mode of administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the composition which produces a therapeutic effect.
  • compositions of this invention include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of compositions of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • adjuvants which are well-known in the art include, for example, inorganic adjuvants (such as aluminum salts, e.g., aluminum phosphate and aluminumhydroxide), organic adjuvants (e.g., squalene), oil-based adjuvants, virosomes (e.g., virosomes which contain a membrane-bound heagglutinin and neuraminidase derived from the influenza virus).
  • inorganic adjuvants such as aluminum salts, e.g., aluminum phosphate and aluminumhydroxide
  • organic adjuvants e.g., squalene
  • oil-based adjuvants e.g., virosomes which contain a membrane-
  • Prevention of presence of microorganisms may be ensured both by sterilization procedures, supra, and by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given alone or as a pharmaceutical composition containing, for example, 0.001 to 90% (more preferably, 0.005 to 70%, such as 0.01 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
  • the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a composition of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect.
  • Such an effective dose will generally depend upon the factors described above. It is preferred that administration be intravenous, intramuscular, intraperitoneal, or subcutaneous, preferably administered proximal to the site of the target.
  • the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation (composition).
  • compositions can be administered with medical devices known in the art.
  • a therapeutic composition of the invention can be administered with a needleless hypodermic injection device, such as the devices disclosed in U.S. Patent Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556.
  • a needleless hypodermic injection device such as the devices disclosed in U.S. Patent Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556.
  • Examples of well-known implants and modules useful in the present invention include: U.S. Patent No. 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Patent No. 4.,486,194, which discloses a therapeutic device for administering medications through the skin; U.S. Patent No.
  • the monoclonal antibodies of the invention can be formulated to ensure proper distribution in vivo.
  • the blood-brain barrier excludes many highly hydrophilic compounds.
  • the therapeutic compounds of the invention cross the BBB (if desired)
  • they can be formulated, for example, in liposomes.
  • liposomes For methods of manufacturing liposomes, see, e.g., U.S. Patents 4,522,811; 5,374,548; and 5,399,331.
  • the liposomes may comprise one or more moieties which are selectively transported into specific cells or organs, thus enhance targeted drug delivery (see, e.g., V. V. Ranade (1989) J. Clin. Pharmacol. 29:685).
  • Exemplary targeting moieties include folate or biotin (see, e.g., U.S. Patent 5,416,016 to Low et ah); mannosides (Umezawa et ah, (1988) Biochem. Biophys. Res. Commun. 153:1038); antibodies (P.G. Bloeman e/ ⁇ /. (1995) FEBS Lett. 357: 140; M. Owais et al. (1995) Antimicrob. Agents Chemother. 39: 180); surfactant protein A receptor (Briscoe et ah (1995) Am. J. Physiol.
  • the present invention also provides methods of using antibodies and antigen- binding portions thereof that bind ErbB3 in a variety of ex vivo and in vivo diagnostic and therapeutic applications.
  • antibodies of the invention can be used for treating a disease associated with ErbB3 dependent signaling, including a variety of cancers.
  • the present invention provides a method for treating a disease associated with ErbB3 dependent signaling by administering to a subject an antibody or antigen binding portion thereof of the invention in an amount effective to treat the disease.
  • Suitable diseases include, for example, a variety of cancers including, but not limited to, melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal cancer, colon cancer, lung cancer, and prostate cancer.
  • the antibody can be administered alone or with another therapeutic agent which acts in conjunction with or synergistically with the antibody to treat the disease associated with ErbB3 mediated signaling.
  • therapeutic agents include, for example, the anticancer agents described infra (e.g., cytotoxins, chemotherapeutic agents, small molecules and radiation).
  • the present invention provides a method for diagnosing a disease (e.g., a cancer) associated with ErbB3 upregulation in a subject, by contacting antibodies or antigen binding portions of the invention (e.g., ex vivo or in vivo) with cells from the subject, and measuring the level of binding to ErbB3 on the cells. Abnormally high levels of binding to ErbB3 indicate that the subject has a disease associated with ErbB3 upregulation.
  • a disease e.g., a cancer
  • antibodies or antigen binding portions of the invention e.g., ex vivo or in vivo
  • kits comprising antibodies and antigen binding portions thereof of the invention which optionally include instructions for use in treating or diagnosing a disease associated with ErbB3 upregulation and/or ErbB3 dependent signaling.
  • the kits may include a label indicating the intended use of the contents of the kit.
  • the term label includes any writing, marketing materials or recorded material supplied on or with the kit, or which otherwise accompanies the kit.
  • Other embodiments of the present invention are described in the following
  • the practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, recombinant DNA technology, immunology (especially, e.g., antibody technology), and standard techniques in polypeptide preparation. See, e.g., Sambrook, Fritsch and Maniatis, Molecular Cloning: Cold Spring Harbor Laboratory Press (1989); Antibody
  • a cryopulverizer (Covaris Inc) was used for the pulverization of tumors. Tumors were stored in special bags (pre- weighed before the addition of the tumor) and placed in liquid nitrogen while handling them. For small tumors, 200 uL of Lysis buffer was first added to the bag containing the tumor, frozen in liquid nitrogen and then pulverized to improve the recovery of the tumor from the bag. Pulverized tumors were transferred to 2 mL Eppendorf tubes and placed in liquid nitrogen until ready for further processing Lysis of Tumor Cells Tumors were lysed in Lysis buffer supplemented with protease and phosphatase inhibitors. Lysis Buffer was added to the tumor aliquots in a final concentration of about 62.5 mg/mL.
  • ELISA reagents for the total and phospho-ErbB3 ELISAs were purchased from R&D Systems as Duoset kits.
  • 96-well Nunc Maxisorb plates were coated with 50 uL of an antibody and incubated overnight at room temperature. Next morning, plates were washed 3 times with 1000 ⁇ l/well in the BioTek plate washer with PBST (0.05% Tween-20). Plates were subsequently blocked for about an 1 hr at room temperature with 2 % BSA in PBS. The plates were washed 3 times with 1000 ⁇ l/well in the BioTek plate washer with PBST (0.05%Tween-20). 50 ⁇ L of cell lysates and standards diluted in 50% Lysis buffer and 1%BSA were used in duplicates for further processing.
  • a human Fab-phage library including a unique combination of immunoglobulin sequences obtained from human donors was initially screened for ErbB3 binders.
  • a human Fab-phage library including a unique combination of immunoglobulin sequences obtained from human donors (Hoet et al. supra, incorporated by reference in its entirety herein) was initially screened for ErbB3 binders.
  • purified ErbB3 and a Chinese hamster ovary cell line expressing cell surface ErbB3 73 unique Fab sequences from the library were identified. These 73 clones were then reformatted as Fab only without the phage.
  • VH and VL regions were reformatted using expression constructs for expression as an IgGl or IgG2 isotype.
  • the constructs included a Selexis backbone which has a cassette designed for substitution of the appropriate heavy and light chain sequences.
  • the Selexis vectors included a CMV promoter and a matching poly-A signal.
  • nucleic acid sequences for the codon-optimized VH and VL of Ab #6 are set forth in SEQ ID NOs:25 and 26, respectively, and those for Ab #3 are set forth in SEQ ID NOs: 27 and 28, respectively, as shown in Figure 22.
  • the dissociation constants of the anti-ErbB3 antibodies were measured using two independent techniques, i.e., a Surface Plasmon Resonance Assay and a cell binding assay using MALME-3M cells.
  • the Surface Plasmon Resonance Assay (also referred to as the Flexchip assay) was performed as described in Wassaf et al. (2006) Analytical Biochem., 351:241 -253.
  • the cell binding assay for determining the K D values of Ab #6 and Ab #3 was performed as follows.
  • MALME-3M cells were detached with 2 mis trypsin-EDTA + 2 mis RMPI + 5mM EDTA at room temperature for 5 minutes.
  • Complete RPMI (10 mis) was added immediately to the trypsinized cells, resuspended gently and spun down in a Beckman tabletop centrifuge at 1100 rpm for 5 minutes.
  • Cells were resuspended in BD stain buffer (PBS + 2% fetal bovine serum + 0.1% sodium azide, Becton Dickinson) at a concentration of 2 x 10 6 cells per ml and 50 ⁇ l (1 x 10 5 cells) aliquots were plated in a 96-well titer plate.
  • a 150 ⁇ l solution of 200 nM anti-ErbB3 antibody (Ab #6 or Ab #3) in BD stain buffer was prepared in an eppendorf tube and serially diluted 2-fold into 75 ⁇ l BD stain buffer. The concentrations of the diluted antibody ranged from 200 nM to 0.4 nM. 50 ⁇ l aliquots of the different protein dilutions were then added directly to the 50 ul cell suspension giving the final concentrations of 100 nM, 50 nM, 25 nM, 12 nM, 6 nM, 3 nM, 1.5 nM, 0.8 nM, 0.4 nM and 0.2 nM of the antibody. Aliquoted cells in the 96-well plate were incubated with the protein dilutions for
  • the binding specificity of an IgG2 isotype of Ab #6 to ErbB3 was assayed using ELISA as follows. Identification of the epitope bound by Ab #6 was also analyzed. Specifically, 96-well Nunc Maxisorb plates were coated with 50 ⁇ l of 5 ⁇ g/ml protein (recombinant human ErbB3, recombinant human EGFR or unrelated protein (BSA)) and incubated overnight at room temperature. The next morning, plates were washed 3 times with 1000 ⁇ l/well of PBST (0.05% Tween-20) in the BioTek plate washer. The wells were blocked for 1 hr at room temperature with 2 % BSA in PBS.
  • PBST 0.05% Tween-20
  • the plates were washed 3 times with 1000 ⁇ l/well of PBST (0.05%Tween-20) in the BioTek plate washer. About 50 ⁇ L of the Ab #6 was added at several dilutions (1 ⁇ M and serial 2 fold dilutions) in 2% BSA, PBST. All samples were run in duplicate and incubated for 2hrs at 4°C on a plate shaker. The plates were washed plates 3 times with 1000 ⁇ l/well of PBST (0.05%Tween-20) in the BioTek plate washer.
  • ErbB3 was cloned into the yeast display vector pYD2 (a modified version of pYDl (Invitrogen) with a stop codon engineered in front of the His tag) between the Nhe and BsiWI restriction sites.
  • the plasmid was transformed into the yeast strain EBYlOO (Invitrogen) and clones containing the plasmid selected on Trp- selective medium.
  • the clone was grown in glucose containing medium overnight at 3O 0 C and expression of the ErbB3 truncation mutant was induced by transfer to a galactose-containing medium for 2 days at 18 0 C.
  • Yeast displaying the ErbB3 truncation mutant were stained with 50 nM of Ab #6, followed by a goat anti-human antibody labeled with Alexa dye-647. A separate sample was stained with the goat anti-human antibody only to show that there is no non-specific binding to yeast of the secondary antibody. Analysis was performed by flow cytometry on the FACS Calibur cell sorter (BD Biosciences).
  • MALME-3M cells were seeded in 96 well tissue culture plates and grown in RPMI- 1640 media supplemented with antibiotics, 2mM L-glutamine and 10% fetal bovine serum (FBS) for 24 hours at 37 0 C and 5% carbon dioxide. Media was then switched to RPMI- 1640 MEDIA with antibiotics, 2mM L-glutamine with and without the antibody at concentrations of IuM, 25OnM, 63nM, 16nM, 4.OnM, 1.OnM, 24OpM, 6IpM and 15pM.
  • FBS fetal bovine serum
  • Cells were grown for 24 hours at 37°C and 5% carbon dioxide, washed with cold PBS, then harvested with mammalian protein extract (MPER) lysis (Pierce, 78505) buffer containing 15OmM NaCl, 5mM sodium pyrophosphate, lOuM bpV (phen), 5OuM phenalarsine, ImM sodium orthovanadate, and protease inhibitor cocktail (Sigma, P714). Cell lysates were diluted two-fold with 4% bovine serum albumin in phosphate buffered saline with 0.1% tween-20, then analyzed by ELISA with mouse anti-human ErbB3 capture antibody and biotinylated mouse anti-human ErbB3 secondary detection antibody. Signal was generated with streptavidin conjugated to horseradish-peroxidase reacted with chemiluminescent substrate (Pierce, 37070). ELISAS were visualized using a luminometer.
  • MPER mammalian protein extract
  • MALME-3M cells were trypsinized from a 15 cm dish and washed once with RPMI + 10% fetal bovine serum. Cell pellets were resuspended at a density of 1 x 10 6 cells per ml. Two aliquots of 2 x 10 5 cells were added to a 12-well tissue culture plate and resuspended in a final volume of 800 ul RPMI + 10% fetal bovine serum. To one well, Ab #6 IgGl or Ab #6IgG2 isotype was added to a final concentration of 100 nM (treated sample) and to the other well, an equivalent volume of PBS was (untreated sample) was added.
  • MALME-3M cells were trypsinized from a 15 cm dish and washed once with RPMI + 10% fetal bovine serum. Cell pellets were resuspended at a density of 1 x 10 6 cells per ml. Two aliquots of 2 x 10 5 cells were added to a 12-well tissue culture plate and resuspended in a final volume of 800 ⁇ l RPMI + 10% fetal bovine serum.
  • the anti-ErbB3 antibody was added to a final concentration of 100 nM (treated sample) and to the other well, an equivalent volume of PBS was (untreated sample) was added. The following day, treated and untreated cells were trypsinized, washed and incubated with 100 nM anti- ErbB3 antibody in BD stain buffer for 30 minutes on ice. Cells were washed twice with 1 ml BD stain buffer and incubated with 100 ⁇ l of a 1:500 dilution of Alexa 647-labeled goat anti-human Alexa 647 for 45 minutes on ice.
  • T-cell deficient nu/nu mice (3-4 week old female mice originated at NIH; outbred; albino background) were purchased from Charles River Labs (Wilmington, MA).
  • MALME-3M cells for implantation were grown in culture (RPMI media, 10% FBS, L-glutamine and antibiotics, 37°C, 5% CO2) to about 80% confluency before harvesting. Cells were kept on ice until implantation. Mice were implanted via subcutaneous injection with lOOul MALME-3M cells on the right flank and allowed to recover while being monitored for initial tumor growth.
  • mice were dosed with IgG2a (Sigma, M7769-5MG) by intravenous injection. Mice were dosed intra-peritoneally every other day with either 15 ⁇ g or 100 ⁇ g of antibody number 6 and tumors were measured three times per week and recorded in a Microsoft EXCEL spreadsheet.
  • Ab #6 caused downregulation of total ErbB3 as soon as 24 hours post-injection in tumors treated with either IgGl or IgG2 isotype of Ab #6).
  • PBS was used as a control
  • the samples were pulverized in a cryopulverizer (Covaris Inc). Tumors were stored in special bags (pre- weighed before the addition of the tumor) and placed in liquid nitrogen while handling them. For small tumors, 200 ⁇ L of Lysis buffer was first added to the bag with the tumor, frozen in liquid nitrogen and then pulverized to improve the recovery of the tumor from the bag. Pulverized tumors were transferred to 2 ml Eppendorf tubes and placed in liquid nitrogen until lysed. Tumors were lysed in Lysis buffer supplemented with protease and phosphotase inhibitors. Lysis Buffer was added to the tumor aliquots in a final concentration of 62.5 mg/ml.
  • Tumor samples were homogenized by vortexing for 30 seconds and letting them sit on ice for 30 min. The lysates were spun for 10 minutes in Qiagen Qiashredder columns for further homogenization of the samples. Cleared lysates were aliquoted into fresh tubes.
  • the BCA assay was performed as set forth in the materials and methods section supra.
  • the total levels of ErbB3 were determined by ELISA.
  • the ELISA reagents were purchased from R&D Systems as Duoset kits.
  • 96-well Nunc Maxisorb plates were coated with 50 ⁇ l of respective capture antibody and incubated overnight at room temperature. The next morning, the plates were washed 3 times with 1000 ⁇ l/well in a BioTek plate washer with PBST (0.05% Tween-20) and then blocked for 1 hour at room temperature with 2 % BSA in PBS. The plates were then washed three times with 1000 ⁇ l/well in the BioTek plate washer with PBST (0.05%Tween-20). Lysates (50 ⁇ l) and standards were diluted in 50% Lysis buffer and 1%BSA; all samples were run in duplicate.
  • MALME3M, ACHN and NCI/ ADRr cells were seeded in 96 well tissue culture plates and grown in RPMI- 1640 media supplemented with antibiotics, 2mM L- glutamine and 10% fetal bovine serum (FBS) for 24 hours at 37 degrees Celsius and 5% carbon dioxide. Media was then switched to RPMI- 1640 media with antibiotics, 2mM L-glutamine and with and without the antibody at IuM, 25OnM, 63nM, 16nM, 4.OnM, 1.OnM, 24OpM, 6IpM and 15pM concentrations.
  • FBS fetal bovine serum
  • Cells were grown for 96 hours at 37°C and 5% carbon dioxide, then harvested with CellTiter-Glo® Luminescent Cell Viability Assay (Promega, G7573) and analyzed on a luminometer. Media containing no serum and antibody was used as control.
  • Ab #6 inhibited proliferation of MALME-3M cells (Figure 9), ADRr ovarian cancer cells ( Figure 10) and ACHN cells ( Figure 11) which express ErbB3. Specifically, Ab # 6 inhibited proliferation of MALME-3M cells by about 19.6%, as measured using the Cell Titer Glow assay, and inhibited proliferation of ADRr ovarian cancer cells by about 30.5%. Also, as shown in Figure 11, Ab # 6 inhibited proliferation of ACHN cells by about 25.4%.
  • Example 5 The samples were pulverized using the technique described in Example 5 supra, with respect to Figure 8.
  • the BCA assay was performed as set forth in the Materials and Methods section supra, and the ELISA assay was performed as described in Example 5 supra with respect to Figure 8.
  • BTC betacellulin
  • HRG heregulin
  • ErbB3 phosphorylation was also examined, as follows.
  • Ovarian ADRr cells were preincubated with Ab #6 for 30 minutes prior to stimulation with 50 mM BTC, 10 mM HRG or 333 nM TGF- ⁇ . Following pre incubation, the media was removed and the cells were stimulated for 5 minutes at 37 0 C, 5% CO2 with 5OnM BTC or 333nM TGF- ⁇ (for PE498).
  • HRG controls (5 minutes, 5nM), 10% serum and 0% serum controls were also used.
  • OVCAR 5 and OVCAR 8 cell lines were obtained from the National Cancer Institute, Division of Cancer Treatment and Diagnostics ("DCTD").
  • DCTD Cancer Treatment and Diagnostics
  • the ELISA was performed as described in the Materials and Methods section supra.
  • ADRr cells or MALME-3M cells (1 x 10 5 ) were pre-incubated with 25 ⁇ M of anti-ErbB3 Ab # 6 or 25 ⁇ M of Erbitux (as control) in 50 ⁇ l BD stain buffer for 30 minutes on ice. After 30 minutes, 50 ⁇ l of 400 nM biotinylated BTC was added to the cells and incubated for another 30 minutes on ice. This gave a final concentration of 12.5 ⁇ M antibodies and 200 nM BTC.
  • betacellulin does not show any appreciable binding to ErbBl negative MALME-3M cells.
  • BTC does show binding to ErbBl positive ADRr cells.
  • Erbitux is an anti-EGFR antibody which specifically binds EGFR and was included as a control to demonstrate that EGF-like ligands bind to EGFR, and which is described in e.g., Adams et al. (2005), Nature Biotechnology 23, 1147 - 1157.
  • MALME-3M cells were seeded in 96 well tissue culture plates and grown in RPMI- 1640 media supplemented with antibiotics, 2mM L-glutamine and 10% fetal bovine serum (FBS) for 24 hours at 37°C and 5% carbon dioxide. Cells were serum starved in RPMI- 1640 media with antibiotics and 2mM L-glutamine for 24 hours at 37°C and 5% carbon dioxide.
  • FBS fetal bovine serum
  • Cells were pre-treated with and without the anti-ErbB3 antibody (IgG2 isotype of Ab #6) at l ⁇ M, 25OnM, 63nM, 16nM, 4.OnM, LOnM, 24OpM and 6IpM concentrations for 30 minutes then stimulated with HRGl -betal -ECD for 10 minutes at 37°C and 5% carbon dioxide.
  • IgG2 isotype of Ab #6 IgG2 isotype of Ab #6
  • Cells were washed with cold PBS then harvested with mammalian protein extract (MPER) lysis (Pierce, 78505) buffer containing 15OmM NaCl 5mM sodium pyrophosphate, lOuM bpV (phen), 50 ⁇ M phenalarsine, ImM sodium orthovanadate, and protease inhibitor cocktail (Sigma, P714).
  • MPER mammalian protein extract
  • Cell lysates were diluted two-fold with 4% bovine serum albumin in phosphate buffered saline with 0.1% tween-20, then analyzed by ELISA for AKT (a downstream effector of ErbB3) and ErbB3 phosphorylation.
  • lysates were run on an ELISA plate with a capture antibody specific for AKT and biotinylated detection antibody specific to the phosphorylation site on serine 473 of AKT. Signal was generated with streptavidin conjugated to horseradish-peroxidase reacted with chemiluminescent substrate (Pierce, 37070).
  • chemiluminescent substrate Pierce, 37070
  • lysates were run on an ELISA plate with a capture antibody specific for ErbB3 and an anti-phosphotyrosine detection antibody conjugated to horseradish-peroxidase. This was then reacted with chemiluminescent substrate (Pierce, 37070). ELISAs were visualized using a luminometer.
  • Ab #6 was a potent inhibitor of heregulin- mediated signaling in MALME-3M cells, as measured by decreased phosphorylation of ErbB3 ( Figure 16A) and AKT ( Figure 16B). Notably, Ab #6 inhibited the phosphorylation of AKT by almost 100%.
  • Example 9 Inhibition of Ovarian, Prostate, and Pancreatic Tumor Growth
  • mice T-cell deficient nu/nu mice (3-4 week old female mice originated at NIH; outbred; albino background) were purchased from Charles River Labs (Wilmington, MA) for xenograft studies.
  • ADRr cells for implantation were grown in culture (RPMI media, 10% FBS, L-glutamine and antibiotics, 37°C, 5% CO2) to about 85% confluency before harvesting. Cells were kept on ice until implantation. Mice were implanted via subcutaneous injection with lOO ⁇ l ADRr cells on the right flank and allowed to recover while being monitored for initial tumor growth.
  • Tumors were measured (length by width) by digital caliper and the mice were dosed with IgG2a (Sigma, M7769-5MG) by intravenous injection. Mice were dosed intra-peritoneally every third day with either 30 ⁇ g or 300 ⁇ g of Ab #6 and tumors were measured three times per week and recorded in a Microsoft Excel spreadsheet. Final tumor measurements (L x W) were taken, the mice were euthanized by C02 asphyxiation and tumors were excised, snap frozen in liquid nitrogen, and were stored at -80 0 C (for biochemical analysis). Final tumor measurements were analyzed and graphed by tumor area and tumor volume, as described in Burtrum et ah, supra. .
  • ADRr cells (1 x 10 5 ) were incubated with 10 ⁇ M of an anti-ErbB3 antibody (e.g., Ab #6 or Ab/Fab # 3) in 50 ⁇ l BD stain buffer for 30 minutes on ice. After 30 minutes, 50 ⁇ l of 40 nM biotinylated heregulin EGF was added to the cells and incubated for another 10 minutes on ice. This gave a final concentration of 5 ⁇ M antibody and 20 nM heregulin EGF.
  • an anti-ErbB3 antibody e.g., Ab #6 or Ab/Fab # 3
  • PE phycoerythrin
  • ADRr cells (1 x 10 5 ) were pre-incubated with 25 ⁇ M of Ab #6 or 25 ⁇ M of Erbitux (as control) in 50 ⁇ l BD stain buffer for 30 minutes on ice. After 30 minutes, 50 ⁇ l of 400 nM biotinylated HB-EGF was added to the cells and incubated for another 30 minutes on ice. This gave a final concentration of 12.5 ⁇ M antibodies and 200 nM HB- EGF.
  • HB-EGF binds to ErbB on ADRr cells and Ab #6 does not inhibit this binding, evidencing that Ab #6 is specific for inhibiting the binding of ErbB3 ligands (e.g., heregulin and epiregulin) to ErbB3.
  • ErbB3 ligands e.g., heregulin and epiregulin
  • Ab #6 shows a potent inhibitory effect at high levels in all three cell lines with the highest being in COLO-357 (Fig. 24A). Ab #6 also shows a similar effect in vivo by inhibiting VEGF secretion in three different xenografts, the highest being in COLO-357 xenograft (Fig. 24B). Inhibition of VEGF correlates with inhibition of ErbB3 phosphorylation (Fig. 24 C). Inhibition of VEGF secretion also correlates with inhibition of angiogenesis of the tumor cells.
  • myeloma cell-secreted factors such as VEGF and bFGF, trigger angiogenesis (see, e.g., Leung et al. (1989) Science 246(4935): 1306-9; Yen et al. (2000) Oncogene 19(31):3460-9).
  • Ab #6 to inhibit the migration of cells expressing ErbB3 (e.g., MCF-7 cells) was examined using a trans-well assay (Millipore Corp., Billerica, MA, Cat # ECM552). First, MCF-7 cells were serum-starved overnight and then incubated in the presence or absence of Ab #6 (8uM final concentration) for 15 minutes at room temperature. The cells were then transferred to an upper chamber that is separated from a lower chamber by a collagen type I-coated membrane through which the cells can migrate. 10%FBS was added to media in the lower chamber to act as a chemoattractant in the presence of absence of Ab #6.
  • MCF-7 cells were serum-starved overnight and then incubated in the presence or absence of Ab #6 (8uM final concentration) for 15 minutes at room temperature. The cells were then transferred to an upper chamber that is separated from a lower chamber by a collagen type I-coated membrane through which the cells can migrate. 10%FBS was added to media in the lower chamber to act as a chem
  • Example 13 Inhibition of Spheroid Growth The ability of Ab #6 to inhibit the spheroid growth of cells expressing ErbB3 was examined using an assay which approximates conditions of a developing tumor growth (Herman et al. (2007) Journal of Biomolecular Screening Electronic publication). AdrR and DUl 45 spheroids were initiated at a frequency of 1 spheroid per well of a 96 well plate using the hanging drop method (Herrman et al., 2008). Individual spheroids were then treated with either Ab #6 (8 uM final concentration), Heregulin- ⁇ 1 EGF domain (R&D Systems, Minneapolis, MN, Cat # 396-HB, 3.4 nM final concentration), or a combination of both, as indicated. The diameters of the spheroids were measured using light microscopy (10X objective) at day 1 and day 13.
  • Ab #6 inhibits spheroid growth in AdrR cells (Fig. 26A). In addition, 3.4nM HRG stimulates spheroid growth and Ab #6 inhibits the HRG effect (Fig. 26B). Spheroids derived from DU145 did not increase in size during 13 days of the experiment; however, growth was significantly stimulated by HRGl -beta 1. In these cells, 8uM Ab #6 inhibits HRG induced spheroid growth (Fig. 26C).
  • Example 14 Inhibition of Signaling The ability of Ab #6 to inhibit the signaling induced by different ligands was examined. For example, the effect of Ab #6 on HRG and BTC binding to AdrR cells expressing ErbB3 receptor was tested. As shown in Figures 27A and B, using FACS analysis, Ab #6 competes with HRG and not BTC for binding to AdrR cells. Accordingly, blocking by Ab #6 of HRG binding to ErbB3 would prevent signaling induced by HRG.
  • HGF Hepatocyte Growth Factor
  • ErbB3 phosphorylation in AdrR cells in a dose dependent manner as shown in Figure 28.
  • Ab #6 inhibits HGF induced erbB3 phosphorylation.
  • HRG and BTC were found to induce phosphorylation of both ErbBl and ErbB3.
  • HRG was found to be a more potent inducer of ErbB3 phosphorylation while BTC was a potent inducer of ErbBl phosphorylation (Fig. 29). This phosphorylation is likely to be driven by the complex between ErbBl and ErbB3.
  • HRG binding to ErbB3 induces complex formation between ErbBl and ErbB3, leading to the activation of both receptors.
  • BTC binding to ErbBl stimulates complex formation between ErbBl and ErbB3, leading to the phosphorylation of both ErbBl and ErbB3.
  • Antibody Inhibition of ligand stimulated ErbB3 phosphorylation.
  • AdrR cells were plated into 96 well plate at a density of 30,000 cells/well/ 100 uL in RPMI medium containing 10% FBS and allowed to grow overnight;
  • the cells were then stimulated with 10 nM HRG and HGF for 10 minutes, or 10 nM BTC and EGF for 5 minutes;
  • the reaction was stopped by removing the culture medium and washing the cells once with ice cold PBS;
  • the cells were then lysed in 25 mM Tris, pH+7.5, 150 mM NaCl, ImM EDTA, 1.0% Triton X-100, 1.0% CHAPS, 10% v/v glycerol, containing IX protease inhibitor and IX phosphatase inhibitor; and
  • ErbB3 phosphorylation was measured in cell lysates using Human Phospho- ErbB3 ELISA kit (R&D Systems, Minneapolis, MN, Cat. No. DYC1769) according to manufacturer's instructions.
  • AdrR cells were pre-incubated with buffer (control), or 250 nM Ab #6 for 60 minutes at room temperature, then treated with 10 nM HRG or 10 nM BTC or control buffer for 10 minutes.
  • the cells were lysed in 25 mM Tris, pH+7.5, 15O mM NaCl, ImM EDTA, 1.0% Triton X-100, 1.0% CHAPS, 10% v/v glycerol, containing 0.2mM PMSF, 50mTU/mL aprotinin, and 100 uM leupeptin, and the crude lysate were centrifuged briefly to remove insoluble material.
  • the immunoprecipitates were then washed with ice-cold lysis buffer 3 times, resuspended in 30 ul of 2X SDS sample buffer, heat denatured at 95 0 C for 7 minutes and run on 4-12% Bis-Tris Gels. SDS- PAGE and electro-transferred to PVDF membrane in Tri-Glycine buffer with 10% MeOH. The membrane was blocked for lhour in 10ml of blocking buffer (Li-Cor Biosciences, Lincoln, NE, Cat# 927-40000) and then incubated with the anti-ErbB2 antibody at 1 : 1000 (Cell Signaling

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.

Description

ANTIBODIES AGAINST E RB B 3 AND USES THEREOF
Background of the Invention The ErbB/HER subfamily of polypeptide growth factor receptors include the epidermal growth factor (EGF) receptor (EGFR, ErbBl/HERl), the neu oncogene product (ErbB2/HER2), and the more recently identified ErbB3/HER3 and ErbB4/HER4 receptor proteins (see, e.g., Hynes et. al. (1994) Biochim. Biophys. Acta Rev. Cancer 1198, 165-184). Each of these receptors is predicted to consist of an extracellular ligand-binding domain, a membrane-spanning domain, a cytosolic protein tyrosine kinase (PTK) domain and a C-terminal phosphorylation domain (see, e.g., Kim et al., (\99S) Biochem. J. 334, 189-195).
Experiments in vitro have indicated that the protein tyrosine kinase activity of the ErbB3 protein is attenuated significantly relative to that of other ErbB/HER family members and this attenuation has been attributed, in part, to the occurrence of non- conservative amino acid substitutions in the predicted catalytic domain of ErbB3 (see, e.g., Guy et al. (1994) Proc. Natl. Acad. Sci. USA. 91, 8132-8136; Sierke et al. (1997) Biochem. J. 322, 757-763). However, the ErbB3 protein has been shown to be phosphorylated in a variety of cellular contexts. For example, ErbB3 is constitutively phosphorylated on tyrosine residues in a subset of human breast cancer cell lines overexpressing this protein (see, e.g., Kraus et al. (1993) Proc. Natl. Acad. Sci. USA. 90, 2900-2904; and Kim et al. Supra; see, also, Schaefer et al. (2006) Neoplasia 8(7): 613-22 and Schaefer et al. Cancer Res (2004) 64(10):3395-405).
Although, the role of ErbB3 in cancer has been explored (see, e.g., Horst et al. (2005) 115, 519-527; Xue et al. (2006) Cancer Res. 66, 1418-1426), ErbB3 remains largely unappreciated as a target for clinical intervention. Current immunotherapies primarily focus on inhibiting the action of ErbB2 and, in particular, heterodimerization of ErbB2/ErbB3 complexes (see, e.g., Sliwkowski et al. (1994) J. Biol. Chem. 269(20): 14661-14665 (1994)). Accordingly, it is an object of the present invention to provide improved immunotherapies that effectively inhibit ErbB3 signaling, and can be used to treat and diagnose a variety of cancers.
Summary of the Invention
The present invention provides a novel class of monoclonal antibodies which binds to the ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. As described herein, EGF-like ligands include EGF, TGF-α, betacellulin, heparin-binding epidermal growth factor, biregulin and amphiregulin, which bind to EGFR and induce dimerization of EGFR with ErbB3. This dimerization, in turn, causes phosphorylation of ErbB3, and activates signaling through the receptor. Monoclonal antibodies of the present invention, thus, are useful for treating and diagnosing a variety of cancers associated with ErbB3 -mediated cellular signaling. Accordingly, in one embodiment, the present invention provides monoclonal antibodies (and antigen binding portions thereof) which bind to ErbB3 and inhibit EGF- like ligand mediated phosphorylation of ErbB3.
In another embodiment, the antibodies are further characterized by one or more of the following properties: (i) inhibition of ErbB3 ligand-mediated signaling, including signaling mediated by binding of ErbB3 ligands, such as heregulin, epiregulin, epigen and BIR, to ErbB3; (ii) inhibition of proliferation of cells expressing ErbB3; (iii) the ability to decrease levels of ErbB3 on cell surfaces (e.g., by inducing internalization of ErbB3); (iv) inhibition of VEGF secretion of cells expressing ErbB3; (v) inhibition of the migration of cells expressing ErbB3; (vi) inhibition of spheroid growth of cells expressing ErbB3 ; and/or (vii) binding to an epitope located on domain I (residues 20- 209) of ErbB3, for example, an epitope involving or spanning residues 20-202 of the amino acid sequence of ErbB3.
Particular monoclonal antibodies and antigen binding portions thereof of the present invention exhibit a KD of 50 nM or less, as measured by a surface plasmon resonance assay or a cell binding assay
In further embodiments, particular monoclonal antibodies and antigen binding portions thereof of the present invention include a heavy chain variable region comprising an amino acid sequence which is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:35, or SEQ ID NO: 37. Other particular monoclonal antibodies and antigen binding portions thereof of the present invention include a light chain variable region comprising an amino acid sequence which is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to the light chain variable region amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:36, or SEQ ID NO:38. The antibodies may also include both of the aforementioned heavy chain and light chain variable regions.
The variable heavy and light chain regions of the antibodies or antigen binding portions thereof typically include one or more complementarity determining regions (CDRs). These include one or more CDRl, CDR2, and CDR3 regions. Accordingly, other particular antibodies and antigen binding portions thereof of the present invention include one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ID NO: 7; a heavy chain variable region CDR2 comprising SEQ ID NO:8; a heavy chain variable region CDR3 comprising SEQ ID NO:9; a light chain variable region CDRl comprising SEQ ID NO: 10; a light chain variable region CDR2 comprising SEQ ID NO: 11 ; a light chain variable region CDR3 comprising SEQ ID NO: 12; and combinations thereof.
Still other particular antibodies and antigen binding portions thereof of the present invention include one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ID NO: 13; a heavy chain variable region CDR2 comprising SEQ ID NO: 14; a heavy chain variable region CDR3 comprising SEQ ID NO: 15; a light chain variable region CDRl comprising SEQ ID NO: 16; a light chain variable region CDR2 comprising SEQ ID NO: 17; a light chain variable region CDR3 comprising SEQ ID NO: 18; and combinations thereof.
Still other particular antibodies and antigen binding portions thereof of the present invention include; or one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ID NO: 19; a heavy chain variable region CDR2 comprising SEQ ID NO:20; a heavy chain variable region CDR3 comprising SEQ ID NO:21; a light chain variable region CDRl comprising SEQ ID NO:22; a light chain variable region CDR2 comprising SEQ ED NO: 23; a light chain variable region CDR3 comprising SEQ DD NO:24; and combinations thereof.
Still other particular antibodies and antigen binding portions thereof of the present invention include; or one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ID NO:39; a heavy chain variable region CDR2 comprising SEQ ID NO:40; a heavy chain variable region CDR3 comprising SEQ ID NO:41; a light chain variable region CDRl comprising SEQ ID NO:42; a light chain variable region CDR2 comprising SEQ ED NO:43; a light chain variable region CDR3 comprising SEQ ED NO:44; and combinations thereof. Still other particular antibodies and antigen binding portions thereof of the present invention include; or one or more CDR sequences selected from a heavy chain variable region CDRl comprising SEQ ED NO:45; a heavy chain variable region CDR2 comprising SEQ ED NO:46; a heavy chain variable region CDR3 comprising SEQ ED NO:47; a light chain variable region CDRl comprising SEQ ED NO:48; a light chain variable region CDR2 comprising SEQ ED NO:49; a light chain variable region CDR3 comprising SEQ ED NO:50; and combinations thereof.
The antibodies and antigen binding portions thereof may also comprise one or more CDRs which are at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to any of the aforementioned CDRs, or combinations of CDRs. In one embodiment, the antibodies and antibody portions thereof are fully human
(i.e., contains human CDR and framework sequences). Particular human antibodies of the present invention include those having a heavy chain variable region that is from a human VH3 germ line gene, and/or a light chain variable region from human VL2 germ line gene.
Also encompassed by the present invention are monoclonal antibodies and portions thereof that bind to the same or overlapping epitopes bound by any of the antibodies or portions thereof described herein (e.g., an epitope located on domain I of ErbB3, such as an epitope involving or spanning, residues 20-202 of the amino acid sequence of ErbB3). Antibodies which have the same activity as the antibodies described herein, e.g., antibodies having the same sequence as Ab #6, are also encompassed by the present invention. Antibodies of the present invention include all known forms of antibodies and other protein scaffolds with antibody-like properties. For example, the antibody can be a human antibody, a humanized antibody, a bispecific antibody, a chimeric antibody or a protein scaffold with antibody-like properties, such as fibronectin or Ankyrin repeats. The antibody also can be a Fab, Fab'2, ScFv, SMTP, afϊϊbody, nanobody, or a domain antibody. The antibody also can have any of the following isotypes: IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD, and IgE.
In yet another embodiment, the present invention further provides compositions comprising combinations of antibodies or antigen binding portions described herein, formulated with an acceptable carrier and/or adjuvant. In a particular embodiment, the composition comprises two or more antibodies that bind different epitopes on ErbB3 or antibodies described herein combined with anti-cancer antibodies which do not bind ErbB3.
In still another embodiment, the present invention provides isolated nucleic acids encoding the antibodies and antigen binding portions thereof described herein. In particular embodiments, the nucleic acid encodes a heavy chain variable region comprising a nucleotide sequence which is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to, or which hybridizes under high stringency conditions to, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:35, or SEQ ID NO:37; or a light chain variable region comprising a nucleotide sequence which is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) identical to, or which hybridizes under high stringency conditions to, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:36, or SEQ ID NO:38; or combinations of such heavy and light variable regions.
The present invention further provides transgenic non-human mammals, hybridomas, and transgenic plants that express and/or produce the antibodies and antigen binding portions described herein.
Also provided by the invention are kits comprising one or more isolated monoclonal antibodies or antigen binding portions thereof described herein and, optionally, instructions for use in treating or diagnosing a disease associated with ErbB3 dependent signaling, such as cancers.
Antibodies and antigen binding portions thereof of the present invention can be used in a broad variety of therapeutic and diagnostic applications, particularly oncological applications. Accordingly, in another aspect, the invention provides method for inhibiting EGF-like ligand mediated phosphorylation of ErbB3 in a subject by administering one or more antibodies or antigen binding portions thereof described herein in an amount sufficient to inhibit EGF-like mediated phosphorylation of ErbB3. The invention further provides methods for treating a variety of cancers in a subject, including, but not limited to, melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal/colon cancer, lung cancer, clear cell sarcoma, and prostate cancer, by administering one or more antibodies or antigen binding portions thereof described herein in an amount sufficient to treat the cancer. The antibodies or antigen binding portions thereof can be administered alone or in combination with other therapeutic agents, such as anti-cancer agents, e.g., other antibodies, chemotherapeutic agents and/or radiation.
In yet other embodiments, the invention provides methods for diagnosing and prognosing diseases {e.g., cancers) associated with ErbB3. In one embodiment, this is achieved by contacting antibodies or antigen binding portions of the invention (e.g., ex vivo or in vivo) with cells from the subject, and measuring the level of binding to ErbB3 on the cells, wherein abnormally high levels of binding to ErbB3 indicate that the subject has a cancer associated with ErbB3.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
Brief Description of the Drawings
Figures IA and IB are bar graphs depicting the binding of various anti-ErbB3 antibody candidates (Fabs, referred to as Abs herein) to ErbB3 expressed on MALME- 3M melanoma cells using a goat anti-human Alexa 647 secondary antibody. Figures 2A-2D are graphs depicting the KD values of various anti-ErbB3 antibody candidates. Figures 2A and 2B are graphs depicting the KD value of Antibody # 6 (referred to as Ab #6) and Antibody # 3 (referred to as Ab #3), respectively, as measured using surface plasmon resonance (SPR) technology. Figures 2C and 2D are graphs depicting the KD values of Ab #6 and Ab #3, respectively, as measured using a cell binding assay using MALME-3M melanoma cells.
Figure 3 is a graph depicting the binding specificity of an anti-ErbB3 antibody (Ab #6) to ErbB3 using ELISA. EGFR, BSA and TGF-α were used as controls. Figure 4 is a graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to decrease total ErbB3 levels in MALME-3M melanoma cells in vitro, as measured using ELISA.
Figures 5 A and 5B are graphs depicting the ability of an anti-ErbB3 antibody (Ab #6) to downregulate ErbB3 receptors on MALME-3M cells, measured using FACS analysis. Figure 5A shows the results using an IgGl isotype of the antibody. Figure 5B shows the results using an IgG2 isotype of the antibody.
Figures 6A-6D are graphs depicting the timecourse of antibody-mediated ErbB3 downregulation (Ab #6), as measured using FACS analysis. Figure 7 is a bar graph depicting the ability of various anti-ErbB3 antibodies to downregulate ErbB3 in melanoma cells in vivo.
Figure 8 is a bar graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to downregulate ErbB3 in ADRr xenografts in vivo.
Figure 9 is a graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit proliferation of MALME-3M cells in a Cell Titer Glow Assay.
Figure 10 is a graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit cell proliferation in an ovarian cell line, ADRr.
Figure 11 is a graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit proliferation of ACHN cells. Figure 12 is a bar graph depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit ErbB3 phosphorylation in ADRr xenografts in vivo.
Figures 13A-13C are graphs depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit betacellulin and heregulin-mediated phosphorylation of ErbB3 in ADRr cells. Figures 14A-14B are graphs depicting the ability of an anti-ErbB3 antibody (Ab
#6 IgG2 isotype) to inhibit ErbB3 phosphorylation in ovarian tumor cell lines OVCAR 5 and OVCAR 8.
Figures 15A-15C are graphs depicting the ability of betacellulin (BTC) to bind ErbBl as shown by a lack of binding to ErbBl negative MALME-3M cells (Figure 17A); binding to ErbBl positive ADRr cells at concentrations of 10 nM (Figure 17B) and 200 nM (Figure 17B), respectively, and the inhibition of such binding by Erbitux.
Figures 16A-16B are graphs depicting the ability of an anti-ErbB3 antibody (Ab #6 IgG2 isotype) to inhibit heregulin-mediated signaling in MALME-3M cells. Figure 16A depicts the ability of the Ab #6 to inhibit heregulin-mediated phosphorylation of ErbB3 in MALME-3M cells and 16B depicts the ability of Ab #6 to inhibit phosphorylation of AKT in MALME-3M cells. Figures 17A-D are graphs depicting the ability of an anti-ErbB3 antibody (Ab #6) to inhibit (A) ovarian (ADRr cells), (B) prostate Dul45 cells), (C) ovarian (0vCAR8 cells), and (D) pancreatic (Colo357 cells) tumor growth via xenograft studies.
Figures 18Aand 18B are graphs depicting the ability of Ab #6 (Figure 18A) and Fab for Ab #3 (Figure 18B) to inhibit heregulin binding to ErbB3 on MALME-3M cells, as measured using FACS analysis.
Figures 19Aand 19B are graphs depicting the ability of Ab #6 to inhibit the binding of epiregulin to ErbB3 on ADRr cells. Figure 19A depicts the binding of epiregulin to ADRr cells, and Figure 19B depicts the ability of both Erbitux and Ab #6 to inhibit epiregulin binding to ADRr cells.
Figures 2OA and 2OB are graphs depicting the ability of heparin binding epidermal growth factor (HB-EGF) to bind ErbB on ADRr cells (Figure 20A) and the inability of an anti-ErbB3 antibody (Ab #6) to inhibit such binding (Figure 20B).
Figures 21 A-21C show the amino acid sequences of the variable heavy and light chain regions of antibodies: Ab #6, Ab #3, Ab #14, Ab #17, and Ab #19.
Figures 22A-22B show the nucleotide sequences of the variable heavy and light chain regions of antibodies: Ab #6, Ab #3, and Ab #14.
Figure 23 shows the amino acid sequences of the variable light chain regions of antibodies: Ab #6, Ab #17, and Ab #19, which have been reverted to the corresponding germline amino acid sequence. Amino acid residue changes are underlined.
Figures 24A-24C are graphs showing the ability of Ab #6 to inhibit VEGF secretion of tumor cells.
Figure 25 is a graph showing the effect of Ab #6 on cell migration.
Figures 26 A-C are graphs showing (A) inhibition of spheroid growth in AdrR cells, (B) inhibition of HRG induced spheroid growth in AdrR, and (C) inhibition of HRG induced spheroid growth in Du 145 cells.
Figures 27 A and B are graphs showing the effect of Ab #6 on (A) HRG and (B) BTC binding to AdrR cells.
Figure 28 is a graph showing the effect of Ab #6 on HGF induced ErbB3 phosphorylation.
Figures 29 A and B show the effect of Ab #6 on phosphorylation of (A) pErbBl and pErbB3 and (B) HRG induced ErbB2/3 complex formation.
Figure 30 is a graph showing Ab #6 binds amino acid residues 20-202 of ErbB3.
Detailed Description of the Invention
In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description. I. Definitions
The terms "ErbB3," "HER3," "ErbB3 receptor," and "HER3 receptor," as used interchangeably herein, refer human ErbB3 protein, as described in U.S. Pat. No. 5,480,968 and Plowman et al., Proc. Natl. Acad. Sci. USA, 87:4905-4909 (1990); see, also, Kani et al., Biochemistry 44: 15842-857 (2005), Cho and Leahy, Science 297: 1330- 1333 (2002)).
The term "EGF-like ligand," as used herein, refers to ligands of epidermal growth factor receptor (EGFR), including epidermal growth factor (EGF) and closely related proteins, such as transforming growth factor-α (TGF-α), betacellulin (BTC), heparin-binding epidermal growth factor (HB-EGF), biregulin (BIR) and amphiregulin (AR), which bind to EGFR on the surface of cells and stimulate the receptor's intrinsic protein-tyrosine kinase activity. Specifically, EGF-like ligands induce formation of EGFR (also referred to as ErbBl) and ErbB3 protein complex (see e.g., Kim et al., (1998) Biochem J., 334: 189-195), which results in phosphorylation of tyrosine residues in the complex.
The antibodies and antigen binding portions thereof of the present invention inhibit EGF-like ligand mediated phosphorylation of ErbB3 and, in certain embodiments, exhibit one or more of the following additional properties: (i) inhibition of one or more of heregulin, epiregulin, epigen and biregulin (BIR)-mediated signaling through ErbB3; (ii) inhibition of proliferation of cells expressing ErbB3; (iii) the ability to decrease levels of ErbB3 on cell surfaces; (iv) inhibition of VEGF secretion of cells expressing ErbB3; (v) inhibition of the migration of cells expressing ErbB3; (vi) inhibition of spheroid growth of cells expressing ErbB3; and/or (vii) binding to an epitope located on domain I of ErbB3, e.g., an epitope which involves or spans residues 20-202 of the amino acid sequence of ErbB3.
The term "inhibition" as used herein, refers to any statistically significant decrease in biological activity, including full blocking of the activity. For example, "inhibition" can refer to a decrease of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% in biological activity. Accordingly, the phrase "inhibition of EGF-like ligand mediated phosphorylation of ErbB3," as used herein, refers to the ability of an antibody or antigen binding portion to statistically significantly decrease the phosphorylation of ErbB3 induced by an EGF- like ligand, relative to the phosphorylation in an untreated (control) cell. The cell which expresses ErbB3 can be a naturally occurring cell or cell line or can be recombinantly produced by introducing nucleic acid encoding ErbB3 into a host cell. In one embodiment, the antibody or antigen binding portion thereof inhibits EGF-like ligand mediated phosphorylation of ErbB3 by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100%, as determined, for example, by Western blotting followed by probing with an anti-phosphotyrosine antibody as described in Kim et al., (1998) Biochem J., 334:189-195 and the Examples infra.
The phrase "inhibition of heregulin, epiregulin, epigen or biregulin-mediated signaling through ErbB3," as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease signaling mediated by an ErbB3 ligand (e.g., heregulin, epiregullin, epigen and biregulin) through ErbB3, relative to the signaling in the absence of the antibody (control). ErbB3-ligands are also referred to herein as "heregulin-like ligands." This means that, in the presence of the antibody or antigen binding portion thereof, a signal mediated in a cell expressing ErbB3 by one or more of heregulin, epiregulin, epigen and biregulin, relative to a control (no antibody), is statistically significantly decreased. An ErbB3-ligand mediated signal can be measured by assaying for the level or activity of an ErbB3 substrate, and/or a protein which is present in a cellular cascade involving ErbB3. In one embodiment, the antibody or antigen binding portion thereof decreases the level or activity of an ErbB3 substrate and/or that of a protein in a cellular cascade involving ErbB3, by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% relative to the level or activity in the absence of such antibody or antigen binding portion thereof (control). Such ErbB3- ligand mediated signaling can be measured using art recognized techniques which measure the level or activity of a substrate of ErbB3 (e.g., SHC or PI3K) or a protein in a cellular cascade involving ErbB3 (e.g., AKT) using kinase assays for such proteins (see, e.g., Horst et al. supra, Sudo et al. (2000) Methods Enzymol, 322:388-92; and Morgan et al. (1990) Eur. J. Biochem., 191:761-767). In a particular embodiment, the antibody or antigen binding portion thereof inhibits ErbB3-ligand (e.g., heregulin, epiregulin, epigen or biregulin) mediated signaling through ErbB3 by inhibiting the binding of the ErbB3-ligand (e.g., one or more of heregulin, epiregulin, epigen or biregulin) to ErbB3. Some ligands (e.g., biregulin or BIR) function both as EGF-like ligands (i.e., bind to EGFR/ErbBl) as well as ErbB3-like ligands (i.e., bind to ErbB3).
The phrase "inhibition of heregulin, epiregulin, epigen or biregulin binding to ErbB3," as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease the binding of an ErbB3 ligand (e.g., one or more of heregulin, epiregulin, epigen or biregulin) to ErbB3, relative to the binding in the absence of the antibody (control). This means that, in the presence of the antibody or antigen binding portion thereof, the amount of the ErbB3 -ligand (e.g., heregulin, epiregulin, epigen or biregulin) which binds to ErbB3 relative to a control (no antibody), is statistically significantly decreased. The amount of an ErbB3 ligand which binds ErbB3 may be decreased in the presence of an antibody or antigen binding portion thereof of the invention by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% relative to the amount in the absence of the antibody or antigen binding portion thereof (control). A decrease in ErbB3-ligand binding can be measured using art recognized techniques which measure the level of binding of labeled ErbB3-ligand (e.g., radiolabeled heregulin, epiregulin, epigen or biregulin) to cells expressing ErbB3 in the presence or absence (control) of the antibody or antigen binding portion thereof.
The phrase "inhibition of proliferation of a cell expressing ErbB3," as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease proliferation of a cell expressing ErbB3 relative to the proliferation in the absence of the antibody. In one embodiment, the proliferation of a cell expressing ErbB3 (e.g., a cancer cell) may be decreased by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen binding portion thereof of the present invention, relative to the proliferation measured in the absence of the antibody or antigen binding portion thereof (control). Cellular proliferation can be assayed using art recognized techniques which measure rate of cell division, the fraction of cells within a cell population undergoing cell division, and/or rate of cell loss from a cell population due to terminal differentiation or cell death (e.g., using a cell titer glow assay or thymidine incorporation).
The phrase "the ability to decrease levels of ErbB3 on cell surfaces," as used herein, refers to the ability of an antibody or antigen binding portion thereof to statistically significantly reduce the amount of ErbB3 found on the surface of a cell which has been exposed to the antibody relative to an untreated (control) cell. For example, a decrease in levels of ErbB3 on cell surfaces may result from increased internalization of ErbB3 (or increased ErbB3 endocytosis). In one embodiment, the antibody or antigen binding portion thereof decreases cell surface expression of ErbB3 by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% and/or increases internalization of the ErbB3 receptor by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% relative to the cell surface expression or internalization in the absence of the antibody or antigen binding portion thereof (control). The levels of ErbB3 on surfaces of cells and/or internalization of the ErbB3 receptor in the absence and the presence of an antibody or antigen-binding portion thereof can be readily measured using art recognized techniques, such as those described in Horst et al., supra and in the examples herein. The phrase "inhibition of VEGF secretion of cells expressing ErbB3," as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease VEGF secretion of a cell expressing ErbB3 relative to the VEGF secretion in the absence of the antibody. In one embodiment, the VEGF secretion of a cell expressing ErbB3 (e.g., a cancer cell) may be decreased by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen binding portion thereof of the present invention, relative to the VEGF secretion measured in the absence of the antibody or antigen binding portion thereof (control). VEGF secretion can be assayed using art recognized techniques, such as those described herein.
The phrase "inhibition of the migration of cells expressing ErbB3," as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease the migration of a cell expressing ErbB3 relative to the migration of the cell in the absence of the antibody. In one embodiment, the migration of a cell expressing ErbB3 (e.g., a cancer cell) may be decreased by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen binding portion thereof of the present invention, relative to cell migration measured in the absence of the antibody or antigen binding portion thereof (control). Cell migration can be assayed using art recognized techniques, such as those described herein.
The phrase "inhibition of spheroid growth of cells expressing ErbB3," as used herein, refers to the ability of an antibody or an antigen-binding portion thereof to statistically significantly decrease the migration of a cell expressing ErbB3 relative to the migration of the cell in the absence of the antibody. In one embodiment, the migration of a cell expressing ErbB3 (e.g., a cancer cell) may be decreased by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen binding portion thereof of the present invention, relative to cell migration measured in the absence of the antibody or antigen binding portion thereof (control). Cell migration can be assayed using art recognized techniques, such as those described herein. The term "antibody" or "immunoglobulin," as used interchangeably herein, includes whole antibodies and any antigen binding fragment (i.e., "antigen- binding portion") or single chains thereof. An "antibody" comprises at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CHl, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino- teπninus to carboxy-terminus in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (CIq) of the classical complement system. Exemplary antibodies of the invention include antibodies#l, 3 and 14, and antigen-binding portions thereof.
The term "antigen-binding portion" of an antibody (or simply "antibody portion"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., ErbB3). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen- binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHl domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (Hi) a Fd fragment consisting of the VH and CHl domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb including VH and VL domains; (vi) a dAb fragment (Ward et al. (1989) Nature 341, 544-546), which consists of a VH domain; (vii) a dAb which consists of a VH or a VL domain; and (viii) an isolated complementarity determining region (CDR) or (ix) a combination of two or more isolated CDRs which may optionally be joined by a synthetic linker. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242, 423-426; and Huston et al. (1988) Proc. Natl. Acad. ScI USA 85, 5879- 5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antigen-binding portions can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact immunoglobulins. The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Monoclonal antibodies can be prepared using any art recognized technique and those described herein such as, for example, a hybridoma method, as described by Kohler et al (1975) Nature, 256:495, a transgenic animal, as described by, for example, (see e.g., Lonberg, et al. (1994) Nature 368(6474): 856-859), recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567), or using phage antibody libraries using the techniques described in, for example, Clackson et al, Nature, 352:624-628 (1991) and Marks et al, J. MoI. Biol, 222:581-597 (1991). Monoclonal antibodies include chimeric antibodies, human antibodies and humanized antibodies and may occur naturally or be recombinantly produced.
The term "recombinant antibody," refers to antibodies that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for immunoglobulin genes (e.g., human immunoglobulin genes) or a hybridoma prepared therefrom, (b) antibodies isolated from a host cell transformed to express the antibody, e.g., from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial antibody library (e.g., containing human antibody sequences) using phage display, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of immunoglobulin gene sequences (e.g., human immunoglobulin genes) to other DNA sequences. Such recombinant antibodies may have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies can be subjected to in vitro mutagenesis and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
The term "chimeric immunoglobulin" or antibody refers to an immunoglobulin or antibody whose variable regions derive from a first species and whose constant regions derive from a second species. Chimeric immunoglobulins or antibodies can be constructed, for example by genetic engineering, from immunoglobulin gene segments belonging to different species. The term "human antibody," as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences as described, for example, by Kabat et al. (See Kabat, et al. (1991) Sequences of proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences. The human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
The human antibody can have at least one ore more amino acids replaced with an amino acid residue, e.g., an activity enhancing amino acid residue which is not encoded by the human germline immunoglobulin sequence. Typically, the human antibody can have up to twenty positions replaced with amino acid residues which are not part of the human germline immunoglobulin sequence. In a particular embodiment, these replacements are within the CDR regions as described in detail below. The term "humanized immunoglobulin" or "humanized antibody" refers to an immunoglobulin or antibody that includes at least one humanized immunoglobulin or antibody chain (i.e., at least one humanized light or heavy chain). The term "humanized immunoglobulin chain" or "humanized antibody chain" (i.e., a "humanized immunoglobulin light chain" or "humanized immunoglobulin heavy chain") refers to an immunoglobulin or antibody chain (i.e., a light or heavy chain, respectively) having a variable region that includes a variable framework region substantially from a human immunoglobulin or antibody and complementarity determining regions (CDRs) (e.g., at least one CDR, preferably two CDRs, more preferably three CDRs) substantially from a non-human immunoglobulin or antibody, and further includes constant regions (e.g., at least one constant region or portion thereof, in the case of a light chain, and preferably three constant regions in the case of a heavy chain). The term "humanized variable region" (e.g. , "humanized light chain variable region" or "humanized heavy chain variable region") refers to a variable region that includes a variable framework region substantially from a human immunoglobulin or antibody and complementarity determining regions (CDRs) substantially from a non-human immunoglobulin or antibody.
A "bispecific" or "bifunctional antibody" is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab1 fragments. See, e.g., Songsivilai & Lachmann, (1990) Clin. Exp. Immunol. 79, 315-321; Kostelny et al. (1992) J. Immunol. 148, 1547-1553. In a particular embodiment, a bispecific antibody according to the present invention includes binding sites for both ErbB3 and IGFl-R (i.e., insulin-like growth factor 1-receptor). In another embodiment, a bispecific antibody according to the present invention includes binding sites for both ErbB3 and C-MET. In other embodiments, a bispecific antibody includes a binding site for ErbB3 and a binding site for ErbB2, ERbB3, ErbB4, EGFR, Lewis Y, MUC-I, EpCAM, CA125, prostate specific membrane antigen, PDGFR-α, PDGFR-β, C-KIT, or any of the FGF receptors.
As used herein, a "heterologous antibody" is defined in relation to the transgenic non-human organism or plant producing such an antibody.
An "isolated antibody," as used herein, is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to ErbB3 is substantially free of antibodies that specifically bind antigens other than ErbB3). In addition, an isolated antibody is typically substantially free of other cellular material and/or chemicals. In one embodiment of the invention, a combination of "isolated" monoclonal antibodies having different ErbB3 binding specificities are combined in a well defined composition. As used herein, "isotype" refers to the antibody class (e.g., IgM or IgGl) that is encoded by heavy chain constant region genes. In one embodiment, an antibody or antigen binding portion thereof is of an isotype selected from an IgGl, an IgG2, an IgG3, an IgG4, an IgM, an IgAl, an IgA2, an IgAsec, an IgD, or an IgE antibody isotype. In some embodiments, a monoclonal antibody of the invention is of the IgGl isotype. In other embodiments, a monoclonal antibody of the invention is of the IgG2 isotype.
As used herein, "isotype switching" refers to the phenomenon by which the class, or isotype, of an antibody changes from one Ig class to one of the other Ig classes. As used herein, "nonswitched isotype" refers to the isotypic class of heavy chain that is produced when no isotype switching has taken place; the CH gene encoding the nonswitched isotype is typically the first CH gene immediately downstream from the functionally rearranged VDJ gene. Isotype switching has been classified as classical or non-classical isotype switching. Classical isotype switching occurs by recombination events which involve at least one switch sequence regions in a gene encoding an antibody. Non-classical isotype switching may occur by, for example, homologous recombination between human σμ and human ∑μ (δ-associated deletion). Alternative non-classical switching mechanisms, such as intertransgene and/or interchromosomal recombination, among others, may occur and effectuate isotype switching. As used herein, the term "switch sequence" refers to those DNA sequences responsible for switch recombination. A "switch donor" sequence, typically a μ switch region, will be 5' (i.e., upstream) of the construct region to be deleted during the switch recombination. The "switch acceptor" region will be between the construct region to be deleted and the replacement constant region (e.g., γ, ε, etc.). As there is no specific site where recombination always occurs, the final gene sequence will typically not be predictable from the construct.
An "antigen" is an entity (e.g., a proteinaceous entity or peptide) to which an antibody or antigen-binding portion thereof binds. In various embodiments of the present invention, an antigen is ErbB3 or a ErbB3-like molecule. In a particular embodiment according to the invention, an antigen is human ErbB3.
The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds. Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include techniques in the art and those described herein, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g. , Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E. Morris, Ed. (1996).
Also encompassed by the present invention are antibodies that bind the same or an overlapping epitope as the antibodies of the present invention, i.e., antibodies that compete for binding to ErbB3, or bind epitopes which overlap with epitopes bound by the antibodies described herein, i.e., an epitope located on domain I of ErbB3. Antibodies that recognize the same epitope can be identified using routine techniques such as an immunoassay, for example, by showing the ability of one antibody to block the binding of another antibody to a target antigen, i.e., a competitive binding assay. Competitive binding is determined in an assay in which the immunoglobulin under test inhibits specific binding of a reference antibody to a common antigen, such as ErbB3. Numerous types of competitive binding assays are known, for example: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see Stahli et al., (1983) Methods in Enzymology 9:242); solid phase direct biotin-avidin EIA (see Kirkland et al, (1986) J. Immunol. 137:3614); solid phase direct labeled assay, solid phase direct labeled sandwich assay (see Harlow and Lane, (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Press); solid phase direct label RIA using 1-125 label (see Morel et al., (1988) MoI. Immunol. 25(1):7); solid phase direct biotin-avidin EIA (Cheung et al., (1990) Virology 176:546); and direct labeled RIA. (Moldenhauer et al, (1990) Scand J. Immunol. 32:77). Typically, such an assay involves the use of purified antigen (e.g., ErbB3) bound to a solid surface or cells bearing either of these, an unlabeled test immunoglobulin and a labeled reference immunoglobulin. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test immunoglobulin. Usually the test immunoglobulin is present in excess. Usually, when a competing antibody is present in excess, it will inhibit specific binding of a reference antibody to a common antigen by at least 50-55%, 55-60%, 60- 65%, 65-70% 70-75% or more.
As used herein, the terms "specific binding," "specifically binds," "selective binding," and "selectively binds," mean that an antibody or antigen-binding portion thereof, exhibits appreciable affinity for a particular antigen or epitope and, generally, does not exhibit significant cross-reactivity with other antigens and epitopes. "Appreciable" or preferred binding includes binding with an affinity of at least 106, 107, 108, 109 M"1, or 1010 M"1. Affinities greater than 107M'1, preferably greater than 108 M"1 are more preferred. Values intermediate of those set forth herein are also intended to be within the scope of the present invention and a preferred binding affinity can be indicated as a range of affinities, for example, 106 to 1010 M"1, preferably 107 to 1010 M" \ more preferably 108 to 1010 M"1. An antibody that "does not exhibit significant cross- reactivity" is one that will not appreciably bind to an undesirable entity (e.g., an undesirable proteinaceous entity). For example, in one embodiment, an antibody or antigen-binding portion thereof that specifically binds to ErbB3 will appreciably bind that ErbB3 molecule but will not significantly react with other ErbB molecules and non- ErbB proteins or peptides. Specific or selective binding can be determined according to any art-recognized means for determining such binding, including, for example, according to Scatchard analysis and/or competitive binding assays.
The term "KD," as used herein, is intended to refer to the dissociation equilibrium constant of a particular antibody-antigen interaction or the affinity of an antibody for an antigen. In one embodiment, the antibody or antigen binding portion thereof according to the present invention binds an antigen (e.g., ErbB3) with an affinity (KD) of 50 nM or better (i.e., or less) (e.g., 40 nM or 30 nM or 20 nM or 10 nM or less), as measured using a surface plasmon resonance assay or a cell binding assay. In a particular embodiment, an antibody or antigen binding portion thereof according to the present invention binds ErbB3 with an affinity (KD) of 8 nM or better (e.g., 7 nM, 6 nM, 5 nM, 4 nM, 2 nM, 1.5 nM, 1.4 nM, 1.3 nM, InM or less), as measured by a surface plasmon resonance assay or a cell binding assay. In other embodiments, an antibody or antigen binding portion thereof binds an antigen (e.g., ErbB3) with an affinity (KD) of approximately less than 10"7 M, such as approximately less than 10 "8 M, 10'9 M or 10'10 M or even lower when determined by surface plasmon resonance (SPR) technology in a BIACORE 3000 instrument using recombinant ErbB3 as the analyte and the antibody as the ligand, and binds to the predetermined antigen with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.
The term "K0Jf ," as used herein, is intended to refer to the off rate constant for the dissociation of an antibody from the antibody/antigen complex.
The term "EC50," as used herein, refers to the concentration of an antibody or an antigen-binding portion thereof, which induces a response, either in an in vitro or an in vivo assay, which is 50% of the maximal response, i.e., halfway between the maximal response and the baseline.
As used herein, "glycosylation pattern" is defined as the pattern of carbohydrate units that are covalently attached to a protein, more specifically to an immunoglobulin protein.
The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.
The term "rearranged" as used herein refers to a configuration of a heavy chain or light chain immunoglobulin locus wherein a V segment is positioned immediately adjacent to a D-J or J segment in a conformation encoding essentially a complete VH or VL domain, respectively. A rearranged immunoglobulin gene locus can be identified by comparison to germline DNA; a rearranged locus will have at least one recombined heptamer/nonamer homology element.
The term "unrearranged" or "germline configuration" as used herein in reference to a V segment refers to the configuration wherein the V segment is not recombined so as to be immediately adjacent to a D or J segment. The term "nucleic acid molecule," as used herein, is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.
The term "isolated nucleic acid molecule," as used herein in reference to nucleic acids encoding antibodies or antibody portions (e.g., VH, VL, CDR3) that bind to ErbB3, is intended to refer to a nucleic acid molecule in which the nucleotide sequences encoding the antibody or antibody portion are free of other nucleotide sequences encoding antibodies that bind antigens other than ErbB3, which other sequences may naturally flank the nucleic acid in human genomic DNA. The term "modifying," or "modification," as used herein, is intended to refer to changing one or more amino acids in the antibodies or antigen-binding portions thereof. The change can be produced by adding, substituting or deleting an amino acid at one or more positions. The change can be produced using known techniques, such as PCR mutagenesis. For example, in some embodiments, an antibody or an antigen-binding portion thereof identified using the methods of the invention can be modified, to thereby modify the binding affinity of the antibody or antigen-binding portion thereof to ErbB3. The present invention also encompasses "conservative amino acid substitutions" in the sequences of the antibodies of the invention, i.e., nucleotide and amino acid sequence modifications which do not abrogate the binding of the antibody encoded by the nucleotide sequence or containing the amino acid sequence, to the antigen, i.e., ErbB3. Conservative amino acid substitutions include the substitution of an amino acid in one class by an amino acid of the same class, where a class is defined by common physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature, as determined, for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix. Six general classes of amino acid side chains have been categorized and include: Class I (Cys); Class II (Ser, Thr, Pro, Ala, GIy); Class III (Asn, Asp, GIn, GIu); Class IV (His, Arg, Lys); Class V (He, Leu, VaI, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of an Asp for another class III residue such as Asn, GIn, or GIu, is a conservative substitution. Thus, a predicted nonessential amino acid residue in an anti-ErbB3 antibody is preferably replaced with another amino acid residue from the same class. Methods of identifying nucleotide and amino acid conservative substitutions which do not eliminate antigen binding are well- known in the art (see, e.g., Brummell et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10):879-884 (1999); and Burks et al. Proc. Natl. Acad. Sci. USA 94:.412-417 (1997)).
The term "non-conservative amino acid substitution" refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, GIu, or GIn.
Alternatively, in another embodiment, mutations (conservative or non- conservative) can be introduced randomly along all or part of an anti-ErbB3 antibody coding sequence, such as by saturation mutagenesis, and the resulting modified anti- ErbB3 antibodies can be screened for binding activity. A "consensus sequence" is a sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A "consensus framework" of an immunoglobulin refers to a framework region in the consensus immunoglobulin sequence. Similarly, the consensus sequence for the CDRs of can be derived by optimal alignment of the CDR amino acid sequences of ErbB3 antibodies of the present invention.
For nucleic acids, the term "substantial homology" indicates that two nucleic acids, or designated sequences thereof, when optimally aligned and compared, are identical, with appropriate nucleotide insertions or deletions, in at least about 80% of the nucleotides, usually at least about 90% to 95%, and more preferably at least about 98% to 99.5% of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to the complement of the strand. The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions/total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
The percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM 120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. MoI. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. MoI. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al, (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs {e.g., XBLAST and NBLAST) can be used.
The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. A nucleic acid is "isolated" or "rendered substantially pure" when purified away from other cellular components or other contaminants, e.g., other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis and others well known in the art. See, F. Ausubel, et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
The nucleic acid compositions of the present invention, while often in a native sequence (except for modified restriction sites and the like), from either cDNA, genomic or mixtures thereof may be mutated, in accordance with standard techniques to provide gene sequences. For coding sequences, these mutations, may affect amino acid sequence as desired. In particular, DNA sequences substantially homologous to or derived from native V, D, J, constant, switches and other such sequences described herein are contemplated (where "derived" indicates that a sequence is identical or modified from another sequence). The term "operably linked" refers to a nucleic acid sequence placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. With respect to transcription regulatory sequences, operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. For switch sequences, operably linked indicates that the sequences are capable of effecting switch recombination.
The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. The terms, "plasmid" and "vector" may be used interchangeably. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno- associated viruses), which serve equivalent functions.
The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. The terms "treat," "treating," and "treatment," as used herein, refer to therapeutic or preventative measures described herein. The methods of "treatment" employ administration to a subject, an antibody or antigen binding portion of the present invention, for example, a subject having a disease or disorder associated with ErbB3 dependent signaling or predisposed to having such a disease or disorder, in order to prevent, cure, delay, reduce the severity of, or ameliorate one or more symptoms of the disease or disorder or recurring disease or disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment. The term "disease associated with ErbB3 dependent signaling," or "disorder associated with ErbB3 dependent signaling," as used herein, includes disease states and/or symptoms associated with a disease state, where increased levels of ErbB3 and/or activation of cellular cascades involving ErbB3 are found. It is understood that ErbB3 heterodimerizes with other ErbB proteins such as, EGFR and ErbB2, when increased levels of ErbB3 are found. Accordingly, the term "disease associated with ErbB3 dependent signaling," also includes disease states and/or symptoms associated with disease states where increased levels of EGFR/ErbB3 and/or ErbB2/ErbB3 heterodimers are found. In general, the term "disease associated with ErbB3 dependent signaling," refers to any disorder, the onset, progression or the persistence of the symptoms of which requires the participation of ErbB3. Exemplary ErbB3 -mediated disorders include, but are not limited to, for example, cancer.
The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, melanoma, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer. In a particular embodiment, a cancer treated or diagnosed using the methods of the present invention is selected from melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal/colon cancer, lung cancer, and prostate cancer.
The term "effective amount," as used herein, refers to that amount of an antibody or an antigen binding portion thereof that binds ErbB3, which is sufficient to effect treatment, prognosis or diagnosis of a disease associated with ErbB3 dependent signaling, as described herein, when administered to a subject. A therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The dosages for administration can range from, for example, about 1 ng to about 10,000 mg, about 5 ng to about 9,500 mg, about 10 ng to about 9,000 mg, about 20 ng to about 8,500 mg, about 30 ng to about 7,500 mg, about 40 ng to about 7,000 mg, about 50 ng to about 6,500 mg, about 100 ng to about 6,000 mg, about 200 ng to about 5,500 mg, about 300 ng to about 5,000 mg, about 400 ng to about 4,500 mg, about 500 ng to about 4,000 mg, about 1 μg to about 3,500 mg, about 5 μg to about 3,000 mg, about 10 μg to about 2,600 mg, about 20 μg to about 2,575 mg, about 30 μg to about 2,550 mg, about 40 μg to about 2,500 mg, about 50 μg to about 2,475 mg, about 100 μg to about 2,450 mg, about 200 μg to about 2,425 mg, about 300 μg to about 2,000, about 400 μg to about 1,175 mg, about 500 μg to about 1,150 mg, about 0.5 mg to about 1,125 mg, about 1 mg to about 1,100 mg, about 1.25 mg to about 1,075 mg, about 1.5 mg to about 1,050 mg, about 2.0 mg to about 1,025 mg, about 2.5 mg to about 1,000 mg, about 3.0 mg to about 975 mg, about 3.5 mg to about 950 mg, about 4.0 mg to about 925 mg, about 4.5 mg to about 900 mg, about 5 mg to about 875 mg, about 10 mg to about 850 mg, about 20 mg to about 825 mg, about 30 mg to about 800 mg, about 40 mg to about 775 mg, about 50 mg to about 750 mg, about 100 mg to about 725 mg, about 200 mg to about 700 mg, about 300 mg to about 675 mg, about 400 mg to about 650 mg, about 500 mg, or about 525 mg to about 625 mg, of an antibody or antigen binding portion thereof, according to the invention. Dosage regiments may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (i.e., side effects) of an antibody or antigen binding portion thereof are minimized and/or outweighed by the beneficial effects.
The term "patient" includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.
As used herein, the term "subject" includes any human or non-human animal. For example, the methods and compositions of the present invention can be used to treat a subject having cancer. In a particular embodiment, the subject is a human. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.
The term "sample" refers to tissue, body fluid, or a cell from a patient or a subject. Normally, the tissue or cell will be removed from the patient, but in vivo diagnosis is also contemplated. In the case of a solid tumor, a tissue sample can be taken from a surgically removed tumor and prepared for testing by conventional techniques. In the case of lymphomas and leukemias, lymphocytes, leukemic cells, or lymph tissues can be obtained and appropriately prepared. Other patient samples, including urine, tear drops, serum, cerebrospinal fluid, feces, sputum, cell extracts etc. can also be useful for particular tumors.
The terms "anti-cancer agent" and "antineoplastic agent" refer to drugs used to treat malignancies, such as cancerous growths. Drug therapy may be used alone, or in combination with other treatments such as surgery or radiation therapy. Several classes of drugs may be used in cancer treatment, depending on the nature of the organ involved. For example, breast cancers are commonly stimulated by estrogens, and may be treated with drugs which inactive the sex hormones. Similarly, prostate cancer may be treated with drugs that inactivate androgens, the male sex hormone. Anti-cancer agents of the present invention include, among others, the following agents:
Anti-Cancer Agent Comments Examples
Antibodies Antibodies which bind Al 2 (fully humanized mAb)
(a) antibodies other IGF-IR (insulin-like 19Dl 2 (fully humanized mAb) than anti-ErbB3 growth factor type 1 CP751-871 (fully humanized mAb) antibodies; and receptor), which is H7C10 (humanized mAb)
(b) anti-ErbB3 expressed on the cell alphaIR3 (mouse) antibodies which surface of must human scFV/FC (mouse/human chimera) bind different cancers EM/164 (mouse) epitopes
Antibodies which bind Matuzumab (EMD72000) EGFR (epidermal growth Erbitux® / Cetuximab (Imclone) factor receptor); Vectibix® / Panitumumab (Amgen) Mutations affecting mAb 806 EGFR expression or Nimotuzumab (TheraCIM) activity could result in cancer
Antibodies which bind AVEO (AV299) (AVEO) cMET (Mesenchymal AMG102 (Amgen) epithelial transition 5D5 (OA-5D5) (Genentech) factor); a member of the MET family of receptor tyrosine kinases)
Anti-ErbB3 antibodies Ab #14 (MM 121-14) described herein which bind different Herceptin® (Trastuzumab; Genentech) epitopes 1B4C3; 2D1D12 (U3 Pharma AG)
Small Molecules IGF-IR (insulin-like NVP-AEW541-A Targeting IGFlR growth factor type 1 BMS-536,924 (lH-benzoimidazol-2-yl)-lH- receptor), which is pyridin-2-one) expressed on the cell BMS-554,417 surface of must human Cycloligan cancers TAE226
PQ401
Small Molecules EGFR (epidermal growth Iressa® / Gefitinib (AstraZeneca) Targeting EGFR factor receptor); CI-1033 (PD 183805) (Pfizer) Mutations affecting Lapatinib (GW-572016) (GlaxoSmithKline) EGFR expression or Tykerb® / Lapatinib Ditosylate (SmithKline activity could result in Beecham) cancer Tarceva®/ Erlotinib HCL (OSI-774) (OSI
Pharma)
PKI- 166 (Novartis) PD-158780
EKB-569
Tyrphostin AG 1478(4-(3-Chloroanillino)-
6,7-dimethoxyquinazoline)
Small Molecules cMET (Mesenchymal PHA665752 Targeting cMET epithelial transition ARQ 197 factor); a member of the MET family of receptor tyrosine kinases)
Antimetabolites An antimetabolite is a Flourouracil (5-FU) chemical with a similar Capecitabine / XELODA® (HLR Roche) structure to a substance (a 5-Trifluoromethyl-2'-deoxyuridine metabolite) required for Methotrexate sodium (Trexall) (Barr) normal biochemical Raltitrexed / Tomudex® (AstraZaneca) reactions, yet different Pemetrexed / Alimta® (Lilly) enough to interfere with Tegafur the normal functions of Cytosine Arabinoside (Cytarabine, Ara-C) / cells, including cell Thioguanine® (GlaxoSmithKline) division. 5-azacytidine
6-mercaptopurine (Mercaptopurine, 6-MP)
Azathioprine / Azasan® (AAIPHARMA
LLC)
6-thioguanine (6-TG) / Purinethol® (TEVA)
Pentostatin / Nipent® (Hospira Inc.)
Fludarabine phosphate / Fludara® (Bayer
Health Care)
Cladribine (2-CdA, 2- chlorodeoxyadenosine) / Leustatin® (Ortho
Biotech)
Alkylating agents An alkylating Ribonucleotide Reductase Inhibitor (RNR) antineoplastic agent is an Cyclophosphamide / Cytoxan (BMS) alkylating agent that Neosar (TEVA) attaches an alkyl group to Ifosfamide /Mitoxana® (ASTA Medica) DNA. Since cancer cells Thiotepa (Bedford, Abraxis, Teva) generally proliferate BCNU→ 1 ,3 -bis(2-chloroethyl)- 1 -nitosourea unrestrictively more than CCNU→ l,-(2-chloroethyl)-3-cyclohexyl-l- do healthy cells they are nitrosourea (methyl CCNU)
Hexamethylmelamine (Altretamine, HMM) / more sensitive to DNA
Hexalen® (MGI Pharma Inc.) damage, and alkylating
Busulfan / Myleran (GlaxoSmithKline) agents are used clinically
Procarbazine HCL / to treat a variety of Matulane (Sigma Tau Pharmaceuticals, Inc.) tumours. Dacarbazine (DTIC)
Chlorambucil / Leukaran® (SmithKline
Beecham)
Melphalan / Alkeran® (GlaxoSmithKline) Cisplatin (Cisplatinum, CDDP) / Platinol (Bristol Myers)
Carboplatin / Paraplatin (BMS) Oxaliplatin / Eloxitan® (Sanofi-Aventis US)
Topoisomerase Topoisomerase inhibitors Doxorubicin HCL / Doxil® (Alza) inhibitors are chemotherapy agents Daunorubicin citrate / Daunoxome® (Gilead)
Mitoxantrone HCL/Novantrone (EMD designed to interfere with
Serono) the action of
Actinomycin D topoisomerase enzymes
Etoposide / Vepesid® (BMS)/ Etopophos® (topoisomerase I and II),
(Hospira, Bedford, Teva Parenteral, Etc.) which are enzymes that
Topotecan HCL / Hycamtin® control the changes in
(GlaxoSmithKline) DNA structure by Teniposide (VM-26) / Vumon® (BMS) catalyzing the breaking Irinotecan HCL(CPT-I l) / and rejoining of the Camptosar® (Pharmacia & Upjohn) phosphodiester backbone of DNA strands during the normal cell cycle.
Microtubule Microtubules are one of Vincristine / Oncovin® (Lilly) the Vinblastine sulfate/Velban®(discontinued) targeting agents the components of cytoskeleton. They have (Lilly) diameter of ~ 24 run and Vinorelbine tartrate / Navelbine® length varying from (PierreFabre) several micrometers to Vindesine sulphate / Eldisine® (Lilly) possibly millimeters in Paclitaxel / Taxol® (BMS) axons of nerve cells. Docetaxel / Taxotere® (Sanofi Aventis US) Microtubules serve as Nanoparticle paclitaxel (ABI-007) / structural components Abraxane® (Abraxis BioScience, Inc.) within cells and are Ixabepilone / IXEMPRA™ (BMS) involved in many cellular processes including mitosis, cytokinesis, and vesicular transport.
Kinase inhibitors Imatinib mesylate / Gleevec (Novartis)
Tyrosine kinases are Sunitinib malate / Sutent® (Pfizer) enzymes within the cell Sorafenib tosylate / Nexavar® (Bayer) that function to attach Nilotinib hydrochloride monohydrate / phosphate groups to the Tasigna® (Novartis) amino acid tyrosine. By blocking the ability of protein tyrosine kinases to function, these compounds provide a tool for controlling cancerous cell growth.
Protein synthesis L-asparaginase / Elspar® (Merck & Co.)
Induces cell apoptosis inhibitors
Immunotherapeutic Induces cancer patients to Alpha interferon agents exhibit immune Angiogenesis Inhibitor / Avastin® responsiveness (Genentech)
IL-2→ Interleukin 2 (Aldesleukin) / Proleukin
® (Chiron)
IL-12→ Interleukin 12
Hormones Hormone therapies Toremifene citrate / Fareston® (GTX, Inc.)
Fulvestrant / Faslodex® (AstraZeneca) associated with
Raloxifene HCL / Evista® (Lilly) menopause and aging
Anastrazole / Arimidex® (AstraZeneca) seek to increase the
Letrozole / Femara® (Novartis) amount of certain
Fadrozole (CGS l 6949A ) hormones in your body to
Exemestane / Aromasin® (Pharmacia & compensate for age- or
Upjohn) disease-related hormonal
Leuprolide acetate / Eligard® (QTL USA) declines. Hormone Lupron® (TAP Pharm.) therapy as a cancer Goserelin acetate / Zoladex® (AstraZeneca) treatment either reduces Triptorelin pamoate / Trelstar® (Watson the level of specific Labs) hormones or alters the Buserelin / Suprefact® (Sanofi Aventis) cancer's ability to use Nafarelin these hormones to grow Cetrorelix / Cetrotide® (EMD Serono) and spread. Bicalutamide / Casodex® (AstraZeneca)
Nilutamide / Nilandron® (Aventis Pharm.)
Megestrol acetate / Megace® (BMS)
Somatostatin Analogs (Octreotide acetate /
Sandostatin® (Novartis))
Glucocorticoids Anti-inflammatory drugs Prednisolone used to reduce swelling Dexamethasone / Decadron® (Wyeth) that causes cancer pain.
Aromatose inhibitors Includes imidazoles Ketoconazole
mTOR inhibitors SiroUmus (Rapamycin) /
The mTOR signaling
Rapamune® (Wyeth) pathway was originally Temsirolimus (CCI-779) / Torisel® (Wyeth) discovered during studies Deforolimus (AP23573) (Ariad Pharm.) of the Everolimus (RADOOl) /Certican® (Novartis) immunosuppressive agent rapamycin. This highly conserved pathway regulates cell proliferation and metabolism in response to environmental factors, linking cell growth factor receptor signaling via phosphoinositide-3 - kinase (PI-3K) to cell growth, proliferation, and angiogenesis.
Chemotherapeutic Adriamycin, 5-Fluorouracil, Cytoxin, agents Bleomycin, Mitomycin C, Daunomycin,
Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins
One or more anti-cancer agents may be administered either simultaneously or before or after administration of an antibody or antigen binding portion thereof of the present invention.
Various aspects of the invention are described in further detail in the following subsections. π. Methods for Producing Antibodies of the Invention
(i) Monoclonal Antibodies
Monoclonal antibodies of the invention can be produced using a variety of known techniques, such as the standard somatic cell hybridization technique described by Kohler and Milstein (1975) Nature 256: 495, viral or oncogenic transformation of B lymphocytes or phage display technique using libraries of human antibody genes. In particular embodiments, the antibodies are fully human monoclonal antibodies.
Accordingly, in one embodiment, a hybridoma method is used for producing an antibody that binds ErbB3. In this method, a mouse or other appropriate host animal can be immunized with a suitable antigen in order to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the antigen used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes can then be fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and
Practice, pp.59-103 (Academic Press, 1986)). Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies:Principles and Practice, pp. 59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI- 1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal. The monoclonal antibodies secreted by the subclones can be separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
In another embodiment, antibodies and antibody portions that bind ErbB3 can be isolated from antibody phage libraries generated using the techniques described in, for example, McCafferty et al, Nature, 348:552-554 (1990). Clackson et al, Nature, 352:624-628 (1991), Marks et al, J. MoI. Biol., 222:581-597 (1991) and Hoet et al (2005) Nature Biotechnology 23, 344-348 ; U.S. Patent Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner et al; U.S. Patent Nos. 5,427,908 and 5,580,717 to Dower et al; U. S. Patent Nos. 5,969, 108 and 6, 172, 197 to McCafferty et al. ; and U. S . Patent Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 6,593,081 to Griffiths et al. Additionally, production of high affinity (nM range) human antibodies by chain shuffling (Marks et al, Bio/Technology, 10:779-783 (1992)), as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al, Nuc. Acids. Res., 21:2265-2266 (1993)) may also be used.
In a particular embodiment, the monoclonal antibody or antigen binding portion thereof that binds ErbB3 is produced using the phage display technique described by Hoet et al, supra. This technique involves the generation of a human Fab library having a unique combination of immunoglobulin sequences isolated from human donors and having synthetic diversity in the heavy-chain CDRs is generated. The library is then screened for Fabs that bind to ErbB3.
In yet another embodiment, human monoclonal antibodies directed against ErbB3 can be generated using transgenic or transchromosomic mice carrying parts of the human immune system rather than the mouse system (see e.g., Lonberg, et al. (1994) Nature 368(6474): 856-859; Lonberg, N. et al (1994), supra; reviewed in Lonberg, N. (1994) Handbook of Experimental Pharmacology 113:49-101; Lonberg, N. and Huszar, D. (1995) Intern. Rev. Immunol 13: 65-93, and Harding, F. and Lonberg, N. (1995) Ann. NY. Acad Sci. 764:536-546. See further, U.S. Patent Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; and 5,770,429; all to Lonberg and Kay; U.S. Patent No. 5,545,807 to Surani et al ; PCT Publication Nos. WO 92/03918, WO 93/12227, WO 94/25585, WO 97/13852, WO 98/24884 and WO 99/45962, all to Lonberg and Kay; and PCT Publication No. WO 01/14424 to Koπnan et al).
In another embodiment, human antibodies of the invention can be raised using a mouse that carries human immunoglobulin sequences on transgenes and transchomosomes, such as a mouse that carries a human heavy chain transgene and a human light chain transchromosome (see e.g., PCT Publication WO 02/43478 to Ishida et al). Still further, alternative transgenic animal systems expressing human immunoglobulin genes are available in the art and can be used to raise anti-ErbB3 antibodies of the invention. For example, an alternative transgenic system referred to as the Xenomouse (Abgenix, Inc.) can be used; such mice are described in, for example, U.S. Patent Nos. 5,939,598; 6,075,181; 6,114,598; 6, 150,584 and 6,162,963 to Kucherlapati et al.
Moreover, alternative transchromosomic animal systems expressing human immunoglobulin genes are available in the art and can be used to raise anti-ErbB3 antibodies of the invention. For example, mice carrying both a human heavy chain transchromosome and a human light chain tranchromosome can be used; as described in Tomizuka et al. (2000) Proc. Natl. Acad Sci. USA 97:722-727. Furthermore, cows carrying human heavy and light chain transchromosomes have been described in the art (Kuroiwa et al. (2002) Nature Biotechnology 20:889-894) and can be used to raise anti- ErbB3 antibodies of the invention. In yet another embodiment, antibodies of the present invention can be prepared using a transgenic plant and/or cultured plant cells (such as, for example, tobacco, maize and duckweed) that produce such antibodies. For example, transgenic tobacco leaves expressing antibodies or antigen binding portions thereof can be used to produce such antibodies by, for example, using an inducible promoter (see, e.g., Cramer et al., Curr. Top. Microbol. Immunol. 240:95 118 (1999)). Also, transgenic maize can be used to express such antibodies and antigen binding portions thereof (see, e.g., Hood et al., Adv. Exp. Med Biol. 464:127 147 (1999)). Antibodies can also be produced in large amounts from transgenic plant seeds including antibody portions, such as single chain antibodies (scFv's), for example, using tobacco seeds and potato tubers (see, e.g., Conrad et al., Plant MoI. Biol. 38:101 109 (1998)). Methods of producing antibodies or antigen binding portions in plants can also be found in, e.g., Fischer et al., Biotechnol. Appl. Biochem. 30:99 108 (1999), Ma et al, Trends Biotechnol. 13:522 7 (1995); Ma et al., Plant Physiol. 109:341 6 (1995); Whitelam et al, Biochem. Soc. Trans. 22:940 944 (1994) and U.S. Patent Nos. 6,040,498 and 6,815,184. The binding specificity of monoclonal antibodies or portions thereof that bind
ErbB3 prepared using any technique including those disclosed here, can be determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme- linked immunoabsorbent assay (ELISA). The binding affinity of a monoclonal antibody or portion thereof also can be determined by the Scatchard analysis of Munson et al, Anal. Biochem., 107:220 (1980).
In certain embodiments, an ErbB3 antibody or portion thereof produced using any of the methods discussed above may be further altered or optimized to achieve a desired binding specificity and/or affinity using art recognized techniques, such as those described herein.
In one embodiment, partial antibody sequences derived from an ErbB3 antibody may be used to produce structurally and functionally related antibodies. For example, antibodies interact with target antigens predominantly through amino acid residues that are located in the six heavy and light chain complementarity determining regions (CDRs). For this reason, the amino acid sequences within CDRs are more diverse between individual antibodies than sequences outside of CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of specific naturally occurring antibodies by constructing expression vectors that include CDR sequences from the specific naturally occurring antibody grafted onto framework sequences from a different antibody with different properties (see, e.g., Riechmann, L. et al, 1998, Nature 332:323- 327; Jones, P. et al, 1986, Nature 321 :522-525; and Queen, C. et al, 1989, Proc. Natl. Acad See. U.S.A. 86:10029-10033). Such framework sequences can be obtained from public DNA databases that include geπnline antibody gene sequences.
Thus, one or more structural features of an anti-ErbB3 antibody of the invention, such as the CDRs, can be used to create structurally related anti-ErbB3 antibodies that retain at least one functional property of the antibodies of the invention, e.g., inhibiting EGF-like ligand mediated phosphorylation of ErbB3; inhibiting one or more of heregulin, epiregulin, epigen or biregulin-mediated signaling through ErbB3; inhibiting proliferation or cells expressing ErbB3; and/or decreasing levels of ErbB3 on cell surfaces.
In a particular embodiment, one or more CDR regions selected from SEQ ID NOs:7-12, SEQ ID NOs: 13-18, SEQ ID NOs: 19-24, SEQ ID NOs:39-44, and SEQ ID NOs:45-50 is combined recombinantly with known human framework regions and CDRs to create additional, recombinantly-engineered, anti-ErbB3 antibodies of the invention. The heavy and light chain variable framework regions can be derived from the same or different antibody sequences. It is well known in the art that antibody heavy and light chain CDR3 domains play a particularly important role in the binding specificity/affinity of an antibody for an antigen (see, Hall et al, J. Imunol, 149: 1605-1612 (1992); Polymenis et al, J. Immunol, 152:5318-5329 (1994); lahn et al, Immunobiol, 193:400-419 (1995); Klimka et al, Brit. J. Cancer, 83:252-260 (2000); Beiboer et al, J. MoI Biol, 296:833-849 (2000); Rader et al, Proc. Natl. Acad ScL USA, 95:8910-8915 (1998); Barbas et al, J. Am. Chem. Soc, 116:2161-2162 (1994); Ditzel ef α/., J. Immunol, 157:739-749 (1996)). Accordingly, in certain embodiments, antibodies are generated that include the heavy and/or light chain CDR3s of the particular antibodies described herein (e.g., SEQ ED NOs:9, 15, 21, 41, 47 and/or SEQ ID NOs:12, 18, 24, 44, 50). The antibodies can further include the heavy and/or light chain CDRl and/or CDR2s of the antibodies of the present invention (e.g., SEQ ID NOs:7-8 and/or SEQ ED NOs: 10-11; SEQ ID NOs: 13- 14 and/or SEQ ID NOs: 16-17; SEQ ID NOs:20-21 and/or SEQ ID NOs:22-23; SEQ ID NOs:39-40 and/or SEQ ID NOs:42-43; or SEQ ID NOs:45-46 and/or SEQ ID NOs:48- 49).
The CDRl, 2, and/or 3 regions of the engineered antibodies described above can comprise the exact amino acid sequence(s) as those disclosed herein (e.g., CDRs of Ab #6, Ab #3, Ab #14, Ab #17, or Ab #19, set forth in SEQ ID NOs:7-12, 13-18, 19-24, 39- 44, and 45-50, respectively). However, the ordinarily skilled artisan will appreciate that some deviation from the exact CDR sequences may be possible while still retaining the ability of the antibody to bind ErbB3 effectively (e.g., conservative amino acid substitutions). Accordingly, in another embodiment, the engineered antibody may be composed of one or more CDRs that are, for example, 90%, 95%, 98%, 99% or 99.5% identical to one or more CDRs of Ab #6, Ab #3 or Ab #14.
In another embodiment, one or more residues of a CDR may be altered to modify binding to achieve a more favored on-rate of binding. Using this strategy, an antibody having ultra high binding affinity of, for example, 1010 M'1 or more, can be achieved. Affinity maturation techniques, well known in the art and those described herein, can be used to alter the CDR region(s) followed by screening of the resultant binding molecules for the desired change in binding. Accordingly, as CDR(s) are altered, changes in binding affinity as well as immunogenicity can be monitored and scored such that an antibody optimized for the best combined binding and low immunogenicity are achieved. In addition to, or instead of, modifications within the CDRs, modifications can also be made within one or more of the framework regions, FRl, FR2, FR3 and FR4, of the heavy and/or the light chain variable regions of an antibody, so long as these modifications do not eliminate the binding affinity of the antibody.
In another embodiment, the antibody is further modified with respect to effector function, so as to enhance the effectiveness of the antibody in treating cancer, for example. For example cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176: 1191-1195 (1992) and Shopes, B. J. Immunol.
148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al. Anti-Cancer Drug Design 3:219-230 (1989).
Also encompassed by the present invention are bispecific antibodies and immunoconjugates, as discussed below.
(ii) Bispecific Antibodies
Bispecific antibodies of the present invention include at least one binding specificity for ErbB3 and at least one binding specificity for another antigen, such as the product of an oncogene. Bispecific antibodies can be prepared as full length antibodies or antibody fragments {e.g. F(ab')2 bispecific antibodies).
Methods for making bispecific antibodies are well known in the art (see, e.g., WO 05117973 and WO 06091209). For example, production of full length bispecific antibodies can be based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (see, e.g., Millstein et al, Nature, 305:537-539 (1983)). Further details of generating bispecific antibodies can be found, for example, in Suresh et al., Methods in Enzymology, 121:210 (1986) and in Brennan et al., Science, 229: 81 (1985), which describes a chemical linkage process for making bispecific antibodies. Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers (see, e.g., Kostelny et al., J. Immunol, 148(5):1547-1553 (1992)). Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported (see, e.g., Gruber et al, J. Immunol, 152:5368 (1994)).
In a particular embodiment, the bispecific antibody comprises a first antibody or binding portion thereof which binds to ErbB3 and a second antibody or binding portion thereof which binds to ErbB2, ERbB3, ErbB4, EGFR, IGFl-R, C-MET, Lewis Y, MUC-I, EpCAM, CAl 25, prostate specific membrane antigen, PDGFR-α, PDGFR-β, C-KIT, or any of the FGF receptors.
(iii) Immunoconjugates
Immunoconjugates of the present invention can be formed by conjugating the antibodies or antigen binding portions thereof described herein to another therapeutic agent. Suitable agents include, for example, a cytotoxic agent (e.g., a chemotherapeutic agent), a toxin {e.g. an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), and/or a radioactive isotope (i.e., a radio conjugate).
Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated anti-ErbB3 antibodies. Examples include 212 Bi, 131 1, 131 In, 90Y and 186 Re.
Immunoconjugates of the invention can be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), dϋsocyanates (such as tolyene 2,6-dϋsocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Yitetta et al., Science 238: 1098 (1987). Carbon- 14-labeled 1- isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody (see, e.g., WO94/11026).
DI. Methods for Screening Antibodies of the Invention
Subsequent to producing antibodies or antigen binding portions that bind ErbB3, such antibodies, or portions thereof, can be screened for various properties, such as those described herein, using a variety of assays that are well known in the art. In one embodiment, the antibodies or antigen binding portions thereof are screened for the ability to inhibit EGF- like ligand mediated phosphorylation of ErbB3. This can be done by treating cells expressing ErbB3 with an EGF-like ligand in the presence and absence of the antibody or antigen binding portion thereof. The cells can then be lysed and the crude lysates can be centrifuged to remove insoluble material. ErbB3 phosphorylation can be measured, for example, by Western blotting followed by probing with an anti-phosphotyrosine antibody as described in Kim et al, supra and the Examples below.
In other embodiments, the antibodies and antigen binding portions are further screened for one or more of the following properties: (1) inhibition of ErbB3 -ligand {e.g., heregulin, epiregulin, epigen or biregulin) mediated signaling through ErbB3; (2) inhibition of proliferation of cells expressing ErbB3; (3) the ability to decrease levels of ErbB3 on cell surface (e.g., by inducing internalization of ErbB3), (4) inhibition of VEGF secretion of cells expressing ErbB3; (5) inhibition of the migration of cells expressing ErbB3; (6) inhibition of spheroid growth of cells expressing ErbB3; and/or (7) binding to an epitope located on domain I of ErbB3, each of which can be readily measured using art recognized techniques and those discussed herein.
Inhibition of one or more of heregulin, epiregulin, epigen or biregulin-mediated signaling through ErbB3 can be readily measured using routine assays, such as, described in Horst et al. supra. For example, the ability of an antibody or antigen binding portion thereof to inhibit heregulin, epiregulin, epigen or biregulin-mediated signaling through ErbB3 can be measured by kinase assays for known substrates of ErbB3 such as, for example, SHC and PI3K, as described in, for example, Horst et al. supra, Sudo et al, (2000) Methods Enzymol, 322:388-92; and Morgan et al. (1990) Eur. J. Biochem., 191:761-767, following stimulation by one or more of heregulin, epiregulin, epigen or biregulin. Accordingly, cells expressing ErbB3 can be stimulated with one or more of heregulin, epiregulin, epigen or biregulin, and incubated with a candidate antibody or antigen-binding portion thereof. Cell lysates subsequently prepared from such cells can be immunoprecipitated with an antibody for a substrate of ErbB3 (or a protein in a cellular pathway involving ErbB3) such as, for example, an anti- JNK-I antibody, and assayed for kinase activity (e.g., JNK kinase activity or PI3- kinase activity) using art recognized techniques. A decrease in or complete disappearance in level or activity (e.g., kinase activity) of a ErbB3 substrate or protein in a pathway involving ErbB3 in the presence of the antibody or antigen binding portion thereof, relative to the level or activity in the absence of the antibody or antigen binding portion thereof, is indicative of an antibody or antigen binding portion which inhibits one or more of heregulin, epiregulin, epigen or biregulin-mediated signaling.
In certain embodiments, the antibody or antigen binding portion thereof inhibits ErbB3-ligand (e.g., heregulin, epiregulin, epigen or biregulin) mediated signaling by decreasing the binding of one or more of heregulin, epiregulin, epigen or biregulin to ERbB3.
In order to select for those antibodies or antigen binding portions thereof which inhibit the binding of one or more of heregulin, epiregulin, epigen or biregulin to ErbB3, cells which express ErbB3 (e.g. MALME-3M cells, as described in the Examples infra), can be contacted with a labeled ErbB3-ligand (e.g., radiolabeled heregulin, epiregulin, epigen or biregulin) in the absence (control) or presence of the anti-ErbB3 antibody or antigen binding portion thereof. If the antibody or antigen binding portion thereof inhibits heregulin, epiregulin, epigen or biregulin binding to ErbB3, then a statistically significantly decrease in the amount of label recovered (e.g., radiolabeled heregulin, epiregulin, epigen or biregulin), relative to the amount in the absence of the antibody or antigen binding portion thereof, will be observed. The antibody or antigen binding portion thereof may inhibit the binding of the ErbB3-ligand (e.g., heregulin, epiregulin, epigen or biregulin) by any mechanism. For example, the antibody or antigen binding portion thereof may inhibit binding of the ErbB3 ligand (e.g., one or more of heregulin, epiregulin, epigen or biregulin) to ErbB3 by binding to the same site or an overlapping site on ErbB3 as the ErbB3 ligand.
Alternatively, the antibody or antigen binding portion thereof may inhibit binding of an ErbB3 ligand by altering or distorting the conformation of ErbB3, such that it is unable to bind to the ErbB3 ligand.
Antibodies and antigen binding portions thereof that decrease levels of ErbB3 on cell surfaces can be identified by their ability to downregulate ErbB3 on tumor cells. In certain embodiments, the antibodies or antigen binding portions thereof decrease ErbB3 cell surface expression by inducing internalization (or increasing endocytosis) of Erbb3. To test this, ErbB3 can be biotinylated and the number of ErbB3 molecules on the cell surface can be readily determined, for example, by measuring the amount of biotin on a monolayer of cells in culture in the presence or absence of an antibody or antigen binding portion thereof, for example, as described in, e.g., Waterman et al., J. Biol. Chem. (1998), 273: 13819-27, followed by immunoprecipitation of ErbB3 and probing with streptavidin. A decrease in detection of biotinylated ErbB3 over time in the presence of an antibody or antigen binding portion is indicative of an antibody which decreases ErbB3 levels on cell surfaces.
Antibodies or antigen binding portions thereof of the present invention can also be tested for their ability to inhibit proliferation of cells expressing ErbB3, for example, tumor cells, using art recognized techniques, such as the Cell Titer Glow Assay described in the Examples below (also see, e.g., Macallan et al, Proc. Natl. Acad Sd. (1998) 20;95(2):708-13; Perez et al. (1995) Cancer Research 55, 392-398).
In another embodiment, the antibodies or antigen binding portions thereof are screened for the ability to inhibit VEGF secretion of cells expressing ErbB3. This can be done by using well-known assays, such as the VEGF ELISA kit available from R&D Systems (Minneapolis, MN, Cat.#DY293B). Similarly, the antibodies or portions can be screened for the ability to inhibit the migration of cells expressing ErbB3 (e.g., MCF-7 cells) using a trans-well assay (Millipore Corp., Billerica, MA, Cat # ECM552) as described herein.
In another embodiment, the antibodies or antigen binding portions thereof are screened for the ability to inhibit spheroid growth of cells expressing ErbB3. This can be done by using an assay which approximates conditions of a developing tumor growth (see, e.g., Herman et al. (2007) Journal of Biomolecular Screening Electronic publication) as described herein. Antibodies or antigen binding portions thereof that bind to the same or overlapping epitopes as one or more antibodies of the present invention can also be identified using standard techniques known in the art and described herein. For example, in order to screen for antibodies which bind to the same or an overlapping epitope on ErbB3 bound by an antibody of interest, a cross-blocking assay, such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed.
IV. Pharmaceutical Compositions In another aspect, the present invention provides a composition, e.g., a pharmaceutical composition, containing one or a combination of monoclonal antibodies, or antigen-binding portion(s) thereof, of the present invention, formulated together with a pharmaceutically acceptable carrier. In one embodiment, the compositions include a combination of multiple {e.g., two or more) isolated antibodies of the invention, which bind different epitopes on ErbB3.
As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, i.e., antibody, bispecifϊc and multispecific molecule, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.
A "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see e.g., Berge, S.M., et al. (1977) J. Pharm. Sci. 66:1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl- substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N- methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.
Pharmaceutical compositions of the invention can be administered alone or in combination therapy, i.e., combined with other agents. For example, the combination therapy can include a composition of the present invention with at least one or more additional therapeutic agents, such as the anti-cancer agents described infra. The pharmaceutical compositions of the invention can also be administered in conjunction with radiation therapy and/or surgery. A composition of the present invention can be administered by a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
To administer a compound of the invention by certain routes of administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. For example, the compound may be administered to a subject in an appropriate carrier, for example, liposomes, or a diluent. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al. (1984) J. Neuroimmunol. 7:27).
Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions. Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization micro filtration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze- drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. For example, the human antibodies of the invention may be administered once or twice weekly by subcutaneous injection or once or twice monthly by subcutaneous injection. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
For the therapeutic compositions, formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated, and the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the composition which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.001 per cent to about ninety percent of active ingredient, preferably from about 0.005 per cent to about 70 per cent, most preferably from about 0.01 per cent to about 30 per cent. Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate. Dosage forms for the topical or transdermal administration of compositions of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Particular examples of adjuvants which are well-known in the art include, for example, inorganic adjuvants (such as aluminum salts, e.g., aluminum phosphate and aluminumhydroxide), organic adjuvants (e.g., squalene), oil-based adjuvants, virosomes (e.g., virosomes which contain a membrane-bound heagglutinin and neuraminidase derived from the influenza virus). Prevention of presence of microorganisms may be ensured both by sterilization procedures, supra, and by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given alone or as a pharmaceutical composition containing, for example, 0.001 to 90% (more preferably, 0.005 to 70%, such as 0.01 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, a suitable daily dose of a composition of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. It is preferred that administration be intravenous, intramuscular, intraperitoneal, or subcutaneous, preferably administered proximal to the site of the target. If desired, the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation (composition).
Therapeutic compositions can be administered with medical devices known in the art. For example, in a preferred embodiment, a therapeutic composition of the invention can be administered with a needleless hypodermic injection device, such as the devices disclosed in U.S. Patent Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556. Examples of well-known implants and modules useful in the present invention include: U.S. Patent No. 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Patent No. 4.,486,194, which discloses a therapeutic device for administering medications through the skin; U.S. Patent No. 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system having multi-chamber compartments; and U.S. Patent No. 4,475,196, which discloses an osmotic drug delivery system. Many other such implants, delivery systems, and modules are known to those skilled in the art.
In certain embodiments, the monoclonal antibodies of the invention can be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds of the invention cross the BBB (if desired), they can be formulated, for example, in liposomes. For methods of manufacturing liposomes, see, e.g., U.S. Patents 4,522,811; 5,374,548; and 5,399,331. The liposomes may comprise one or more moieties which are selectively transported into specific cells or organs, thus enhance targeted drug delivery (see, e.g., V. V. Ranade (1989) J. Clin. Pharmacol. 29:685). Exemplary targeting moieties include folate or biotin (see, e.g., U.S. Patent 5,416,016 to Low et ah); mannosides (Umezawa et ah, (1988) Biochem. Biophys. Res. Commun. 153:1038); antibodies (P.G. Bloeman e/ α/. (1995) FEBS Lett. 357: 140; M. Owais et al. (1995) Antimicrob. Agents Chemother. 39: 180); surfactant protein A receptor (Briscoe et ah (1995) Am. J. Physiol. 1233:134), different species of which may comprise the formulations of the inventions, as well as components of the invented molecules; pl20 (Schreier et al. (1994) J. Biol. Chem. 269:9090); see also K. Keinanen; M.L. Laukkanen (1994) FEBS Lett. 346:123; JJ. Killion; I.J. Fidler (1994) Immunomethods 4:273. V. Methods of Using Antibodies of the Invention
The present invention also provides methods of using antibodies and antigen- binding portions thereof that bind ErbB3 in a variety of ex vivo and in vivo diagnostic and therapeutic applications. For example, antibodies of the invention can be used for treating a disease associated with ErbB3 dependent signaling, including a variety of cancers.
In one embodiment, the present invention provides a method for treating a disease associated with ErbB3 dependent signaling by administering to a subject an antibody or antigen binding portion thereof of the invention in an amount effective to treat the disease. Suitable diseases include, for example, a variety of cancers including, but not limited to, melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal cancer, colon cancer, lung cancer, and prostate cancer.
The antibody can be administered alone or with another therapeutic agent which acts in conjunction with or synergistically with the antibody to treat the disease associated with ErbB3 mediated signaling. Such therapeutic agents include, for example, the anticancer agents described infra (e.g., cytotoxins, chemotherapeutic agents, small molecules and radiation).
In another embodiment, the present invention provides a method for diagnosing a disease (e.g., a cancer) associated with ErbB3 upregulation in a subject, by contacting antibodies or antigen binding portions of the invention (e.g., ex vivo or in vivo) with cells from the subject, and measuring the level of binding to ErbB3 on the cells. Abnormally high levels of binding to ErbB3 indicate that the subject has a disease associated with ErbB3 upregulation.
Also within the scope of the present invention are kits comprising antibodies and antigen binding portions thereof of the invention which optionally include instructions for use in treating or diagnosing a disease associated with ErbB3 upregulation and/or ErbB3 dependent signaling. The kits may include a label indicating the intended use of the contents of the kit. The term label includes any writing, marketing materials or recorded material supplied on or with the kit, or which otherwise accompanies the kit. Other embodiments of the present invention are described in the following
Examples.
The present invention is further illustrated by the following examples which should not be construed as further limiting. The contents of Sequence Listing, figures and all references, patents and published patent applications cited throughout this application are expressly incorporated herein by reference. Examples Materials and Methods
Throughout the examples, the following materials and methods were used unless otherwise stated.
In general, the practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, recombinant DNA technology, immunology (especially, e.g., antibody technology), and standard techniques in polypeptide preparation. See, e.g., Sambrook, Fritsch and Maniatis, Molecular Cloning: Cold Spring Harbor Laboratory Press (1989); Antibody
Engineering Protocols (Methods in Molecular Biology), 510, Paul, S., Humana Pr (1996); Antibody Engineering: A Practical Approach (Practical Approach Series, 169), McCafferty, Ed., IrI Pr (1996); Antibodies: A Laboratory Manual, Harlow et al, C.S.H.L. Press, Pub. (1999); and Current Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons (1992). In vitro and in vivo model systems for assaying HCV biology are described, for example, in Cell culture models and animal models of viral hepatitis. Part II: hepatitis C, Lab. Anim. (NY).;34(2):39-47 (2005) and in The chimpanzee model of hepatitis C virus infections, ILAR J.;42(2): 117-26 (2001).
Cell Lines
All the cell lines used in the experiments described below were obtained from the National Cancer Institute or provided by investigators, as indicated. Cell Lines:
MCF7- ATCC cat. No. HTB-22 T47D- ATCC cat. No. HTB-133
Colo357- These cells were obtained from an academic investigator and are described by KoIb et al. (2006) Int. J. Cancer, 120:514-523. Dul45- ATCC cat. No. HTB-81
OVCAR8- source already described in provisional application. H1975 ATCC cat. No. CRL-5908
Pulverization of Tumor Cells
A cryopulverizer (Covaris Inc) was used for the pulverization of tumors. Tumors were stored in special bags (pre- weighed before the addition of the tumor) and placed in liquid nitrogen while handling them. For small tumors, 200 uL of Lysis buffer was first added to the bag containing the tumor, frozen in liquid nitrogen and then pulverized to improve the recovery of the tumor from the bag. Pulverized tumors were transferred to 2 mL Eppendorf tubes and placed in liquid nitrogen until ready for further processing Lysis of Tumor Cells Tumors were lysed in Lysis buffer supplemented with protease and phosphatase inhibitors. Lysis Buffer was added to the tumor aliquots in a final concentration of about 62.5 mg/mL. Tumor samples were homogenized by vortexing for 30 sec and incubating on ice for about 30 min. The lysates were spun for about 10 min in Qiagen Qiashredder columns for further homogenization of the samples. Cleared lysates were aliquoted into fresh tubes for further processing. BCA Assay
BCA assay (Pierce) was performed following the manufacturer's protocol on all tumor samples. The total protein concentration (in mg/mL) of each tumor sample was later used in the normalization of the ELISA results ELISA Assay
All ELISA reagents for the total and phospho-ErbB3 ELISAs were purchased from R&D Systems as Duoset kits. 96-well Nunc Maxisorb plates were coated with 50 uL of an antibody and incubated overnight at room temperature. Next morning, plates were washed 3 times with 1000 μl/well in the BioTek plate washer with PBST (0.05% Tween-20). Plates were subsequently blocked for about an 1 hr at room temperature with 2 % BSA in PBS. The plates were washed 3 times with 1000 μl/well in the BioTek plate washer with PBST (0.05%Tween-20). 50 μL of cell lysates and standards diluted in 50% Lysis buffer and 1%BSA were used in duplicates for further processing. Samples were incubated for 2hrs at 4°C on a plate shaker and washed 3 times with 1000 μl/well in the BioTek plate washer with PBST (0.05%Tween-20). About 50 μl of a detection antibody diluted in 2% BSA, PBST was added and incubated for about 1 hr at room temperature. For phosphor-ErbB3, the detection antibody was directly conjugated to horse radish peroxidase (HRP) and incubated for 2 hrs at room temperature. The plate was washed 3 times with 1000 μl/well in the BioTek plate washer with PBST
(0.05%Tween-20). About 50 μl of Streptavidin-HRP was added and incubate for 30 min at room temperature (except for pErbB3). The plates were washed 3 times with 1000 μl/well in the BioTek plate washer with PBST (0.05%Tween-20). About 50 μL of Supersignal Pico ELISA substrate was added and the plate was read using a Fusion plate reader. The data was analysed using EXCEL. Duplicate samples were averaged and the error bars were used to represent the standard deviation between the two replicates.
Example 1; Production of Antibodies Using Phage Display
In order to obtain human anti-ErbB3 antibodies referred to herein as Ab #6, Ab #3, Ab #14, Ab #17, and Ab #19, a human Fab-phage library including a unique combination of immunoglobulin sequences obtained from human donors (Hoet et al. supra, incorporated by reference in its entirety herein) was initially screened for ErbB3 binders. Using purified ErbB3 and a Chinese hamster ovary cell line expressing cell surface ErbB3, 73 unique Fab sequences from the library were identified. These 73 clones were then reformatted as Fab only without the phage. Using high throughput methods, these Fabs were expressed on a small scale and tested for binding using ELISA and the Flexchip method which is a high-throughput surface plasmon resonance (SPR) technology. The 73 Fabs without the phage were spotted on a chip surface and the binding kinetics and epitope blocking to a ErbB3-his fusion target protein or a ErbB3- Fcprotein (R & D Systems) were measured. The equilibrium binding constant and on/off rates for the Fabs were calculated from the data obtained. Binding of the various Fabs to MALME-3M cells was next examined using about 500 nM of the Fabs and a 1:750 dilution of a goat anti-human Alexa 647 secondary antibody. As shown in Figures IA and IB, several candidate Fabs exhibited appreciable staining of MALME-3M cells.
Example 2; Optimization of anti-ErbB3 Fabs
Subsequent to the identification of Fabs which blocked the binding of ErbB3 ligand, heregulin, to ErbB3, the VH and VL sequences of the Fabs were codon- optimized as follows.
Specifically, the VH and VL regions were reformatted using expression constructs for expression as an IgGl or IgG2 isotype. The constructs included a Selexis backbone which has a cassette designed for substitution of the appropriate heavy and light chain sequences. The Selexis vectors included a CMV promoter and a matching poly-A signal.
The nucleic acid sequences for the codon-optimized VH and VL of Ab #6 are set forth in SEQ ID NOs:25 and 26, respectively, and those for Ab #3 are set forth in SEQ ID NOs: 27 and 28, respectively, as shown in Figure 22.
Example 3: Binding Affinity for ErbB3
The dissociation constants of the anti-ErbB3 antibodies were measured using two independent techniques, i.e., a Surface Plasmon Resonance Assay and a cell binding assay using MALME-3M cells.
Surface Plasmon Resonance Assay
The Surface Plasmon Resonance Assay (also referred to as the Flexchip assay) was performed as described in Wassaf et al. (2006) Analytical Biochem., 351:241 -253. The KD value was calculated based on the formula KD = KZK3.
The KD values of Ab #6 and Ab #3, respectively, as measured using the Surface Plasmon Resonance Assay, are depicted in Figures 2 A and 2B. Ab #6 had a KD value of about 4 nM and Ab #3 had a KD value of about 8 nM, as depicted in Figures 2A and 2B, respectively.
Cell Binding Assay The cell binding assay for determining the KD values of Ab #6 and Ab #3 was performed as follows.
MALME-3M cells were detached with 2 mis trypsin-EDTA + 2 mis RMPI + 5mM EDTA at room temperature for 5 minutes. Complete RPMI (10 mis) was added immediately to the trypsinized cells, resuspended gently and spun down in a Beckman tabletop centrifuge at 1100 rpm for 5 minutes. Cells were resuspended in BD stain buffer (PBS + 2% fetal bovine serum + 0.1% sodium azide, Becton Dickinson) at a concentration of 2 x 106 cells per ml and 50 μl (1 x 105 cells) aliquots were plated in a 96-well titer plate.
A 150 μl solution of 200 nM anti-ErbB3 antibody (Ab #6 or Ab #3) in BD stain buffer was prepared in an eppendorf tube and serially diluted 2-fold into 75 μl BD stain buffer. The concentrations of the diluted antibody ranged from 200 nM to 0.4 nM. 50 μl aliquots of the different protein dilutions were then added directly to the 50 ul cell suspension giving the final concentrations of 100 nM, 50 nM, 25 nM, 12 nM, 6 nM, 3 nM, 1.5 nM, 0.8 nM, 0.4 nM and 0.2 nM of the antibody. Aliquoted cells in the 96-well plate were incubated with the protein dilutions for
30 minutes at room temperature on a platform shaker and washed 3 times with 300 μl BD stain buffer. Cells were then incubated with 100 μl of a 1 :750 dilution of Alexa 647-labeled goat anti-human IgG in BD stain buffer for 45 minutes on a platform shaker in the cold room. Finally, cells were washed twice, pelleted and resuspended in 250 μl BD stain buffer + 0.5 μg/ml propidium iodide. Analysis of 10,000 cells was done in a FACScalibur flow cytometer using the FL4 channel. MFI values and the corresponding concentrations of the anti-ErbB3-antibodies were plotted on the y-axis and x-axis, respectively. The KD of the molecule was determined by GraphPad Prism using the one- site binding model for a non-linear regression curve. The KD value was calculated based on the formula Y=B max* X/ KD + X (Bmax
= fluorescence at saturation. X= antibody concentration. Y = degree of binding). As shown in Figures 2C and 2D, Ab # 6 and Ab #3 had KD values of about 4 nM and 1.3 nM, respectively, in a cell binding assay using MALME-3M cells.
Example 4: Binding Specificity / Epitope Binding for ErbB3
The binding specificity of an IgG2 isotype of Ab #6 to ErbB3 was assayed using ELISA as follows. Identification of the epitope bound by Ab #6 was also analyzed. Specifically, 96-well Nunc Maxisorb plates were coated with 50 μl of 5 μg/ml protein (recombinant human ErbB3, recombinant human EGFR or unrelated protein (BSA)) and incubated overnight at room temperature. The next morning, plates were washed 3 times with 1000 μl/well of PBST (0.05% Tween-20) in the BioTek plate washer. The wells were blocked for 1 hr at room temperature with 2 % BSA in PBS. The plates were washed 3 times with 1000 μl/well of PBST (0.05%Tween-20) in the BioTek plate washer. About 50 μL of the Ab #6 was added at several dilutions (1 μM and serial 2 fold dilutions) in 2% BSA, PBST. All samples were run in duplicate and incubated for 2hrs at 4°C on a plate shaker. The plates were washed plates 3 times with 1000 μl/well of PBST (0.05%Tween-20) in the BioTek plate washer. 50 μl of human IgG detection antibody (HRP conjugated (Bethyl Inc; 1 :75000 dilution in 2% BSA, PBST)) was added and the plates were incubated for 1 hr at room temperature. The plates were washed plate 3 times with 1000 μl/well of PBST (0.05%Tween-20) in the BioTek plate washer. 50 μL of Supersignal Pico ELISA substrate was added and the plate was read on the Fusion plate reader. The data was analyzed using the EXCEL program. Duplicate samples were averaged and the error bars represent the standard deviation between the two replicates.
As shown in Figure 3, Ab #6 bound recombinant ErbB3 in an ELISA, but did not show any appreciable binding to EGFR, BSA or TGF-α. A fragment (truncation mutant) corresponding to amino acid residues 20-202 of
ErbB3 was cloned into the yeast display vector pYD2 (a modified version of pYDl (Invitrogen) with a stop codon engineered in front of the His tag) between the Nhe and BsiWI restriction sites. The plasmid was transformed into the yeast strain EBYlOO (Invitrogen) and clones containing the plasmid selected on Trp- selective medium. The clone was grown in glucose containing medium overnight at 3O0C and expression of the ErbB3 truncation mutant was induced by transfer to a galactose-containing medium for 2 days at 180C. Yeast displaying the ErbB3 truncation mutant were stained with 50 nM of Ab #6, followed by a goat anti-human antibody labeled with Alexa dye-647. A separate sample was stained with the goat anti-human antibody only to show that there is no non-specific binding to yeast of the secondary antibody. Analysis was performed by flow cytometry on the FACS Calibur cell sorter (BD Biosciences).
As shown in Figure 30, Ab #6 bound to the truncation mutant, i.e., amino acid residues 20-202 of ErbB3.
Example 5: Downregulation of Total ErbB3 on Tumor Cells
The ability of Ab #6 to downregulate ErbB3 expression both in vitro and in vivo in tumor cells was tested as follows. MALME-3M cells were seeded in 96 well tissue culture plates and grown in RPMI- 1640 media supplemented with antibiotics, 2mM L-glutamine and 10% fetal bovine serum (FBS) for 24 hours at 370C and 5% carbon dioxide. Media was then switched to RPMI- 1640 MEDIA with antibiotics, 2mM L-glutamine with and without the antibody at concentrations of IuM, 25OnM, 63nM, 16nM, 4.OnM, 1.OnM, 24OpM, 6IpM and 15pM. Cells were grown for 24 hours at 37°C and 5% carbon dioxide, washed with cold PBS, then harvested with mammalian protein extract (MPER) lysis (Pierce, 78505) buffer containing 15OmM NaCl, 5mM sodium pyrophosphate, lOuM bpV (phen), 5OuM phenalarsine, ImM sodium orthovanadate, and protease inhibitor cocktail (Sigma, P714). Cell lysates were diluted two-fold with 4% bovine serum albumin in phosphate buffered saline with 0.1% tween-20, then analyzed by ELISA with mouse anti-human ErbB3 capture antibody and biotinylated mouse anti-human ErbB3 secondary detection antibody. Signal was generated with streptavidin conjugated to horseradish-peroxidase reacted with chemiluminescent substrate (Pierce, 37070). ELISAS were visualized using a luminometer.
As shown in Figure 4, Ab #6 decreased total ErbB3 levels by about 46.9% in MALME-3M cells in vitro, as measured by ELISA. Media containing no serum and antibody was used as control.
In a further experiment, the downregulation of ErbB3 receptors on MALME-3M cells using IgGl and IgG2 isotypes of Ab #6 was examined using FACS analysis.
MALME-3M cells were trypsinized from a 15 cm dish and washed once with RPMI + 10% fetal bovine serum. Cell pellets were resuspended at a density of 1 x 106 cells per ml. Two aliquots of 2 x 105 cells were added to a 12-well tissue culture plate and resuspended in a final volume of 800 ul RPMI + 10% fetal bovine serum. To one well, Ab #6 IgGl or Ab #6IgG2 isotype was added to a final concentration of 100 nM (treated sample) and to the other well, an equivalent volume of PBS was (untreated sample) was added.
The following day, treated and untreated cells were trypsinized, washed and incubated with 100 nM of Ab #6 in BD stain buffer for 30 minutes on ice. Cells were washed twice with 1 ml BD stain buffer and incubated with 100 ul of a 1 :500 dilution of Alexa 647-labeled goat anti-human Alexa 647 for 45 minutes on ice. Cells were then washed and resuspended in 300 ul BD stain buffer + 0.5 ug/ml propidium iodide. Analysis of 10,000 cells was done in a FACScalibur flow cytometer using the FL4 channel. As shown in Figures 5 A and 5B, both IgGl and IgG2 isotypes of Ab #6 downregulated ErbB3 on MALME-3M cells by about 62% and about 66%, respectively.
In order to determine whether this decrease was due to internalization of the ErbB3 receptor on the surface of MALME-3M cells, the expression of ErbB3 in the presence of the antibody over time was measured. Specifically, MALME-3M cells were trypsinized from a 15 cm dish and washed once with RPMI + 10% fetal bovine serum. Cell pellets were resuspended at a density of 1 x 106 cells per ml. Two aliquots of 2 x 105 cells were added to a 12-well tissue culture plate and resuspended in a final volume of 800 μl RPMI + 10% fetal bovine serum. To one well, the anti-ErbB3 antibody was added to a final concentration of 100 nM (treated sample) and to the other well, an equivalent volume of PBS was (untreated sample) was added. The following day, treated and untreated cells were trypsinized, washed and incubated with 100 nM anti- ErbB3 antibody in BD stain buffer for 30 minutes on ice. Cells were washed twice with 1 ml BD stain buffer and incubated with 100 μl of a 1:500 dilution of Alexa 647-labeled goat anti-human Alexa 647 for 45 minutes on ice. Cells were then washed and resuspended in 300 μl BD stain buffer + 0.5 μg/ml propidium iodide. Analysis of 10,000 cells was done in a FACScalibur flow cytometer using the FL4 channel.
As shown in Figure 6, downregulation of ErbB3 in the presence of Ab #6 was measured at 0 hour (Figure 6A), 0.5 hour (Figure 6B), 2 hour (Figure 6C) and 24 hours (Figure 6D). As shown in Figure 6A-6D, about 50% of the cell surface ErbB3 receptors were downregulated after about 30minutes and at about 24 hours, about 93% of the cell surface receptors were downregulation.
The ability of Ab #6 to cause ErbB3 downregulation in vivo in melanoma cells was also examined as follows.
Briefly, T-cell deficient nu/nu mice (3-4 week old female mice originated at NIH; outbred; albino background) were purchased from Charles River Labs (Wilmington, MA). MALME-3M cells for implantation were grown in culture (RPMI media, 10% FBS, L-glutamine and antibiotics, 37°C, 5% CO2) to about 80% confluency before harvesting. Cells were kept on ice until implantation. Mice were implanted via subcutaneous injection with lOOul MALME-3M cells on the right flank and allowed to recover while being monitored for initial tumor growth.
The tumors were measured (length by width) by digital caliper and the mice were dosed with IgG2a (Sigma, M7769-5MG) by intravenous injection. Mice were dosed intra-peritoneally every other day with either 15 μg or 100 μg of antibody number 6 and tumors were measured three times per week and recorded in a Microsoft EXCEL spreadsheet.
Final tumor measurements (L x W) were taken, the mice were euthanized by CO2 asphyxiation and tumors were excised, snap frozen in liquid nitrogen, and were stored at -800C (for biochemical analysis). Final tumor measurements were analyzed and graphed by tumor area and tumor volume as described, for example, in Burtrum et al, (2003) Cancer Res., 63:8912-8921. The data was also analyzed by "normalized' and "non-normalized" means for both tumor volume and tumor area. For the "normalization" of the data, at each time point of measurement, each tumor in each group was divided by the initial tumor size determined by caliper measurement.
As shown in Figure 7, among the various antibodies tested in this assay, Ab #6 caused downregulation of total ErbB3 as soon as 24 hours post-injection in tumors treated with either IgGl or IgG2 isotype of Ab #6). PBS was used as a control
In a further experiment, the ability of Ab #6 to downregulate ErbB3 in ADRr xenografts in vivo was examined.
Briefly, the samples were pulverized in a cryopulverizer (Covaris Inc). Tumors were stored in special bags (pre- weighed before the addition of the tumor) and placed in liquid nitrogen while handling them. For small tumors, 200 μL of Lysis buffer was first added to the bag with the tumor, frozen in liquid nitrogen and then pulverized to improve the recovery of the tumor from the bag. Pulverized tumors were transferred to 2 ml Eppendorf tubes and placed in liquid nitrogen until lysed. Tumors were lysed in Lysis buffer supplemented with protease and phosphotase inhibitors. Lysis Buffer was added to the tumor aliquots in a final concentration of 62.5 mg/ml. Tumor samples were homogenized by vortexing for 30 seconds and letting them sit on ice for 30 min. The lysates were spun for 10 minutes in Qiagen Qiashredder columns for further homogenization of the samples. Cleared lysates were aliquoted into fresh tubes.
The BCA assay was performed as set forth in the materials and methods section supra.
The total levels of ErbB3 were determined by ELISA. The ELISA reagents were purchased from R&D Systems as Duoset kits. 96-well Nunc Maxisorb plates were coated with 50 μl of respective capture antibody and incubated overnight at room temperature. The next morning, the plates were washed 3 times with 1000 μl/well in a BioTek plate washer with PBST (0.05% Tween-20) and then blocked for 1 hour at room temperature with 2 % BSA in PBS. The plates were then washed three times with 1000 μl/well in the BioTek plate washer with PBST (0.05%Tween-20). Lysates (50 μl) and standards were diluted in 50% Lysis buffer and 1%BSA; all samples were run in duplicate. Plates were incubated for 2 hours at 4° C on a plate shaker and then washed three times with 1000 μl/well in a BioTek plate washer with PBST (0.05%Tween-20). Fifty micro liters of detection antibody diluted in 2% BSA, PBST was added and the plates were incubated for 1 hour at room temperature. Plates were washed three times with 1000 μl/well in the BioTek plate washer with PBST (0.05%Tween-20). Fifty microliters of Streptavidin-HRP was added and the plates were incubated for 30 miutes at room temperature. Plates were washed again three times with 1000 μl/well in a BioTek plate washer with PBST (0.05%Tween-20). Fifty microliters of Supersignal Pico ELISA substrate was added and readout was performed on a Fusion plate reader. Data was analyzed using EXCEL. Duplicate samples were averaged and the error bars represent the standard deviation between the two replicates.
The results of this experiment are shown in Figure 8. As shown in Figure 8, Ab #6 downregulated ErbB3 in ADRr xenografts in vivo.
Example 6; Inhibition of Tumor Cell Proliferation
The ability of Ab #6 to inhibit cellular proliferation of cells expressing ErbB3 (e.g., cancer cells) was examined as follows.
MALME3M, ACHN and NCI/ ADRr cells were seeded in 96 well tissue culture plates and grown in RPMI- 1640 media supplemented with antibiotics, 2mM L- glutamine and 10% fetal bovine serum (FBS) for 24 hours at 37 degrees Celsius and 5% carbon dioxide. Media was then switched to RPMI- 1640 media with antibiotics, 2mM L-glutamine and with and without the antibody at IuM, 25OnM, 63nM, 16nM, 4.OnM, 1.OnM, 24OpM, 6IpM and 15pM concentrations. Cells were grown for 96 hours at 37°C and 5% carbon dioxide, then harvested with CellTiter-Glo® Luminescent Cell Viability Assay (Promega, G7573) and analyzed on a luminometer. Media containing no serum and antibody was used as control.
As shown in Figures 9, 10 and 11, Ab #6 inhibited proliferation of MALME-3M cells (Figure 9), ADRr ovarian cancer cells (Figure 10) and ACHN cells (Figure 11) which express ErbB3. Specifically, Ab # 6 inhibited proliferation of MALME-3M cells by about 19.6%, as measured using the Cell Titer Glow assay, and inhibited proliferation of ADRr ovarian cancer cells by about 30.5%. Also, as shown in Figure 11, Ab # 6 inhibited proliferation of ACHN cells by about 25.4%.
Example 7; Inhibition of ErbB3 Phosphorylation in Tumor Cells
The ability of Ab #6 to inhibit ErbB3 phosphorylation in vivo was examined as follows.
The samples were pulverized using the technique described in Example 5 supra, with respect to Figure 8. The BCA assay was performed as set forth in the Materials and Methods section supra, and the ELISA assay was performed as described in Example 5 supra with respect to Figure 8.
The results of this experiment are shown in Figure 12. As shown in Figure 12, Ab #6 significantly inhibited ErbB3 phosphorylation in ADRr ovarian xenografts in vivo, as measured by the amount of phosphorylated ErbB3 (pErbB3) in ng/mg of total protein.
The ability of Ab #6 to inhibit betacellulin (BTC) or heregulin (HRG) induced ErbB3 phosphorylation was also examined, as follows. Ovarian ADRr cells were preincubated with Ab #6 for 30 minutes prior to stimulation with 50 mM BTC, 10 mM HRG or 333 nM TGF-α. Following pre incubation, the media was removed and the cells were stimulated for 5 minutes at 370C, 5% CO2 with 5OnM BTC or 333nM TGF-α (for PE498). HRG controls (5 minutes, 5nM), 10% serum and 0% serum controls were also used. Cells were washed with IX cold PBS and lysed in 30μl cold lysis buffer (M-PER buffer phis sodium vanadate (NaVO4, Sigma), 2-glycerophosphate, phenylarsine oxide, BpV and protease inhibitors) by incubating on ice for 30 minutes. Lysates were stored overnight at -800C.
As shown in Figures 13 A- 13 C, Ab #6 significantly inhibited both betacellulin and heregulin-mediated phosphorylation of ErbB3.
In a further experiment, the ability of Ab #6 to inhibit ErbB3 phosphorylation in ovarian tumor cell lines OVCAR 5 and OVCAR 8 was examined as follows.
The OVCAR 5 and OVCAR 8 cell lines were obtained from the National Cancer Institute, Division of Cancer Treatment and Diagnostics ("DCTD"). The ELISA was performed as described in the Materials and Methods section supra.
The results of this experiment are depicted in Figures 14A and 14B. As depicted in Figures 14A and 14B, Ab #6 inhibited ErbB3 phosphorylation in both OVCAR 5 and OVCAR 8 ovarian cancer cell lines.
As discussed above, Ab #6 inhibits betacellulin-mediated phosphorylation of ErbB3. In order to investigate whether betacellulin-mediated phosphorylation of ErbB3 occurs through ErbBl or ErbB3, the following experiment was performed.
ADRr cells or MALME-3M cells (1 x 105 ) were pre-incubated with 25μM of anti-ErbB3 Ab # 6 or 25 μM of Erbitux (as control) in 50μl BD stain buffer for 30 minutes on ice. After 30 minutes, 50 μl of 400 nM biotinylated BTC was added to the cells and incubated for another 30 minutes on ice. This gave a final concentration of 12.5 μM antibodies and 200 nM BTC. Cells were then washed twice with 500 μl BD stain buffer and incubated with 100 μl of a 1 :200 dilution of streptavidin-PE (PE=phycoerythrin) (Invitrogen) in BD stain buffer for 45 minutes. Finally, cells were washed twice, resuspended in 300 μl of BD stain buffer and analyzed in a FACScalibur flow cytometer. As a positive control, 1 x 105 ADRr or MALME-3M cells were incubated with 200 nM BTC for 30 minutes on ice, washed twice and incubated with a 1 :200 dilution of streptavidin-PE for 45 minutes. To assess background staining from the streptavidin-PE conjugate, cells were incubated with 100 μl of a 1 :200 dilution of streptavidin-PE only for 45 minutes. The results of this experiment are depicted in Figures 15A-15C. As shown in
Figure 15A, betacellulin (BTC) does not show any appreciable binding to ErbBl negative MALME-3M cells. However, as depicted in Figures 15B and 15C, BTC does show binding to ErbBl positive ADRr cells. Also, as shown in Figures 15B and 15C, this binding was blocked by Erbitux, which is an anti-EGFR antibody which specifically binds EGFR and was included as a control to demonstrate that EGF-like ligands bind to EGFR, and which is described in e.g., Adams et al. (2005), Nature Biotechnology 23, 1147 - 1157.
Example 8: Inhibition of Heregulin-Mediated Signaling in Tumor Cells
The ability of Ab # 6 to inhibit heregulin-mediated tumor cell signaling was investigated as follows.
MALME-3M cells were seeded in 96 well tissue culture plates and grown in RPMI- 1640 media supplemented with antibiotics, 2mM L-glutamine and 10% fetal bovine serum (FBS) for 24 hours at 37°C and 5% carbon dioxide. Cells were serum starved in RPMI- 1640 media with antibiotics and 2mM L-glutamine for 24 hours at 37°C and 5% carbon dioxide. Cells were pre-treated with and without the anti-ErbB3 antibody (IgG2 isotype of Ab #6) at lμM, 25OnM, 63nM, 16nM, 4.OnM, LOnM, 24OpM and 6IpM concentrations for 30 minutes then stimulated with HRGl -betal -ECD for 10 minutes at 37°C and 5% carbon dioxide. Cells were washed with cold PBS then harvested with mammalian protein extract (MPER) lysis (Pierce, 78505) buffer containing 15OmM NaCl 5mM sodium pyrophosphate, lOuM bpV (phen), 50μM phenalarsine, ImM sodium orthovanadate, and protease inhibitor cocktail (Sigma, P714). Cell lysates were diluted two-fold with 4% bovine serum albumin in phosphate buffered saline with 0.1% tween-20, then analyzed by ELISA for AKT (a downstream effector of ErbB3) and ErbB3 phosphorylation.
In order to test for AKT phosphorylation, lysates were run on an ELISA plate with a capture antibody specific for AKT and biotinylated detection antibody specific to the phosphorylation site on serine 473 of AKT. Signal was generated with streptavidin conjugated to horseradish-peroxidase reacted with chemiluminescent substrate (Pierce, 37070). In order to assay for ErbB3 phosphorylation, lysates were run on an ELISA plate with a capture antibody specific for ErbB3 and an anti-phosphotyrosine detection antibody conjugated to horseradish-peroxidase. This was then reacted with chemiluminescent substrate (Pierce, 37070). ELISAs were visualized using a luminometer.
As shown in Figures 16A and 16B, Ab #6 was a potent inhibitor of heregulin- mediated signaling in MALME-3M cells, as measured by decreased phosphorylation of ErbB3 (Figure 16A) and AKT (Figure 16B). Notably, Ab #6 inhibited the phosphorylation of AKT by almost 100%. Example 9: Inhibition of Ovarian, Prostate, and Pancreatic Tumor Growth
To assess the efficacy of Ab #6 in vivo, several xenograft models of human cancer were established in nude mice and the inhibition of tumor growth was assessed at multiple doses. For example, T-cell deficient nu/nu mice (3-4 week old female mice originated at NIH; outbred; albino background) were purchased from Charles River Labs (Wilmington, MA) for xenograft studies. ADRr cells for implantation were grown in culture (RPMI media, 10% FBS, L-glutamine and antibiotics, 37°C, 5% CO2) to about 85% confluency before harvesting. Cells were kept on ice until implantation. Mice were implanted via subcutaneous injection with lOOμl ADRr cells on the right flank and allowed to recover while being monitored for initial tumor growth.
Tumors were measured (length by width) by digital caliper and the mice were dosed with IgG2a (Sigma, M7769-5MG) by intravenous injection. Mice were dosed intra-peritoneally every third day with either 30 μg or 300 μg of Ab #6 and tumors were measured three times per week and recorded in a Microsoft Excel spreadsheet. Final tumor measurements (L x W) were taken, the mice were euthanized by C02 asphyxiation and tumors were excised, snap frozen in liquid nitrogen, and were stored at -800C (for biochemical analysis). Final tumor measurements were analyzed and graphed by tumor area and tumor volume, as described in Burtrum et ah, supra. . The data was also analyzed by "normalized' and "non-normalized" means for both tumor volume and tumor area. For the "normalization" of the data, at each time point of measurement, each tumor in each group was divided by the initial tumor size determined by caliper measurement.
The data from three different models derived from human tumor cell lines, ADRr (ovarian), Du 145 (prostate) and OvC AR8 (ovarian) are shown in Figures 17A-C and Colo357 xenograft study is shown in Figure 17D. The data from these studies demonstrated that a 300ug dose of Ab #6 every three days (Q3d) results in significant inhibition of tumor growth (p<0.05 for multiple time points during the studies). Moreover, this inhibitory effect of Ab #6 was further elevated when the dose was increased to 600ug, Q3d, in the Du 145 prostate cancer model as well as a renal and a pancreatic carcinoma xenograft model (ACHN and COLO357). However, further elevating the dose to 1500ug Q3d did not result in increased efficacy (OvCAR8-Figure 17; COLO357) suggesting that the 600ug is saturating in regards to tumor growth inhibition. Pharmacokinetic (PK) analyses of the serum from the animals from these studies demonstrate a dose-dependent increase in the serum retention of Ab #6. Similarly, biochemical analysis of the intra-tumoral levels of Ab #6 from these different studies showed a dose-dependent range of 0 to ~6 pg MM121/ug of total tumor lysate (data not shown). Example 10: Inhibition of binding of ErbB3 Ligands to ErbB3 on Tumor Cells
In a further experiment, the specificity of the antibodies of the invention to inhibit the binding of ErbB3 ligands to ErbB3, and not EGF-like ligands to EGFR, was investigated as follows.
In one experiment, the specificity of Ab #6 and a Fab version of Ab #3 (Ab/Fab #3) to inhibit the binding of ErbB3 ligands (e.g., heregulin and epiregulin) to ErbB3 was investigated.
In order to investigate the ability of Ab #6 and Ab/Fab #3 to inhibit the binding of heregulin to ErbB3, the following experiment was performed.
ADRr cells (1 x 105 ) were incubated with 10 μM of an anti-ErbB3 antibody (e.g., Ab #6 or Ab/Fab # 3) in 50 μl BD stain buffer for 30 minutes on ice. After 30 minutes, 50 μl of 40 nM biotinylated heregulin EGF was added to the cells and incubated for another 10 minutes on ice. This gave a final concentration of 5 μM antibody and 20 nM heregulin EGF. Cells were then washed twice with 500 μl BD stain buffer and incubated with 100 μl of a 1 :200 dilution of streptavidin-PE (PE=phycoerythrin) (Invitrogen) in BD stain buffer for 45 minutes. Finally, cells were washed twice, resuspended in 300 μl of BD stain buffer and analyzed in a FACScalibur flow cytometer. As a positive control, 1 x 105 ADRr cells were incubated with 20 nM heregulin EGF for 10 minutes on ice, washed twice and incubated with a 1 :200 dilution of streptavidin-PE for 45 minutes. In order to assess background staining from the streptavidin-PE conjugate, 1 x 105 ADRr cells were incubated with 100 μl of a 1 :200 dilution of streptavidin-PE only for 45 minutes.
The results of this experiment are shown in Figures 18A and 18B. As depicted in Figures 18A and 18B, both Ab #6 and Ab/Fab #3 were able to inhibit heregulin binding to ErbB3.
Similarly, the ability of Ab #6 to inhibit the binding of another ErbB3-ligand, epiregulin, to ErbB3, was examined as follows.
ADRr cells (1 x 105 ) were pre-incubated with 25 μM of Ab #6 or 25 μM of Erbitux (as control) in 50 μl BD stain buffer for 30 minutes on ice. After 30 minutes, 50 μl of 2 μM biotinylated Epi was added to the cells and incubated for another 30 minutes on ice. This gave a final concentration of 12.5 μM antibodies and 1 μM Epi. Cells were then washed twice with 500 μl BD stain buffer and incubated with 100 μl of a 1 :200 dilution of streptavidin-PE (PE=phycoerythrin) (Invitrogen) in BD stain buffer for 45 minutes. Finally, cells were washed twice, resuspended in 300 μl of BD stain buffer and analyzed in a FACScalibur flow cytometer. As a positive control, 1 x 105 ADRr cells were incubated with 1 μM Epi for 30 minutes on ice, washed twice and incubated with a 1:200 dilution of streptavidin-PE for 45 minutes. To assess background staining from the streptavidin-PE conjugate, cells were incubated with 100 μl of a 1 :200 dilution of streptavidin-PE only for 45 minutes.
The results of this experiment are depicted in Figures 19A and 19B. As shown in Figure 19A, epiregulin binds to ErbB3 positive ADRr cells. Further, as shown in Figure 19B, this binding is inhibited by both Erbitux and Ab #6, suggesting that epiregulin may bind to both EGFR and ErbB3.
A further experiment was performed to investigate whether Ab #6 is able to inhibit the binding of an EGF-like ligand (e.g., HB-EGF) to tumor cells.
ADRr cells (1 x 105 ) were pre-incubated with 25 μM of Ab #6 or 25 μM of Erbitux (as control) in 50 μl BD stain buffer for 30 minutes on ice. After 30 minutes, 50 μl of 400 nM biotinylated HB-EGF was added to the cells and incubated for another 30 minutes on ice. This gave a final concentration of 12.5 μM antibodies and 200 nM HB- EGF. Cells were then washed twice with 500 μl BD stain buffer and incubated with 100 μl of a 1 :200 dilution of streptavidin-PE (PE=phycoerythrin) (Invitrogen) in BD stain buffer for 45 minutes. Finally, cells were washed twice, resuspended in 300 μl of BD stain buffer and analyzed in a FACScalibur flow cytometer. As a positive control, 1 x 105 ADRr cells were incubated with 200 nM HB-EGF for 30 minutes on ice, washed twice and incubated with a 1 :200 dilution of streptavidin-PE for 45 minutes. To assess background staining from the streptavidin-PE conjugate, cells were incubated with 100 μl of a 1 :200 dilution of streptavidin-PE only for 45 minutes.
As shown in Figures 2OA and 2OB, HB-EGF binds to ErbB on ADRr cells and Ab #6 does not inhibit this binding, evidencing that Ab #6 is specific for inhibiting the binding of ErbB3 ligands (e.g., heregulin and epiregulin) to ErbB3.
Example 11: Inhibition of VEGF Secretion in Tumor Cells
The ability of Ab #6 to inhibit VEGF secretion of cells expressing ErbB3 (e.g., cancer cells) was examined using VEGF secretion assay (VEGF ELISA kit available from R&D Systems, Minneapolis, MN, Cat.#DY293B). First, the ability of Ab #6 to inhibit VEGF secretion in the untreated and HRG -betal treated MCF-7, T47D, and COLO-357 cells was analyzed. These studies revealed that COLO-357 secreted the highest amount of VEGF into the media. As these cells also had very high HRG levels (data not shown), addition of HRG to the media was not able to further induce VEGF secretion (Fig. 24A). In contrast, HRG was able to induce VEGF secretion in MCF-7 and T47D cells. Ab #6 shows a potent inhibitory effect at high levels in all three cell lines with the highest being in COLO-357 (Fig. 24A). Ab #6 also shows a similar effect in vivo by inhibiting VEGF secretion in three different xenografts, the highest being in COLO-357 xenograft (Fig. 24B). Inhibition of VEGF correlates with inhibition of ErbB3 phosphorylation (Fig. 24 C). Inhibition of VEGF secretion also correlates with inhibition of angiogenesis of the tumor cells. In particular, it has been identified that myeloma cell-secreted factors, such as VEGF and bFGF, trigger angiogenesis (see, e.g., Leung et al. (1989) Science 246(4935): 1306-9; Yen et al. (2000) Oncogene 19(31):3460-9).
Example 12: Inhibition of Cell Migration
The ability of Ab #6 to inhibit the migration of cells expressing ErbB3 (e.g., MCF-7 cells) was examined using a trans-well assay (Millipore Corp., Billerica, MA, Cat # ECM552). First, MCF-7 cells were serum-starved overnight and then incubated in the presence or absence of Ab #6 (8uM final concentration) for 15 minutes at room temperature. The cells were then transferred to an upper chamber that is separated from a lower chamber by a collagen type I-coated membrane through which the cells can migrate. 10%FBS was added to media in the lower chamber to act as a chemoattractant in the presence of absence of Ab #6. The chambers were incubated at 37°C for 16 hours and then the cells that migrated through the membrane were removed using a detachment buffer and incubated with a cell-binding fluorescent dye. Fluorescence was quantitated using a fluorescent plate reader. The average fluorescence ± SEM (n=2) is shown in Figure 25. As shown in Figure 25, 10% FBS stimulates cell migration (lane 3) as compared to untreated control (lane 1) and 8uM Ab #6 inhibits the FBS induced cell migration (lane 4).
Example 13: Inhibition of Spheroid Growth The ability of Ab #6 to inhibit the spheroid growth of cells expressing ErbB3 was examined using an assay which approximates conditions of a developing tumor growth (Herman et al. (2007) Journal of Biomolecular Screening Electronic publication). AdrR and DUl 45 spheroids were initiated at a frequency of 1 spheroid per well of a 96 well plate using the hanging drop method (Herrman et al., 2008). Individual spheroids were then treated with either Ab #6 (8 uM final concentration), Heregulin-β 1 EGF domain (R&D Systems, Minneapolis, MN, Cat # 396-HB, 3.4 nM final concentration), or a combination of both, as indicated. The diameters of the spheroids were measured using light microscopy (10X objective) at day 1 and day 13.
Ab #6 inhibits spheroid growth in AdrR cells (Fig. 26A). In addition, 3.4nM HRG stimulates spheroid growth and Ab #6 inhibits the HRG effect (Fig. 26B). Spheroids derived from DU145 did not increase in size during 13 days of the experiment; however, growth was significantly stimulated by HRGl -beta 1. In these cells, 8uM Ab #6 inhibits HRG induced spheroid growth (Fig. 26C).
Example 14: Inhibition of Signaling The ability of Ab #6 to inhibit the signaling induced by different ligands was examined. For example, the effect of Ab #6 on HRG and BTC binding to AdrR cells expressing ErbB3 receptor was tested. As shown in Figures 27A and B, using FACS analysis, Ab #6 competes with HRG and not BTC for binding to AdrR cells. Accordingly, blocking by Ab #6 of HRG binding to ErbB3 would prevent signaling induced by HRG.
Additionally, various ligands were tested for inducement of ErBb3 phosphorylation. Three ligands, HRG, BTC, and HGF, were able to stimulate ErbB3 induced phosphorylation in AdrR cells, while EGF could not. As shown in Figure 28, Ab #6 inhibits HGF induced pErbB3 phosphorylation in AdrR cells (Fig. 28). Further, as known in the art (see, e.g., Wallenius et al. (2000) Am J Pathol. 156 (3):821-9 10702398), enhanced HGF signaling has been found in various epithelial and non- epithelial tumors.
ErbB3/cMET interaction and the role of Ab #6 in modulating this interaction It has been shown that non-small-cell lung cancers carrying activating mutations in the epidermal growth factor receptor (EGFR) develop resistance to tyrosine kinase inhibitors by recruiting MET and HER3 and thus activating the PI3 K-AKT cell survival pathway (Engelmann et al. (2007) Science 316: 1039-1043; Gou (2007) PNAS: 105(2): 692-697). The association between EGFR and c-MET in cell lines that carry activating EGFR mutations has been well established by co-immunoprecipitation (Engelmann et al. 2007; Gou 2007). Guo et al. recently demonstrated that c-MET and ErbB3 also exist in a complex in a gastric cell line MKN45 known to be dependent on amplified c-MET, using co-immunoprecipitation.
This c-MET-erbB3 interaction occurs also in AdrR cells carrying the wild type EGFR and is not dependent on amplified c-MET. HGF (Hepatocyte Growth Factor) induces ErbB3 phosphorylation in AdrR cells in a dose dependent manner as shown in Figure 28. In addition, Ab #6 inhibits HGF induced erbB3 phosphorylation.
The effect of HRG and BTC on both ErbBl and ErbB3 phosphorylation has also been investigated, and HRG and BTC were found to induce phosphorylation of both ErbBl and ErbB3. HRG was found to be a more potent inducer of ErbB3 phosphorylation while BTC was a potent inducer of ErbBl phosphorylation (Fig. 29). This phosphorylation is likely to be driven by the complex between ErbBl and ErbB3. Briefly, HRG binding to ErbB3 induces complex formation between ErbBl and ErbB3, leading to the activation of both receptors. The same phenomenon appears likely for BTC, where BTC binding to ErbBl stimulates complex formation between ErbBl and ErbB3, leading to the phosphorylation of both ErbBl and ErbB3.
Antibody Inhibition of ligand (ΗRG. BTC. EGF. and HGF) stimulated ErbB3 phosphorylation.
The ability of Ab #6 to inhibit ligand (HRG, BTC, EGF, and HGF) induced ErbB3 phosphorylation was examined based on the following method:
1. AdrR cells were plated into 96 well plate at a density of 30,000 cells/well/ 100 uL in RPMI medium containing 10% FBS and allowed to grow overnight;
2. The next day, cells were serum-starved by changing medium to FBS-free medium and allowed to grow overnight; 3. Cells were pre-treated with different concentrations of Ab #6 (from 0.01 nM to
10OnM), or buffer (control), for 2hours;
4. The cells were then stimulated with 10 nM HRG and HGF for 10 minutes, or 10 nM BTC and EGF for 5 minutes;
5. The reaction was stopped by removing the culture medium and washing the cells once with ice cold PBS;
6. The cells were then lysed in 25 mM Tris, pH+7.5, 150 mM NaCl, ImM EDTA, 1.0% Triton X-100, 1.0% CHAPS, 10% v/v glycerol, containing IX protease inhibitor and IX phosphatase inhibitor; and
7. ErbB3 phosphorylation was measured in cell lysates using Human Phospho- ErbB3 ELISA kit (R&D Systems, Minneapolis, MN, Cat. No. DYC1769) according to manufacturer's instructions.
Antibody Inhibition of ErbB2-ErbB3 protein complex formation. AdrR cells were pre-incubated with buffer (control), or 250 nM Ab #6 for 60 minutes at room temperature, then treated with 10 nM HRG or 10 nM BTC or control buffer for 10 minutes. The cells were lysed in 25 mM Tris, pH+7.5, 15O mM NaCl, ImM EDTA, 1.0% Triton X-100, 1.0% CHAPS, 10% v/v glycerol, containing 0.2mM PMSF, 50mTU/mL aprotinin, and 100 uM leupeptin, and the crude lysate were centrifuged briefly to remove insoluble material. Supernatant was transferred to a new eppendorf tube, and anti-ErbB3 antibody (Santa Cruz sc-285) was added at 1 :500 dilution. Supernatants were incubated overnight with gentle shaking at 4C. 60 ul of Immobilized Protein A/G agarose beads (Pierce, Rockford, EL, Cat# 20421) was first washed with IX PBS. The cell lysate-antibody mixture was added to the PBS washed beads, and incubated for 2 hours with gentle shaking at 4°C. The immunoprecipitates were then washed with ice-cold lysis buffer 3 times, resuspended in 30 ul of 2X SDS sample buffer, heat denatured at 950C for 7 minutes and run on 4-12% Bis-Tris Gels. SDS- PAGE and electro-transferred to PVDF membrane in Tri-Glycine buffer with 10% MeOH. The membrane was blocked for lhour in 10ml of blocking buffer (Li-Cor Biosciences, Lincoln, NE, Cat# 927-40000) and then incubated with the anti-ErbB2 antibody at 1 : 1000 (Cell Signaling
Technology, Danvers, MA, Cat # 29D8) in 10 ml of blocking buffer (Li-Cor Biosciences, Cat# 927-40000). The signal was detected using goat anti- rabbit IRDye800 at 1 : 5000 (2ul) in 10ml of blocking buffer (Li-Cor Biosciences, Cat# 927-40000). Ab #6 was also shown to completely inhibit HRG stimulated ErbB2/3 complex formation (Fig.29B).
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. Any combination of the embodiments disclosed in the dependent claims are contemplated to be within the scope of the invention.
Incorporation by Reference
All publications, patents, and pending patent applications referred to herein are hereby incorporated by reference in their entirety.

Claims

We claim:
1. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3 and inhibits EGF-like ligand mediated phosphorylation of ErbB3.
2. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3, wherein the antibody or antigen binding portion thereof exhibits one or more of the following properties:
(i) inhibition of heregulin, epiregulin, betacellulin, epigen or biregulin- mediated signaling through ErbB3 ;
(ii) inhibition of proliferation of cells expressing ErbB3;
(iii) the ability to decrease levels of ErbB3 on cell surfaces;
(iv) inhibition of VEGF secretion of cells expressing ErbB3 ;
(v) inhibition of the migration of cells expressing ErbB3; (vi) inhibition of spheroid growth of cells expressing ErbB3 ; and/or
(vii) binding to an epitope located on domain I of ErbB3 .
3. The antibody or antigen binding portion thereof of any one of the preceding claims, wherein the antibody or antigen binding portion thereof binds to ErbB3 with a KD of at least about 8 nM or better, as measured by a surface plasmon resonance assay or a cell binding assay.
4. The antibody or antigen binding portion of any one of the preceding claims, wherein the EGF-like ligand is selected from the group consisting of EGF, TGF-α, betacellulin, heparin-binding epidermal growth factor, amphiregulin and biregulin.
5. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3, wherein the antibody or antigen binding portion thereof comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ED NO:5, SEQ ID NO:35, or SEQ ID NO:37.
6. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3, wherein the antibody or antigen binding portion thereof comprises a light chain variable region comprising an amino acid sequence at least 80% identical to the light chain variable region amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:36, or SEQ ID NO:38.
7. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3, wherein the antibody or antigen binding portion thereof comprises a heavy chain variable region comprising an amino acid sequence at least 95% identical to the heavy chain variable region amino acid sequence set forth in SEQ ID NO:1, SEQ ED NO:3, SEQ ID NO:5, SEQ ID NO:35, or SEQ ID NO:37.
8. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3, wherein the antibody or antigen binding portion thereof comprises a light chain variable region comprising an amino acid sequence at least 95% identical to the light chain variable region amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:36, or SEQ ID NO:38.
9. The antibody or antigen binding portion thereof of claim 7, wherein the antibody or antigen binding portion thereof further comprises a light chain variable region comprising an amino acid sequence at least 95% identical to the light chain variable region amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:36, or SEQ IDNO:38.
10. An isolated antibody or antigen binding portion thereof that binds to the epitope which is same or overlapping with the epitope bound by the antibody of any one of the preceding claims.
11. The antibody or antigen binding portion thereof of any of the preceding claims, which binds to residues 20-202 of the amino acid sequence of ErbB3.
12. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3, wherein the antibody or antigen binding portion thereof comprises: a heavy chain variable region comprising CDRl, CDR2, and CDR3 sequences; and a light chain variable region comprising CDRl, CDR2, and CDR3 sequences, wherein the heavy chain variable region CDR3 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:9, 15, 21, 41, 47 and conservative amino acid substitutions thereof.
13. The antibody or antigen binding portion thereof of claim 12, wherein the light chain variable region CDR3 sequence comprises an amino acid sequence selected from the group consisting of SEQ ED NOs: 12, 18, 24, 44, 50 and conservative sequence modifications thereof.
14. The antibody or antigen binding portion thereof of claim 12 or 13, wherein the heavy chain variable region CDR2 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 14, 20, 40, 46 and conservative sequence modifications thereof.
15. The antibody or antigen binding portion thereof of claims 12-14, wherein the light chain variable region CDR2 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 17, 23, 43, 49 and conservative sequence mo difications thereof.
16. The antibody or antigen binding portion thereof of claims 12-15, wherein the heavy chain variable region CDRl sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 13, 19, 39, 45 and conservative sequence modifications thereof.
17. The antibody or antigen binding portion thereof of claims 12-16, wherein the light chain variable region CDRl sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 16, 22, 42, 48 and conservative sequence modifications thereof.
18. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3 and comprises heavy and light chain variable region CDRl, CDR2 and CDR3 sequences selected from the group consisting of: (a) a heavy chain variable region CDRl comprising SEQ ID NO:7; a heavy chain variable region CDR2 comprising SEQ ID NO:8; a heavy chain variable region CDR3 comprising SEQ ID NO: 9; a light chain variable region CDRl comprising SEQ ID NO: 10; a light chain variable region CDR2 comprising SEQ ID NO: 11; a light chain variable region CDR3 comprising SEQ ID NO: 12; and combinations thereof;
(b) a heavy chain variable region CDRl comprising SEQ ID NO: 13; a heavy chain variable region CDR2 comprising SEQ ID NO: 14; a heavy chain variable region CDR3 comprising SEQ ID NO: 15; a light chain variable region CDRl comprising SEQ ED NO: 16; a light chain variable region CDR2 comprising SEQ DD NO: 17; a light chain variable region CDR3 comprising SEQ ID NO: 18; and combinations thereof;
(c) a heavy chain variable region CDRl comprising SEQ ID NO: 19; a heavy chain variable region CDR2 comprising SEQ DD NO:20; a heavy chain variable region CDR3 comprising SEQ ID NO:21; a light chain variable region CDRl comprising SEQ ID NO:22; a light chain variable region CDR2 comprising SEQ ID NO:23; a light chain variable region CDR3 comprising SEQ ID NO:24; and (d) a heavy chain variable region CDRl comprising SEQ ID NO:39; a heavy chain variable region CDR2 comprising SEQ ID NO:40; a heavy chain variable region CDR3 comprising SEQ ID NO:41; a light chain variable region CDRl comprising SEQ DD NO:42; a light chain variable region CDR2 comprising SEQ ID NO:43; a light chain variable region CDR3 comprising SEQ ID NO:44; and
(e) a heavy chain variable region CDRl comprising SEQ ID NO:45; a heavy chain variable region CDR2 comprising SEQ ID NO:46; a heavy chain variable region CDR3 comprising SEQ ID NO:47; a light chain variable region CDRl comprising SEQ ID NO:48; a light chain variable region CDR2 comprising SEQ ID NO:49; a light chain variable region CDR3 comprising SEQ DD NO: 50;
19. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3 and comprises:
a heavy chain variable region CDRl comprising SEQ DD NO: 7; a heavy chain variable region CDR2 comprising SEQ DD NO:8; a heavy chain variable region CDR3 comprising SEQ DD NO: 9; a light chain variable region CDRl comprising SEQ DD NO: 10; a light chain variable region CDR2 comprising SEQ DD NO: 11 ; and a light chain variable region CDR3 comprising SEQ DD NO: 12.
20. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3 and comprises: a heavy chain variable region comprising CDRl, CDR2, and CDR3 sequences; and a light chain variable region comprising CDRl, CDR2, and CDR3 sequences, wherein: the heavy chain variable region CDR3 sequence comprises an amino acid sequence which is at least 90% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs : 9, 15 and 21.
21. The antibody of claim 20, wherein the light chain variable region CDR3 sequence comprises an amino acid sequence which is at least 90% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 18 and 24.
22. The antibody of claim 20 or 21, wherein the heavy chain variable region CDR2 sequence comprises an amino acid sequence which is at least 90% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 14 and 20.
23. The antibody of claims 20-22, wherein the light chain variable region CDR2 sequence comprises an amino acid sequence which is at least 90% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 17 and 23.
24. The antibody of claims 20-23, wherein the heavy chain variable region CDRl sequence comprises an amino acid sequence which is at least 90% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs:7, 13 and 19.
25. The antibody of claims 20-24, wherein the light chain variable region CDRl sequence comprises an amino acid sequence which is at least 90% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 16 and 22.
26. An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3, wherein the antibody or antigen binding portion thereof: comprises a heavy chain variable region that is from a human VH3 germline gene.
27. The antibody or antigen binding portion thereof of claim 26, wherein the antibody or antigen binding portion thereof further comprises a light chain variable region from human VL2 germline gene.
28. The antibody or antigen binding portion thereof of any one of the preceding claims, wherein the antibody is selected from the group consisting of a human antibody, a humanized antibody, a bispecific antibody and a chimeric antibody.
29. The antibody or antigen binding portion thereof of any one of the preceding claims, wherein the antibody or antigen binding portion thereof is selected from the group consisting of a Fab, Fab'2, ScFv, SMIP, affibody, avimer, nanobody, and a domain antibody.
30. The antibody or antigen binding portion thereof of any one of the preceding claims, wherein the antibody isotype is selected from the group consisting of an IgGl, an IgG2, an IgG3, an IgG4, an IgM, an IgAl, an IgA2, an IgAsec, an IgD, and an IgE antibody.
31. A composition comprising the antibody or antigen binding portion of any one of the preceding claims in a pharmaceutically acceptable carrier.
32. A composition comprising two or more antibodies of any one of the preceding claims, wherein the antibodies bind to different epitopes on ErbB3.
33. An isolated nucleic acid encoding a variable region of a human antibody that binds ErbB3 comprising a sequence at least 90% identical to the heavy chain variable region of SEQ ID NO:25, the light chain variable region of SEQ ID NO:26, the heavy chain variable region of SEQ ID NO:27, the light chain variable region of SEQ ID NO:28, the heavy chain variable region of SEQ ID NO:29, the light chain variable region of SEQ ID NO:30, or combinations thereof.
34. An isolated nucleic acid encoding a variable region of a human antibody that binds ErbB3 comprising a sequence that hybridizes under high stringency to the nucleotide sequence of heavy chain variable region of SEQ ID NO: 25, the light chain variable region of SEQ ID NO:26, the heavy chain variable region of SEQ ID NO:27, the light chain variable region of SEQ ID NO:28, the heavy chain variable region of SEQ ID NO:29, or the light chain variable region of SEQ ID NO:30.
35. An expression vector comprising the nucleic acid of claim 33 or 34.
36. A host cell comprising the nucleic acid of claim 35.
37. A transgenic non-human mammal which expresses a monoclonal antibody or antigen binding portion thereof that binds the same epitope as the antibody or antigen binding portion of any one of the preceding claims.
38. A transgenic plant which expresses a monoclonal antibody or antigen binding portion thereof that binds the same epitope as the antibody or antigen binding portion of any one of the preceding claims.
39. A hybridoma which produces an antibody or antigen binding portion thereof of any one of the preceding claims.
40. A hybridoma which produces a human antibody that binds to ErbB3, wherein the antibody is encoded by: (a) a heavy chain variable region nucleotide sequence set forth in SEQ ID
NO:25 and a light chain variable region nucleotide sequence set forth in SEQ ID NO:26, and conservative sequence modifications thereof;
(b) a heavy chain variable region nucleotide sequence set forth in SEQ ID NO:27 and a light chain variable region nucleotide sequence set forth in SEQ ID NO:28, and conservative sequence modifications thereof; or
(c) a heavy chain variable region nucleotide sequence set forth in SEQ ID NO:29 and a light chain variable region nucleotide sequence set forth in SEQ ID NO:30, and conservative sequence modifications thereof.
41. A kit comprising one or more isolated monoclonal antibodies or antigen binding portions thereof of any one of the preceding claims, and optionally comprising instructions for use in treating or diagnosing a disease associated with ErbB3 dependent signaling.
42. The kit of claim 41, wherein the disease is a cancer.
43. A method of inhibiting EGF-like ligand mediated phosphorylation of ErbB3 in a subject, comprising administering to the subject an isolated monoclonal antibody or antigen binding portion thereof of any one of the preceding claims, in an amount sufficient to inhibit EGF-like mediated phosphorylation of ErbB3.
44. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an isolated monoclonal antibody or antigen binding portion thereof of any one of the preceding claims.
45. The method of claim 44, wherein the cancer is selected from the group consisting of melanoma, breast cancer, ovarian cancer, renal carcinoma, gastrointestinal/colon cancer, lung cancer, clear cell sarcoma ,and prostate cancer.
46. The method of any one of claims 43-45, wherein the subject is human.
47. The method of any one of claims 43-45, wherein the antibody or antigen binding portion thereof is administered intravenously, intramuscularly, or subcutaneously to the subject.
48. The method of any one of claims 44-47, wherein the antibody or antigen binding portion thereof is administered in combination with a second therapeutic agent.
49. The method of claim 48, wherein the second agent is a second antibody or antigen binding portion thereof.
50. The method of claim 48, wherein the second agent is an anti-cancer agent.
51. The method of claim 50, wherein the anti-cancer agent is selected from the group consisting of an antibody, a small molecule, an antimetabolite, an alkylating agent, a topoisomerase inhibitor, a microtubule-targeting agent, a kinase inhibitor, a protein synthesis inhibitor, an immunotherapeutic, a hormone or analog thereof, a somatostatin analog, a glucocorticoid, an aromatose inhibitor, and an mTOR inhibitor.
52. The method of claim 51, wherein the antibody is an anti-IGFIR antibody, an anti-EGFR antibody, or an anti-cmet antibody.
53. The method of claim 51, wherein the small molecule binds IGFlR, EGFR, or cmet,
54. A method of diagnosing a cancer associated with ErbB3 in a subject, comprising (a) contacting ex vivo or in vivo cells from the subject with an isolated monoclonal antibody or antigen binding portion thereof of any of claims 1-30, and (b) measuring the level of binding to ErbB3 on the cells, wherein abnormally high levels of binding to ErbB3 indicate that the subject has a cancer associated with ErbB3.
PCT/US2008/002119 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof WO2008100624A2 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
US12/281,925 US7846440B2 (en) 2007-02-16 2008-02-15 Antibodies against ErbB3 and uses thereof
JP2009549644A JP5564266B2 (en) 2007-02-16 2008-02-15 Antibodies against ERBB3 and uses thereof
ES08725722T ES2431940T3 (en) 2007-02-16 2008-02-15 Antibodies against ERBB3 and their uses
CN200880009633.1A CN101674846B (en) 2007-02-16 2008-02-15 Antibodies against ErbB3 and uses thereof
MX2009008656A MX2009008656A (en) 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof.
CA2678181A CA2678181C (en) 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof
EP08725722.6A EP2129396B1 (en) 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof
AU2008216600A AU2008216600B2 (en) 2007-02-16 2008-02-15 Antibodies against ErbB3 and uses thereof
SI200831098T SI2129396T1 (en) 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof
BRPI0808055-0A BRPI0808055A2 (en) 2007-02-16 2008-02-15 isolated monoclonal antibody or antigen-binding portion, composition, Isolated nucleic acid, expression vector, host cell, hybridoma, kit, use of an isolated monoclonal antibody or antigen-binding portion, method for diagnosing a cancer associated with erbb3 in a patient, and antibody
DK08725722.6T DK2129396T3 (en) 2007-02-16 2008-02-15 Antibodies to ErbB3 and uses thereof
EA200901119A EA020465B1 (en) 2007-02-16 2008-02-15 ISOLATED MONOCLONAL ANTIBODIES WHICH BIND TO ErbB3, KITS AND COMPOSITIONS CONTAINING THEM AND USES THEREOF
PL08725722T PL2129396T3 (en) 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof
NZ579644A NZ579644A (en) 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof
RS20130512A RS53042B (en) 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof
US12/425,874 US20100056761A1 (en) 2007-02-16 2009-04-17 Antibodies against erbb3 and uses thereof
IL200373A IL200373A (en) 2007-02-16 2009-08-13 Monoclonal antibody that binds to erbb3 and pharmaceutical composition comprising such for inhibiting erbb3 signaling in a subject
US12/545,279 US8691225B2 (en) 2007-02-16 2009-08-21 Antibodies against the ectodomain of ErbB3 and uses thereof
ZA2009/06360A ZA200906360B (en) 2007-02-16 2009-09-14 Antibodies agaist erbb3 and uses thereof
MA32222A MA31254B1 (en) 2007-02-16 2009-09-15 Antibodies to erbb3 and their use,
EC2009009637A ECSP099637A (en) 2007-02-16 2009-09-15 ANTIBODIES AGAINST ERBB3 AND THE USES OF THE SAME
HK10105467.1A HK1138771A1 (en) 2007-02-16 2010-06-02 Antibodies against erbb3 and uses thereof
US12/904,492 US8961966B2 (en) 2007-02-16 2010-10-14 Antibodies against ERBB3 and uses thereof
HRP20131113AT HRP20131113T1 (en) 2007-02-16 2013-11-21 Antibodies against erbb3 and uses thereof
US14/181,334 US9487588B2 (en) 2007-02-16 2014-02-14 Antibodies against the ectodomain of ERBB3 and uses thereof
US15/274,989 US20170073427A1 (en) 2007-02-16 2016-09-23 Antibodies against the ectodomain of erbb3 and uses thereof
US16/181,054 US20190292271A1 (en) 2007-02-16 2018-11-05 Antibodies against the ectodomain of erbb3 and uses thereof
US17/376,627 US20220204642A1 (en) 2007-02-16 2021-07-15 Antibodies against the ectodomain of erbb3 and uses thereof
US18/630,602 US20240360243A1 (en) 2007-02-16 2024-04-09 Antibodies against the ectodomain of erbb3 and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90190407P 2007-02-16 2007-02-16
US60/901,904 2007-02-16
US979608P 2008-01-02 2008-01-02
US61/009,796 2008-01-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/281,925 A-371-Of-International US7846440B2 (en) 2007-02-16 2008-02-15 Antibodies against ErbB3 and uses thereof
US12/425,874 Continuation-In-Part US20100056761A1 (en) 2007-02-16 2009-04-17 Antibodies against erbb3 and uses thereof

Publications (2)

Publication Number Publication Date
WO2008100624A2 true WO2008100624A2 (en) 2008-08-21
WO2008100624A3 WO2008100624A3 (en) 2009-01-15

Family

ID=39690706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002119 WO2008100624A2 (en) 2007-02-16 2008-02-15 Antibodies against erbb3 and uses thereof

Country Status (29)

Country Link
US (9) US7846440B2 (en)
EP (4) EP2647388A1 (en)
JP (2) JP5564266B2 (en)
KR (1) KR101598229B1 (en)
CN (1) CN101674846B (en)
AU (1) AU2008216600B2 (en)
BR (1) BRPI0808055A2 (en)
CA (1) CA2678181C (en)
CO (1) CO6231000A2 (en)
CR (1) CR11029A (en)
CY (1) CY1114632T1 (en)
DK (2) DK2129396T3 (en)
EA (1) EA020465B1 (en)
EC (1) ECSP099637A (en)
ES (2) ES2431940T3 (en)
HK (1) HK1138771A1 (en)
HR (2) HRP20131113T1 (en)
HU (1) HUE033472T2 (en)
IL (1) IL200373A (en)
MA (1) MA31254B1 (en)
MX (1) MX2009008656A (en)
NZ (1) NZ579644A (en)
PL (2) PL2129396T3 (en)
PT (2) PT2129396E (en)
RS (1) RS53042B (en)
SG (1) SG178789A1 (en)
SI (2) SI2716301T1 (en)
WO (1) WO2008100624A2 (en)
ZA (1) ZA200906360B (en)

Cited By (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019952A3 (en) * 2008-08-15 2010-06-24 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
WO2010115552A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
WO2010115553A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
WO2010115589A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
WO2011022727A2 (en) * 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
WO2011047180A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
WO2011056124A1 (en) * 2009-11-04 2011-05-12 Affibody Ab Her3 binding polypeptides
WO2011076683A1 (en) 2009-12-22 2011-06-30 Roche Glycart Ag Anti-her3 antibodies and uses thereof
WO2011108502A1 (en) 2010-03-02 2011-09-09 協和発酵キリン株式会社 Modified antibody composition
WO2011112953A2 (en) 2010-03-11 2011-09-15 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
WO2011144749A1 (en) 2010-05-20 2011-11-24 Ablynx Nv Biological materials related to her3
WO2012006552A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
WO2011136911A3 (en) * 2010-04-09 2012-03-08 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
WO2012006341A3 (en) * 2010-07-06 2012-03-22 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
WO2012052230A1 (en) * 2010-10-18 2012-04-26 Mediapharma S.R.L. Erbb3 binding antibody
ITRM20100577A1 (en) * 2010-11-02 2012-05-03 Takis Srl IMMUNOTHERAPY AGAINST THE ERBB-3 RECEPTOR
WO2012019024A3 (en) * 2010-08-04 2012-05-03 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
WO2012059858A1 (en) * 2010-11-01 2012-05-10 Symphogen A/S Anti-her3 antibodies and compositions
EP2486052A2 (en) * 2009-10-09 2012-08-15 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
WO2012125864A2 (en) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
WO2012125573A2 (en) 2011-03-11 2012-09-20 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
WO2012156309A1 (en) * 2011-05-13 2012-11-22 Millegen Antibodies against her3
WO2012156532A1 (en) 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
US20120328623A1 (en) * 2011-06-20 2012-12-27 Kyowa Hakko Kirin Co., Ltd. ANTI-erbB3 ANTIBODY
WO2013078191A1 (en) 2011-11-23 2013-05-30 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2013048883A3 (en) * 2011-09-30 2013-06-27 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
EP2611829A2 (en) * 2010-09-03 2013-07-10 GlaxoSmithKline Intellectual Property Development Limited Novel antigen binding proteins
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US8597652B2 (en) 2009-03-20 2013-12-03 Genentech, Inc. Multispecific anti-HER antibodies
WO2014049003A1 (en) 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8722855B2 (en) 2009-10-28 2014-05-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2014072306A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2014108484A2 (en) 2013-01-11 2014-07-17 F. Hoffmann-La Roche Ag Combination therapy of anti-her3 antibodies
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP2719708A3 (en) * 2009-11-13 2014-09-03 U3 Pharma GmbH Material and methods for treating or preventing HER-3 associated diseases
US8961966B2 (en) 2007-02-16 2015-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against ERBB3 and uses thereof
US8987418B2 (en) 2013-03-15 2015-03-24 Abbvie Inc. Dual specific binding proteins directed against IL-1β and/or IL-17
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2015067986A1 (en) 2013-11-07 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuregulin allosteric anti-her3 antibody
US9035027B2 (en) 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9045551B2 (en) 2012-11-01 2015-06-02 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
WO2015155998A1 (en) 2014-04-10 2015-10-15 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
WO2015159253A1 (en) 2014-04-16 2015-10-22 Gamamabs Pharma Anti-her4 human antibody
WO2015173250A1 (en) * 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Anti-her3 antibodies binding to the beta-hairpin of her3
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
WO2017015008A1 (en) 2015-07-20 2017-01-26 Eli Lilly And Company Her3 antibodies
JP2017070314A (en) * 2011-10-06 2017-04-13 アベオ ファーマシューティカルズ， インコーポレイテッド Predicting tumor response to anti-erbb3 antibody
US9637543B2 (en) 2011-11-09 2017-05-02 The Uab Research Foundation HER3 antibodies and uses thereof
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9725511B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
US9745350B2 (en) 2012-10-05 2017-08-29 Affibody Ab HER3 binding polypeptides
WO2017149143A1 (en) 2016-03-04 2017-09-08 Agency For Science, Technology And Research Anti-lag-3 antibodies
US9783456B1 (en) 1999-06-18 2017-10-10 Zensun (Shanghai) Science & Technology, Co., Ltd. Method for inhibiting cell growth using anti-ErbB-3 and anti-ErbB-2 antibodies
WO2017194265A1 (en) 2016-05-10 2017-11-16 Agency For Science, Technology And Research Anti-CTLA-4 Antibodies
US9840554B2 (en) 2015-06-15 2017-12-12 Abbvie Inc. Antibodies against platelet-derived growth factor (PDGF)
WO2017214233A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214339A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214301A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2018110515A1 (en) 2016-12-12 2018-06-21 第一三共株式会社 Combination of antibody-drug conjugate and immune checkpoint inhibitor
US10017568B2 (en) 2011-05-05 2018-07-10 Merck Patent Gmbh Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same
US10017561B2 (en) 2009-05-13 2018-07-10 I2 Pharmaceuticals, Inc. Neutralizing molecules to influenza viruses
WO2018159582A1 (en) 2017-02-28 2018-09-07 学校法人近畿大学 Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
WO2018182421A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
US10214580B2 (en) 2007-03-27 2019-02-26 I2 Pharmaceuticals, Inc. Constructs and libraries comprising antibody surrogate light chain sequences
WO2019039483A1 (en) 2017-08-23 2019-02-28 第一三共株式会社 Antibody-drug conjugate preparation and lyophilization for same
WO2019044946A1 (en) 2017-08-31 2019-03-07 第一三共株式会社 Novel method for producing antibody-drug conjugate
WO2019044947A1 (en) 2017-08-31 2019-03-07 第一三共株式会社 Improved method for producing antibody-drug conjugate
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
WO2020022475A1 (en) 2018-07-27 2020-01-30 第一三共株式会社 Protein recognizing drug moiety of antibody-drug conjugate
WO2020022363A1 (en) 2018-07-25 2020-01-30 第一三共株式会社 Effective method for manufacturing antibody-drug conjugate
WO2020027100A1 (en) 2018-07-31 2020-02-06 第一三共株式会社 Treatment of metastatic brain tumor by administration of antibody-drug conjugate
WO2020031936A1 (en) 2018-08-06 2020-02-13 第一三共株式会社 Combination of antibody-drug conjugate and tubulin inhibitor
WO2020040245A1 (en) 2018-08-23 2020-02-27 第一三共株式会社 Sensitivity marker for antibody-drug conjugate
WO2020059772A1 (en) 2018-09-20 2020-03-26 第一三共株式会社 Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US10640563B2 (en) 2016-06-08 2020-05-05 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
WO2020122034A1 (en) 2018-12-11 2020-06-18 第一三共株式会社 Combination of antibody-drug conjugate with parp inhibitor
WO2020130125A1 (en) 2018-12-21 2020-06-25 第一三共株式会社 Combination of antibody-drug conjugate and kinase inhibitor
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
US10906974B2 (en) 2017-01-17 2021-02-02 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
US11077202B2 (en) 2017-05-15 2021-08-03 Daiichi Sankyo Company, Limited Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2022102634A1 (en) 2020-11-11 2022-05-19 第一三共株式会社 COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
WO2022192534A1 (en) * 2021-03-11 2022-09-15 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP4218929A1 (en) 2014-03-21 2023-08-02 AbbVie Inc. Anti-egfr antibodies and antibody drug conjugates
US11759527B2 (en) 2021-01-20 2023-09-19 Abbvie Inc. Anti-EGFR antibody-drug conjugates
US11773170B2 (en) 2017-08-09 2023-10-03 Merus N.V. Antibodies that bind EGFR and cMET
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
US11872289B2 (en) 2018-05-18 2024-01-16 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
US11939394B2 (en) 2015-10-23 2024-03-26 Merus N.V. Binding molecules that inhibit cancer growth
WO2024127366A1 (en) 2022-12-16 2024-06-20 Pheon Therapeutics Ltd Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
KR101462819B1 (en) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 Liposomes useful for drug delivery
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer
US20120010388A1 (en) * 2010-04-16 2012-01-12 Gottfried Himmler LeY SPECIFIC BIOTHERAPEUTIC
MX2012012441A (en) 2010-05-04 2013-02-26 Merrimack Pharmaceuticals Inc Antibodies against epidermal growth factor receptor (egfr) and uses thereof.
DK2606070T3 (en) 2010-08-20 2017-03-27 Novartis Ag Antibodies for the epidermal growth factor receptor 3 (HER3)
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP2648738A2 (en) 2010-12-06 2013-10-16 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
CA2822283A1 (en) * 2010-12-23 2012-06-28 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
WO2012099968A1 (en) * 2011-01-19 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating skin cancer associated diseases
WO2012103341A1 (en) * 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
WO2012112730A2 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
US20140234317A1 (en) * 2011-05-06 2014-08-21 Merrimack Pharmaceuticals, Inc. Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
CN107903325B (en) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
WO2012173867A1 (en) * 2011-06-16 2012-12-20 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-erbb3 antibodies in combination with tyrosine kinase inhibitors
AU2012273361A1 (en) * 2011-06-24 2013-03-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel
KR20140063578A (en) * 2011-06-30 2014-05-27 메리맥 파마슈티컬즈, 인크. Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
AU2012294326A1 (en) * 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
EA036739B1 (en) 2011-12-05 2020-12-15 Новартис Аг Antibodies for epidermal growth factor receptor 3 (her3)
NZ627878A (en) 2012-01-13 2016-03-31 Nippon Chemiphar Co P2x4 receptor antagonist
EP2817335A1 (en) * 2012-02-22 2014-12-31 U3 Pharma GmbH Combination of hb-egf binding protein and egfr inhibitor
AU2013201584A1 (en) * 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
MX358728B (en) 2012-05-02 2018-09-03 Symphogen As Humanized pan-her antibody compositions.
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
SG11201504293WA (en) 2012-12-03 2015-06-29 Merrimack Pharmaceuticals Inc Combination therapy for treating her2-positive cancers
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
AU2014239903A1 (en) 2013-03-14 2015-09-17 Genentech, Inc. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
US10239951B2 (en) * 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
KR102127408B1 (en) 2014-01-29 2020-06-29 삼성전자주식회사 Anti-Her3 scFv fragment and Bispecific anti-c-Met/anti-Her3 antibodies comprising the same
KR102359214B1 (en) 2014-04-04 2022-02-07 델 마 파마슈티컬스 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US20160045596A1 (en) 2014-08-05 2016-02-18 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
JP2018513155A (en) * 2015-04-17 2018-05-24 メリマック ファーマシューティカルズ インコーポレーティッド Combination therapy with serivantumab
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
AU2016271138A1 (en) 2015-05-29 2017-12-07 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
CA2992789A1 (en) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
KR102714060B1 (en) 2015-08-21 2024-10-08 입센 바이오팜 리미티드 Method for treating metastatic pancreatic cancer using combination therapy comprising liposomal irinotecan and oxaliplatin
WO2017035482A1 (en) * 2015-08-27 2017-03-02 Merrimack Pharmaceuticals, Inc Combination therapies for treatment of heregulin positive cancers
EP3352859B1 (en) 2015-09-24 2020-09-23 Expression Pathology, Inc. Quantifying met protein for cancer treatment
MA42991A (en) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd STABILIZATION OF PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
KR101746152B1 (en) 2015-12-07 2017-06-13 주식회사 이수앱지스 Antibody specifically binding to ErbB3 and use thereof
CN106854244B (en) * 2015-12-09 2020-05-22 南京英瀚斯生物科技有限公司 Nano antibody aiming at HER3 and clinical application thereof
JP2018536682A (en) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Methods for reducing or preventing the growth of tumors resistant to EGFR and / or ERBB3 blockade
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
MX2019004783A (en) 2016-11-02 2019-08-12 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin).
EP3555120A1 (en) 2016-12-19 2019-10-23 Abcam Plc Monovalent and divalent binding proteins
WO2018204153A1 (en) * 2017-05-02 2018-11-08 Venomyx, Inc. Composition and methods for treating snake envenomation
WO2019118318A1 (en) 2017-12-12 2019-06-20 Calico Biolabs, Inc. Recombinant antibody comprising heavy chain genetically fused to signature peptide and uses thereof
WO2022078490A1 (en) * 2020-10-15 2022-04-21 上海翰森生物医药科技有限公司 Anti-erbb3 antibody or antigen-binding fragment thereof, and medical use thereof
WO2023198138A1 (en) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Antibody or antigen-binding fragment thereof and medical use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035885A1 (en) 1996-03-27 1997-10-02 Genentech, Inc. ErbB3 ANTIBODIES
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69329503T2 (en) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6983227B1 (en) 1995-01-17 2006-01-03 Intertech Ventures, Ltd. Virtual models of complex systems
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CA2258721C (en) 1996-07-12 2014-09-09 Genentech, Inc. Chimeric heteromultimer adhesins
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
GB2336695A (en) 1998-04-20 1999-10-27 Teamware Group Oy Modelling a work process
IL139707A0 (en) 1998-05-15 2002-02-10 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
TR200200472T2 (en) 1999-08-27 2002-06-21 Genentech, Inc. Dosages for treatment with anti-Erb B2 antibodies
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP2330219A3 (en) 2000-04-14 2011-11-23 Metabolon, Inc. Method for drug discovery, disease treatment and diagnosis using metabolomics
US20020064785A1 (en) 2000-05-19 2002-05-30 Genentech Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
CA2417415C (en) 2000-07-31 2012-10-09 Biolex, Inc. Expression of biologically active polypeptides in duckweed
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6871171B1 (en) 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US7638302B2 (en) 2001-05-31 2009-12-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
JP2005508887A (en) 2001-08-03 2005-04-07 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション Screening method based on crystal structure of EGF receptor
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
US20050004018A1 (en) 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
CA2480099C (en) 2002-03-26 2019-01-08 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
WO2004000102A2 (en) 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
CN1678634A (en) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 Immunoglobulin single variable antigen combination area and its opposite constituent
BRPI0408950A (en) 2003-04-01 2006-03-28 Monogram Biosciences Inc method for determining a patient's disease situation, and method for selecting a patient for cancer treatment with one or more dimerically acting drugs
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1664716A4 (en) 2003-08-15 2008-08-13 Smithkline Beecham Corp Biomarkers in cancer
US8554486B2 (en) 2004-02-20 2013-10-08 The Mathworks, Inc. Method, computer program product, and apparatus for selective memory restoration of a simulation
DK2447375T3 (en) 2004-03-31 2019-07-29 Massachusetts Gen Hospital A method for determining the responsiveness of a tumor to target epidermal growth factor receptor treatments
CN1997382A (en) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 Bispecific binding agents for modulating biological activity
WO2005117553A2 (en) 2004-05-27 2005-12-15 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
WO2005121380A1 (en) 2004-06-04 2005-12-22 Smithkline Beecham Corporation Predictive biomarkers in cancer therapy
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
ATE508753T1 (en) 2004-08-06 2011-05-15 Genentech Inc ASSAY AND METHODS USING BIOMARKERS
EP1789451A4 (en) * 2004-08-12 2009-12-02 Dyax Corp Tie complex binding proteins
US20060136139A1 (en) 2004-10-12 2006-06-22 Elcock Adrian H Rapid computational identification of targets
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20090061422A1 (en) 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20090298061A1 (en) 2005-07-29 2009-12-03 Siemens Healthcare Diagnostics Inc. Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy
WO2007041502A2 (en) 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
AU2005337051A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an ErbB receptor drug
AR056857A1 (en) * 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2049568A2 (en) 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
US8367351B2 (en) 2006-05-05 2013-02-05 Historx, Inc. Methods for determining signal transduction activity in tumors
JP2009544007A (en) 2006-07-13 2009-12-10 イェール・ユニバーシティー A method for prognosing cancer based on intracellular localization of biomarkers
US20100178651A1 (en) 2006-11-03 2010-07-15 Christos Hatzis Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance
US20100047829A1 (en) 2006-11-28 2010-02-25 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
EP2647388A1 (en) * 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antibodies Against ERBB3 and Uses Thereof
SI2132573T1 (en) 2007-03-02 2014-07-31 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
JP5926487B2 (en) 2007-04-13 2016-05-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Method for treating cancer resistant to ErbB therapy
MX2009012271A (en) 2007-05-11 2010-02-04 Enzon Pharmaceuticals Inc Rna antagonist compounds for the modulation of her3.
PE20120015A1 (en) 2008-08-15 2012-01-26 Merrimack Pharmaceuticals Inc METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE OF TUMOR CELLS TO A THERAPEUTIC AGENT
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CA2771744A1 (en) 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
DK2544680T3 (en) * 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
US8877687B2 (en) 2010-04-26 2014-11-04 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
UY33498A (en) 2010-07-09 2013-01-03 Sanofi Aventis COMBINATIONS OF KINASE INHIBITORS FOR CANCER TREATMENT
BR112013012213A2 (en) * 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha multi-specific antigen-binding molecules having an alternative function to the function of factors viii, ix ex of blood coagulation, and bispecific antibody, their uses in the prevention or treatment of hemorrhage, nucleic acid, vector, cell, method to produce the aforementioned binding molecules, pharmaceutical composition and kit
AU2011341337A1 (en) 2010-12-10 2013-06-13 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scFv conjugates
WO2012116317A2 (en) 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EA201300996A1 (en) 2011-03-11 2014-01-30 Мерримак Фармасьютикалс, Инк. USE OF EGFR FAMILY RECEPTOR INHIBITORS IN THE TREATMENT OF THE BREAST-GROWTH CANCER
SG192775A1 (en) 2011-03-15 2013-09-30 Merrimack Pharmaceuticals Inc Overcoming resistance to erbb pathway inhibitors
CN105884900A (en) 2011-04-19 2016-08-24 梅里麦克制药股份有限公司 Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies
US20140234317A1 (en) 2011-05-06 2014-08-21 Merrimack Pharmaceuticals, Inc. Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
AU2012273361A1 (en) 2011-06-24 2013-03-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel
KR20140063578A (en) 2011-06-30 2014-05-27 메리맥 파마슈티컬즈, 인크. Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035885A1 (en) 1996-03-27 1997-10-02 Genentech, Inc. ErbB3 ANTIBODIES
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
GUY ET AL., PROC. NATL. ACAD. SCI. USA., vol. 91, 1994, pages 8132 - 8136
HYNES, BIOCHIM. BIOPHYS. ACTA REV. CANCER, vol. 1198, 1994, pages 165 - 184
KIM ET AL., BIOCHEM. J, vol. 334, 1998, pages 189 - 195
KRAUS ET AL., PROC. NATL. ACAD. SCI. USA., vol. 90, 1993, pages 2900 - 2904
LEE; MAIHLE, ONCOGENE, vol. 16, 1998, pages 3243 - 3252
PINKAS-KRAMARSKI, ONCOGENE, vol. 16, 1998, pages 1249 - 1258
SCHAEFER ET AL., CANCER RES, vol. 64, no. 10, 2004, pages 3395 - 405
SCHAEFER ET AL., NEOPLASIA, vol. 8, no. 7, 2006, pages 613 - 22
SIERKE ET AL., BIOCHEM. J., vol. 322, 1997, pages 757 - 763
SLIWKOWSKI ET AL., J. BIOL. CHEM., vol. 269, no. 20, 1994, pages 14661 - 14665
XUE ET AL., CANCER RES., vol. 66, 2006, pages 1418 - 1426

Cited By (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783456B1 (en) 1999-06-18 2017-10-10 Zensun (Shanghai) Science & Technology, Co., Ltd. Method for inhibiting cell growth using anti-ErbB-3 and anti-ErbB-2 antibodies
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
US9988462B2 (en) 2005-12-30 2018-06-05 Daiichi Sankyo Europe Gmbh Material and methods for treating or preventing HER-3 associated diseases
US9487588B2 (en) 2007-02-16 2016-11-08 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ERBB3 and uses thereof
US8961966B2 (en) 2007-02-16 2015-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against ERBB3 and uses thereof
US10214580B2 (en) 2007-03-27 2019-02-26 I2 Pharmaceuticals, Inc. Constructs and libraries comprising antibody surrogate light chain sequences
US10927163B2 (en) 2007-12-21 2021-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US9035027B2 (en) 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
WO2010019952A3 (en) * 2008-08-15 2010-06-24 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
US8597652B2 (en) 2009-03-20 2013-12-03 Genentech, Inc. Multispecific anti-HER antibodies
US9327035B2 (en) 2009-03-20 2016-05-03 Genentech, Inc. Anti-HER antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US11993642B2 (en) 2009-04-07 2024-05-28 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
AU2010234031B2 (en) * 2009-04-07 2015-10-01 Roche Glycart Ag Trivalent, bispecific antibodies
JP2012522524A (en) * 2009-04-07 2012-09-27 ロシュ グリクアート アクチェンゲゼルシャフト Bispecific anti-ErbB-3 / anti-c-Met antibody
JP2012522525A (en) * 2009-04-07 2012-09-27 ロシュ グリクアート アクチェンゲゼルシャフト Bispecific anti-ErbB-2 / anti-c-Met antibody
CN102369214A (en) * 2009-04-07 2012-03-07 罗氏格黎卡特股份公司 Trivalent, bispecific antibodies
CN102361884A (en) * 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 Bispecific anti-erbb-2/anti-c-met antibodies
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
WO2010115552A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
WO2010115553A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
CN102369214B (en) * 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 Trivalent, bispecific antibody
CN102378768A (en) * 2009-04-07 2012-03-14 罗氏格黎卡特股份公司 Bispecific anti-erbb-3/anti-c-met antibodies
JP2012522527A (en) * 2009-04-07 2012-09-27 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
WO2010115589A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
JP2014193181A (en) * 2009-04-07 2014-10-09 Roche Glycart Ag Trivalent, bispecific antibodies
US10017561B2 (en) 2009-05-13 2018-07-10 I2 Pharmaceuticals, Inc. Neutralizing molecules to influenza viruses
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US11673945B2 (en) 2009-06-16 2023-06-13 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
AU2010284018B2 (en) * 2009-08-21 2014-06-05 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ErbB3 and uses thereof
JP2013506622A (en) * 2009-08-21 2013-02-28 メリマック ファーマシューティカルズ インコーポレーティッド Antibodies against ectodomain of ERBB3 and use thereof
WO2011022727A2 (en) * 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
CN103002912A (en) * 2009-08-21 2013-03-27 梅里麦克制药股份有限公司 Antibodies against the ectodomain of ErbB3 and uses thereof
WO2011022727A3 (en) * 2009-08-21 2013-06-27 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
AU2010284018C1 (en) * 2009-08-21 2015-10-15 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ErbB3 and uses thereof
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
EP2486052A4 (en) * 2009-10-09 2013-05-01 Merck Sharp & Dohme Generation, characterization and uses thereof of anti-her 3 antibodies
EP2486052A2 (en) * 2009-10-09 2012-08-15 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
JP2013507926A (en) * 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド Bispecific binding agents targeting IGF-1R and ErbB3 signaling and uses thereof
WO2011047180A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8722855B2 (en) 2009-10-28 2014-05-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US10208128B2 (en) 2009-11-04 2019-02-19 Affibody Ab HER3 binding polypeptides
WO2011056124A1 (en) * 2009-11-04 2011-05-12 Affibody Ab Her3 binding polypeptides
JP2013509861A (en) * 2009-11-04 2013-03-21 アフィボディ・アーベー HER3 binding polypeptide
US9803025B2 (en) 2009-11-13 2017-10-31 Amgen, Inc. Material and methods for treating or preventing HER-3 associated diseases
EP3351558A3 (en) * 2009-11-13 2018-08-29 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
TWI630916B (en) * 2009-11-13 2018-08-01 第一三共歐洲公司 Materials and methods for treating or preventing her-3 associated diseases
EP2896632A3 (en) * 2009-11-13 2015-08-19 U3 Pharma GmbH Material and methods for treating or preventing HER-3 associated diseases
EP2719708A3 (en) * 2009-11-13 2014-09-03 U3 Pharma GmbH Material and methods for treating or preventing HER-3 associated diseases
EP3670539A1 (en) * 2009-11-13 2020-06-24 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
US9101760B2 (en) 2009-11-13 2015-08-11 U3 Pharma Gmbh Material and methods for treating or preventing HER-3 associated diseases
US9611331B2 (en) 2009-12-22 2017-04-04 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
WO2011076683A1 (en) 2009-12-22 2011-06-30 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US8859737B2 (en) 2009-12-22 2014-10-14 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
JP2015109848A (en) * 2009-12-22 2015-06-18 ロシュ グリクアート アーゲー Anti-her3 antibodies and uses thereof
JP2013514793A (en) * 2009-12-22 2013-05-02 ロシュ グリクアート アーゲー Anti-HER3 antibody and use thereof
TWI421092B (en) * 2009-12-22 2014-01-01 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US10196456B2 (en) 2009-12-22 2019-02-05 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
WO2011108502A1 (en) 2010-03-02 2011-09-09 協和発酵キリン株式会社 Modified antibody composition
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US20190119401A1 (en) * 2010-03-11 2019-04-25 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
WO2011112953A2 (en) 2010-03-11 2011-09-15 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2859893A1 (en) 2010-03-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US9518130B2 (en) 2010-03-11 2016-12-13 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US11680108B2 (en) 2010-04-09 2023-06-20 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
US8481687B2 (en) 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
US9228021B2 (en) 2010-04-09 2016-01-05 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
WO2011136911A3 (en) * 2010-04-09 2012-03-08 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
CN102884085A (en) * 2010-04-09 2013-01-16 Aveo制药公司 Anti-ERBB3 antibodies
JP2013523166A (en) * 2010-04-09 2013-06-17 アベオ ファーマシューティカルズ， インコーポレイテッド Anti-ErbB3 antibody
US10494441B2 (en) 2010-04-09 2019-12-03 Aveo Pharmaceuticals, Inc. Anti-ERBB3 antibodies
US9598498B2 (en) 2010-04-09 2017-03-21 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
KR101764453B1 (en) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. Anti-erbb3 antibodies
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
US10808032B2 (en) 2010-05-20 2020-10-20 Ablynx Nv Biological materials related to HER3
JP2013529079A (en) * 2010-05-20 2013-07-18 アブリンクス ナームローゼ・フェノーツハップ Biological materials related to HER3
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
WO2011144749A1 (en) 2010-05-20 2011-11-24 Ablynx Nv Biological materials related to her3
AU2011254557B2 (en) * 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
WO2012006341A3 (en) * 2010-07-06 2012-03-22 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
US8829164B2 (en) 2010-07-06 2014-09-09 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
US8603478B2 (en) 2010-07-06 2013-12-10 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
WO2012006552A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
US9493560B2 (en) 2010-08-03 2016-11-15 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012019024A3 (en) * 2010-08-04 2012-05-03 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2611829A4 (en) * 2010-09-03 2014-05-07 Glaxosmithkline Ip Dev Ltd Novel antigen binding proteins
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
EP2611829A2 (en) * 2010-09-03 2013-07-10 GlaxoSmithKline Intellectual Property Development Limited Novel antigen binding proteins
CN103189392A (en) * 2010-10-18 2013-07-03 米迪亚制药有限责任公司 ErbB3 binding antibody
CN103189392B (en) * 2010-10-18 2016-03-30 米迪亚制药有限责任公司 ErbB3 binding antibody
WO2012052230A1 (en) * 2010-10-18 2012-04-26 Mediapharma S.R.L. Erbb3 binding antibody
US9346889B2 (en) 2010-10-18 2016-05-24 Mediapharma S.R.L. ErbB3 binding antibody
AU2011317743B2 (en) * 2010-10-18 2015-05-21 Mediapharma S.R.L. ErbB3 binding antibody
US9217039B2 (en) 2010-11-01 2015-12-22 Symphogen A/S Anti-HER3 antibodies and compositions
WO2012059858A1 (en) * 2010-11-01 2012-05-10 Symphogen A/S Anti-her3 antibodies and compositions
US20130287684A1 (en) * 2010-11-01 2013-10-31 Symphogen A/S Anti-her3 antibodies and compositions
US9688738B2 (en) 2010-11-02 2017-06-27 Takis S.R.L. Immunotherapy against ErbB-3 receptor
WO2012059224A1 (en) * 2010-11-02 2012-05-10 Takis S.R.L. Immunotherapy against erbb-3 receptor
ITRM20100577A1 (en) * 2010-11-02 2012-05-03 Takis Srl IMMUNOTHERAPY AGAINST THE ERBB-3 RECEPTOR
US10745459B2 (en) 2010-11-02 2020-08-18 Takis S.R.L. Immunotherapy against ErbB-3 receptor
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US10793621B2 (en) 2011-02-28 2020-10-06 Hoffmann-La Roche Inc. Nucleic acid encoding dual Fc antigen binding proteins
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
CN103562226A (en) * 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
WO2012125573A3 (en) * 2011-03-11 2012-12-27 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
AU2012229147B2 (en) * 2011-03-11 2015-12-24 Merrimack Pharmaceuticals, Inc. Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
WO2012125573A2 (en) 2011-03-11 2012-09-20 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
WO2012125864A2 (en) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
EP2815765A1 (en) 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
US9527914B2 (en) 2011-04-19 2016-12-27 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
US9556274B2 (en) 2011-04-19 2017-01-31 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies
US9938346B2 (en) 2011-04-19 2018-04-10 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
WO2012145507A3 (en) * 2011-04-19 2013-11-07 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
US11773159B2 (en) 2011-05-05 2023-10-03 Merck Patent Gmbh Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
US10829552B2 (en) 2011-05-05 2020-11-10 Merck Patent Gmbh Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
US10017568B2 (en) 2011-05-05 2018-07-10 Merck Patent Gmbh Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same
US20140141019A1 (en) * 2011-05-13 2014-05-22 Inserm (Institut Nationalde La Sente Et De La Recherche Medicale) Antibodies against her3
US9346883B2 (en) 2011-05-13 2016-05-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies against HER3
WO2012156309A1 (en) * 2011-05-13 2012-11-22 Millegen Antibodies against her3
US9127065B2 (en) 2011-05-19 2015-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-human HER3 antibodies and uses thereof
WO2012156532A1 (en) 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
US9034328B2 (en) * 2011-06-20 2015-05-19 Kyowa Hakko Kirin Co., Ltd Anti-erbB3 antibody
EP2722343A4 (en) * 2011-06-20 2014-12-17 Kyowa Hakko Kirin Co Ltd ANTI-erbB3 ANTIBODY
WO2012176779A1 (en) 2011-06-20 2012-12-27 協和発酵キリン株式会社 Anti-erbb3 antibody
EP2722343A1 (en) * 2011-06-20 2014-04-23 Kyowa Hakko Kirin Co., Ltd. ANTI-erbB3 ANTIBODY
US20120328623A1 (en) * 2011-06-20 2012-12-27 Kyowa Hakko Kirin Co., Ltd. ANTI-erbB3 ANTIBODY
CN103781800A (en) * 2011-06-20 2014-05-07 协和发酵麒麟株式会社 Anti-erbB3 antibody
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
US11771762B2 (en) 2011-09-30 2023-10-03 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
US9827310B2 (en) 2011-09-30 2017-11-28 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
US8791244B2 (en) 2011-09-30 2014-07-29 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2760893B1 (en) * 2011-09-30 2018-09-12 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US10632194B2 (en) 2011-09-30 2020-04-28 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
US9284380B2 (en) 2011-09-30 2016-03-15 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
EA028879B1 (en) * 2011-09-30 2018-01-31 Ридженерон Фармасьютикалз, Инк. ANTI-ErbB3 ANTIBODIES AND USES THEREOF
WO2013048883A3 (en) * 2011-09-30 2013-06-27 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
JP2017070314A (en) * 2011-10-06 2017-04-13 アベオ ファーマシューティカルズ， インコーポレイテッド Predicting tumor response to anti-erbb3 antibody
US9637543B2 (en) 2011-11-09 2017-05-02 The Uab Research Foundation HER3 antibodies and uses thereof
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
WO2013078191A1 (en) 2011-11-23 2013-05-30 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US11091554B2 (en) 2011-11-23 2021-08-17 Medlmmune, Llc Binding molecules specific for HER3 and uses thereof
EP3608340A1 (en) 2011-11-23 2020-02-12 Medlmmune, LLC Binding molecules specific for her3 and uses thereof
US10040857B2 (en) 2011-11-23 2018-08-07 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US11407836B2 (en) 2012-06-27 2022-08-09 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
EP3401337A1 (en) 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014049003A1 (en) 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
US9745350B2 (en) 2012-10-05 2017-08-29 Affibody Ab HER3 binding polypeptides
US9163093B2 (en) 2012-11-01 2015-10-20 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9045551B2 (en) 2012-11-01 2015-06-02 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9944720B2 (en) 2012-11-01 2018-04-17 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3
US10626177B2 (en) 2012-11-08 2020-04-21 Hoffmann-La Roche Inc. HER3 antigen binding proteins binding to the beta-hairpin of HER3
US9725511B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
US10364290B2 (en) 2012-11-08 2019-07-30 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
WO2014072306A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2014108484A2 (en) 2013-01-11 2014-07-17 F. Hoffmann-La Roche Ag Combination therapy of anti-her3 antibodies
US8987418B2 (en) 2013-03-15 2015-03-24 Abbvie Inc. Dual specific binding proteins directed against IL-1β and/or IL-17
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
WO2015067986A1 (en) 2013-11-07 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuregulin allosteric anti-her3 antibody
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US9688761B2 (en) 2013-12-27 2017-06-27 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
US10273304B2 (en) 2013-12-27 2019-04-30 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
US11279770B2 (en) 2014-02-28 2022-03-22 Merus N.V. Antibody that binds ErbB-2 and ErbB-3
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
EP3470435A1 (en) 2014-02-28 2019-04-17 Merus N.V. Antibody that binds erbb-2 and erbb-3
EP3805268A1 (en) 2014-02-28 2021-04-14 Merus N.V. Antibody that binds erbb-2 and erbb-3
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
US11820825B2 (en) 2014-02-28 2023-11-21 Merus N.V. Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor
EP4218929A1 (en) 2014-03-21 2023-08-02 AbbVie Inc. Anti-egfr antibodies and antibody drug conjugates
KR20200077620A (en) 2014-04-10 2020-06-30 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
KR20160144396A (en) 2014-04-10 2016-12-16 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
KR20230021173A (en) 2014-04-10 2023-02-13 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
US11298359B2 (en) 2014-04-10 2022-04-12 Daiichi Sankyo Company, Limited Anti-HER3 antibody-drug conjugate
WO2015155998A1 (en) 2014-04-10 2015-10-15 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
EP3789042A1 (en) 2014-04-10 2021-03-10 Daiichi Sankyo Company, Limited Method for producing anti-her3 antibody-drug conjugate
KR20220012402A (en) 2014-04-10 2022-02-03 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
KR20200136052A (en) 2014-04-10 2020-12-04 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
KR20210115056A (en) 2014-04-10 2021-09-24 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
KR20220068270A (en) 2014-04-10 2022-05-25 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
KR20210041126A (en) 2014-04-10 2021-04-14 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
KR20240008415A (en) 2014-04-10 2024-01-18 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
KR20220132025A (en) 2014-04-10 2022-09-29 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
US10383878B2 (en) 2014-04-10 2019-08-20 Daiichi Sankyo Company, Limited Anti-HER3 antibody-drug conjugate
KR20190004837A (en) 2014-04-10 2019-01-14 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
WO2015159253A1 (en) 2014-04-16 2015-10-22 Gamamabs Pharma Anti-her4 human antibody
US9783611B2 (en) 2014-05-14 2017-10-10 Hoffman-La Roche Inc. Anti-HER3 antibodies binding to the beta-hairpin of HER3
JP2017521050A (en) * 2014-05-14 2017-08-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Anti-HER3 antibody binding to HER3 beta hairpin
WO2015173250A1 (en) * 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Anti-her3 antibodies binding to the beta-hairpin of her3
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US11999801B2 (en) 2014-12-03 2024-06-04 Hoffman-La Roche Inc. Multispecific antibodies
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016177664A1 (en) 2015-05-06 2016-11-10 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
US9840554B2 (en) 2015-06-15 2017-12-12 Abbvie Inc. Antibodies against platelet-derived growth factor (PDGF)
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
WO2017015008A1 (en) 2015-07-20 2017-01-26 Eli Lilly And Company Her3 antibodies
US11939394B2 (en) 2015-10-23 2024-03-26 Merus N.V. Binding molecules that inhibit cancer growth
WO2017149143A1 (en) 2016-03-04 2017-09-08 Agency For Science, Technology And Research Anti-lag-3 antibodies
WO2017194265A1 (en) 2016-05-10 2017-11-16 Agency For Science, Technology And Research Anti-CTLA-4 Antibodies
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214339A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3888689A1 (en) 2016-06-08 2021-10-06 AbbVie Inc. Anti-egfr antibody drug conjugates
WO2017214233A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
US10640563B2 (en) 2016-06-08 2020-05-05 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
WO2017214301A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2018110515A1 (en) 2016-12-12 2018-06-21 第一三共株式会社 Combination of antibody-drug conjugate and immune checkpoint inhibitor
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
US10906974B2 (en) 2017-01-17 2021-02-02 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
US11434289B2 (en) 2017-01-17 2022-09-06 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
WO2018159582A1 (en) 2017-02-28 2018-09-07 学校法人近畿大学 Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
WO2018182421A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
US11446386B2 (en) 2017-05-15 2022-09-20 Daiichi Sankyo Company, Limited Anti-CDH6 antibody and method of producing an anti-CDH6 antibody-drug conjugate
US11077202B2 (en) 2017-05-15 2021-08-03 Daiichi Sankyo Company, Limited Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate
US11773170B2 (en) 2017-08-09 2023-10-03 Merus N.V. Antibodies that bind EGFR and cMET
WO2019039483A1 (en) 2017-08-23 2019-02-28 第一三共株式会社 Antibody-drug conjugate preparation and lyophilization for same
WO2019044946A1 (en) 2017-08-31 2019-03-07 第一三共株式会社 Novel method for producing antibody-drug conjugate
WO2019044947A1 (en) 2017-08-31 2019-03-07 第一三共株式会社 Improved method for producing antibody-drug conjugate
US11945882B2 (en) 2017-08-31 2024-04-02 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
US11872289B2 (en) 2018-05-18 2024-01-16 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
WO2020022363A1 (en) 2018-07-25 2020-01-30 第一三共株式会社 Effective method for manufacturing antibody-drug conjugate
WO2020022475A1 (en) 2018-07-27 2020-01-30 第一三共株式会社 Protein recognizing drug moiety of antibody-drug conjugate
WO2020027100A1 (en) 2018-07-31 2020-02-06 第一三共株式会社 Treatment of metastatic brain tumor by administration of antibody-drug conjugate
WO2020031936A1 (en) 2018-08-06 2020-02-13 第一三共株式会社 Combination of antibody-drug conjugate and tubulin inhibitor
WO2020040245A1 (en) 2018-08-23 2020-02-27 第一三共株式会社 Sensitivity marker for antibody-drug conjugate
WO2020059772A1 (en) 2018-09-20 2020-03-26 第一三共株式会社 Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
WO2020122034A1 (en) 2018-12-11 2020-06-18 第一三共株式会社 Combination of antibody-drug conjugate with parp inhibitor
WO2020130125A1 (en) 2018-12-21 2020-06-25 第一三共株式会社 Combination of antibody-drug conjugate and kinase inhibitor
WO2022102634A1 (en) 2020-11-11 2022-05-19 第一三共株式会社 COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
US11759527B2 (en) 2021-01-20 2023-09-19 Abbvie Inc. Anti-EGFR antibody-drug conjugates
WO2022192534A1 (en) * 2021-03-11 2022-09-15 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
WO2024127366A1 (en) 2022-12-16 2024-06-20 Pheon Therapeutics Ltd Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof

Also Published As

Publication number Publication date
US7846440B2 (en) 2010-12-07
US20170073427A1 (en) 2017-03-16
US20090291085A1 (en) 2009-11-26
US20190292271A1 (en) 2019-09-26
EP2129396A2 (en) 2009-12-09
DK2129396T3 (en) 2013-11-25
JP5564266B2 (en) 2014-07-30
EP2716301A3 (en) 2014-07-16
MA31254B1 (en) 2010-03-01
HRP20170834T1 (en) 2017-08-25
RS53042B (en) 2014-04-30
PL2129396T3 (en) 2014-02-28
PT2129396E (en) 2013-11-18
ZA200906360B (en) 2014-03-26
CA2678181A1 (en) 2008-08-21
CA2678181C (en) 2016-12-13
CN101674846B (en) 2014-07-02
EA020465B1 (en) 2014-11-28
US8691225B2 (en) 2014-04-08
AU2008216600A1 (en) 2008-08-21
SG178789A1 (en) 2012-03-29
US9487588B2 (en) 2016-11-08
KR20100014426A (en) 2010-02-10
HRP20131113T1 (en) 2014-01-17
EP2716301A2 (en) 2014-04-09
SI2129396T1 (en) 2013-12-31
US20100056761A1 (en) 2010-03-04
JP2014113167A (en) 2014-06-26
EP3248617A3 (en) 2018-02-21
ES2631727T3 (en) 2017-09-04
ES2431940T3 (en) 2013-11-28
DK2716301T3 (en) 2017-07-31
CY1114632T1 (en) 2016-10-05
EP2647388A1 (en) 2013-10-09
EP3248617A2 (en) 2017-11-29
EP2129396B1 (en) 2013-08-21
BRPI0808055A2 (en) 2013-07-30
AU2008216600B2 (en) 2013-09-05
IL200373A0 (en) 2010-04-29
KR101598229B1 (en) 2016-02-26
ECSP099637A (en) 2009-12-28
WO2008100624A3 (en) 2009-01-15
US20220204642A1 (en) 2022-06-30
EA200901119A1 (en) 2010-10-29
EP2716301B1 (en) 2017-04-05
CR11029A (en) 2009-12-29
PT2716301T (en) 2017-07-04
PL2716301T3 (en) 2017-10-31
CN101674846A (en) 2010-03-17
CO6231000A2 (en) 2010-12-20
US8961966B2 (en) 2015-02-24
US20100266584A1 (en) 2010-10-21
SI2716301T1 (en) 2017-07-31
US20110123523A1 (en) 2011-05-26
IL200373A (en) 2013-09-30
NZ579644A (en) 2012-05-25
US20140234329A1 (en) 2014-08-21
US20240360243A1 (en) 2024-10-31
HUE033472T2 (en) 2017-12-28
HK1138771A1 (en) 2010-09-03
JP2010518820A (en) 2010-06-03
MX2009008656A (en) 2009-11-10

Similar Documents

Publication Publication Date Title
US20240360243A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
AU2010284018C1 (en) Antibodies against the ectodomain of ErbB3 and uses thereof
AU2012279132B2 (en) Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
JP2018052959A (en) Antibodies against human epidermal growth factor receptor 3 (her3)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880009633.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12281925

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725722

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2678181

Country of ref document: CA

Ref document number: 200373

Country of ref document: IL

Ref document number: MX/A/2009/008656

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009549644

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 579644

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: A200909492

Country of ref document: UA

Ref document number: 2008216600

Country of ref document: AU

Ref document number: 09100503

Country of ref document: CO

Ref document number: 5461/CHENP/2009

Country of ref document: IN

Ref document number: DZP2009000545

Country of ref document: DZ

Ref document number: CR2009-011029

Country of ref document: CR

Ref document number: 1020097019335

Country of ref document: KR

Ref document number: 2008725722

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200901119

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2008216600

Country of ref document: AU

Date of ref document: 20080215

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0808055

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090814

WWE Wipo information: entry into national phase

Ref document number: P-2013/0512

Country of ref document: RS